Chr	Start	End	Ref	Alt	Func.refGene	Gene.refGene	GeneDetail.refGene	ExonicFunc.refGene	AAChange.refGene	pLi.refGene	pRec.refGene	pNull.refGene	Disease_description.refGene	P(HI).refGene	P(rec).refGene	RVIS.refGene	RVIS_percentile.refGene	GDI.refGene	GDI-Phred.refGene	SIFT_score	SIFT_converted_rankscore	SIFT_pred	Polyphen2_HDIV_score	Polyphen2_HDIV_rankscore	Polyphen2_HDIV_pred	Polyphen2_HVAR_score	Polyphen2_HVAR_rankscore	Polyphen2_HVAR_pred	LRT_score	LRT_converted_rankscore	LRT_pred	MutationTaster_score	MutationTaster_converted_rankscore	MutationTaster_pred	MutationAssessor_score	MutationAssessor_score_rankscore	MutationAssessor_pred	FATHMM_score	FATHMM_converted_rankscore	FATHMM_pred	PROVEAN_score	PROVEAN_converted_rankscore	PROVEAN_pred	VEST3_score	VEST3_rankscore	MetaSVM_score	MetaSVM_rankscore	MetaSVM_pred	MetaLR_score	MetaLR_rankscore	MetaLR_pred	M-CAP_score	M-CAP_rankscore	M-CAP_pred	CADD_raw	CADD_raw_rankscore	CADD_phred	DANN_score	DANN_rankscore	fathmm-MKL_coding_score	fathmm-MKL_coding_rankscore	fathmm-MKL_coding_pred	Eigen_coding_or_noncoding	Eigen-raw	Eigen-PC-raw	GenoCanyon_score	GenoCanyon_score_rankscore	integrated_fitCons_score	integrated_fitCons_score_rankscore	integrated_confidence_value	GERP++_RS	GERP++_RS_rankscore	phyloP100way_vertebrate	phyloP100way_vertebrate_rankscore	phyloP20way_mammalian	phyloP20way_mammalian_rankscore	phastCons100way_vertebrate	phastCons100way_vertebrate_rankscore	phastCons20way_mammalian	phastCons20way_mammalian_rankscore	SiPhy_29way_logOdds	SiPhy_29way_logOdds_rankscore	Interpro_domain	GTEx_V6_gene	GTEx_V6_tissue	Otherinfo
chr1	1139789	1139789	G	T	exonic	TNFRSF18	.	nonsynonymous SNV	TNFRSF18:NM_004195:exon3:c.C388A:p.P130T,TNFRSF18:NM_148901:exon3:c.C388A:p.P130T,TNFRSF18:NM_148902:exon3:c.C388A:p.P130T	8.37E-07	0.089996444	0.91000272	.	0.03798	0.16362	.	.	185.06659	2.95295	0.048	0.400	D	1.0	0.899	D	0.984	0.745	D	0.236	0.158	N	1	0.090	N	2.52	0.738	M	1.64	0.734	T	-5.58	0.889	D	0.539	0.586	-0.415	0.716	T	0.538	0.829	D	0.148	0.831	D	3.791	0.512	23.4	0.994	0.648	0.197	0.205	N	c	0.152	-0.066	0.985	0.308	0.646	0.450	0	3.55	0.396	1.678	0.370	1.048	0.713	0.467	0.265	0.047	0.162	10.935	0.463	TNFR/NGFR cysteine-rich region	.	.	0.5	.	67	chr1	1139789	chr1:1139789	G	T	.	PASS	AN=0;DP=67	GT	0/1
chr1	1581191	1581191	G	-	intronic	CDK11B	.	.	.	0.72829444	0.271588478	0.000117082	.	.	0.14135	.	.	147.53387	2.64628	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	43	chr1	1581190	chr1:1581190	TG	T	42	PASS	AN=2;DP=43	GT	0/1
chr1	6209363	6209363	T	C	exonic	CHD5	.	synonymous SNV	CHD5:NM_015557:exon8:c.A1104G:p.V368V	0.999999995	4.88E-09	1.01E-23	DISEASE: Note=Defects in CHD5 may be a cause of the development of cancers from epithelial, neural and hematopoietic origin. CHD5 is one of the missing genes in the del(1p36), a deletion which is extremely common in this type of cancers. A decrease of its expression, results in increased susceptibility of cells to Ras- mediated transformation in vitro and in vivo (PubMed:17289567). {ECO:0000269|PubMed:17289567}.; 	0.29125	0.11641	-3.065544169	0.489502241	139.76253	2.5774	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	83	15	chr1	6209363	chr1:6209363	T	C	83	PASS	AN=2;DP=15	GT	1/0
chr1	11008497	11008497	G	C	exonic	C1orf127	.	synonymous SNV	C1orf127:NM_001170754:exon12:c.C1695G:p.G565G	1.33E-05	0.955388217	0.044598438	.	0.1648	.	0.986521626	90.48124558	1056.79352	6.24152	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	87	15	chr1	11008497	chr1:11008497	G	C	87	PASS	AN=2;DP=15	GT	1/0
chr1	22032222	22032223	TT	-	exonic	USP48	.	frameshift deletion	USP48:NM_001350164:exon18:c.2180_2181del:p.K727Tfs*8,USP48:NM_001330394:exon19:c.2381_2382del:p.K794Tfs*8,USP48:NM_001350166:exon19:c.2375_2376del:p.K792Tfs*8,USP48:NM_001350167:exon19:c.2378_2379del:p.K793Tfs*8,USP48:NM_001350168:exon19:c.2378_2379del:p.K793Tfs*8,USP48:NM_032236:exon19:c.2381_2382del:p.K794Tfs*8	0.999997429	2.57E-06	2.13E-16	.	0.10091	0.10216	-0.556537043	19.72753008	115.55589	2.33734	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	16	chr1	22032221	chr1:22032221	GTT	G	39	PASS	AN=2;DP=16	GT	0/1
chr1	24859501	24859501	C	-	intronic	RCAN3	.	.	.	0.003206422	0.823874218	0.17291936	.	0.14079	0.09206	-0.139478553	43.29440906	123.07433	2.41603	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	10.22	68	chr1	24859500	chr1:24859500	TC	T	10.22	PASS	AN=0;DP=68	GT	0/1
chr1	24999256	24999256	C	A	UTR3	SRRM1	NM_001303448:c.*479C>A;NM_005839:c.*479C>A;NM_001303449:c.*479C>A	.	.	0.999999022	9.78E-07	2.02E-17	.	0.5312	0.11301	-0.929520514	9.683887709	90.5423	2.04787	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	13	chr1	24999256	chr1:24999256	C	A	.	PASS	AN=0;DP=13	GT	0/1
chr1	37958258	37958258	G	A	UTR3	MEAF6	NM_022756:c.*1442C>T;NM_001270876:c.*1112C>T;NM_001270875:c.*1442C>T	.	.	0.730388139	0.269048652	0.000563209	DISEASE: Note=A chromosomal aberration involving MEAF6 may be a cause of endometrial stromal tumors. Translocation t(1;6)(p34;p21) with PHF1. {ECO:0000269|PubMed:22761769}.; 	0.18507	0.10264	-0.09720619	46.20193442	5.77712	0.21811	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	41	chr1	37958258	chr1:37958258	G	A	.	PASS	AN=0;DP=41	GT	0/1
chr1	54871576	54871576	C	T	intronic	SSBP3	.	.	.	0.999756196	0.000243804	3.40E-10	.	0.15537	0.08395	-0.648365105	16.35999056	29.52993	0.94347	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	65	chr1	54871576	chr1:54871576	C	T	.	PASS	AN=0;DP=65	GT	0/1
chr1	55352523	55352523	C	T	intronic	DHCR24	.	.	.	0.969136893	0.030861185	1.92E-06	.	0.19237	0.23658	-0.822919685	11.76574664	93.19943	2.07714	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	29	chr1	55352523	chr1:55352523	C	T	.	PASS	AN=0;DP=29	GT	0/1
chr1	61331108	61331108	C	T	intergenic	LOC101926964;NFIA-AS2	dist=39852;dist=74808	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	34	chr1	61331108	chr1:61331108	C	T	.	PASS	AN=0;DP=34	GT	0/1
chr1	66102431	66102431	C	T	exonic	LEPR	.	synonymous SNV	LEPR:NM_002303:exon20:c.C3231T:p.I1077I	0.999805342	0.000194658	8.04E-12	DISEASE: Leptin receptor deficiency (LEPRD) [MIM:614963]: A rare disease characterized by normal levels of serum leptin, hyperphagia and severe obesity from an early age. Additional features include alterations in immune function, and delayed puberty due to hypogonadotropic hypogonadism. {ECO:0000269|PubMed:9537324}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.55299	0.08243	-0.216746887	37.69757018	2800.90586	9.9929	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	17	chr1	66102431	chr1:66102431	C	T	.	PASS	AN=0;DP=17	GT	0/1
chr1	78414382	78414385	CATC	-	UTR3	FUBP1	NM_003902:c.*69_*66delGATG;NM_001303433:c.*69_*66delGATG	.	.	0.999972831	2.72E-05	1.62E-12	.	0.60917	0.16996	-0.291981272	33.20358575	48.41037	1.35624	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	17.95	31	chr1	78414381	chr1:78414381	GCATC	G	17.95	PASS	AN=0;DP=31	GT	0/1
chr1	94544155	94544155	G	A	exonic	ABCA4	.	synonymous SNV	ABCA4:NM_000350:exon10:c.C1347T:p.N449N	1.27E-28	0.894718807	0.105281193	DISEASE: Fundus flavimaculatus (FFM) [MIM:248200]: Autosomal recessive retinal disorder very similar to Stargardt disease. In contrast to Stargardt disease, FFM is characterized by later onset and slowly progressive course. {ECO:0000269|PubMed:11379881, ECO:0000269|PubMed:11385708, ECO:0000269|PubMed:9781034}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Macular degeneration, age-related, 2 (ARMD2) [MIM:153800]: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. {ECO:0000269|PubMed:19028736, ECO:0000269|PubMed:9295268}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Cone-rod dystrophy 3 (CORD3) [MIM:604116]: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa. {ECO:0000269|PubMed:10958761, ECO:0000269|PubMed:11385708, ECO:0000269|PubMed:11527935}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 19 (RP19) [MIM:601718]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP19 is characterized by choroidal atrophy. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.09923	0.38763	0.736662821	86.30573248	3827.03692	12.16874	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	77	chr1	94544155	chr1:94544155	G	A	.	PASS	AN=0;DP=77	GT	0/1
chr1	143187103	143187103	G	A	ncRNA_intronic	LOC102723769	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	64	chr1	143187103	chr1:143187103	G	A	.	PASS	AN=0;DP=64	GT	0/1
chr1	150595425	150595425	C	T	intronic	ENSA	.	.	.	0.162369766	0.773694404	0.06393583	.	0.16235	.	0.413500896	76.67492333	9.50386	0.3504	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	77	chr1	150595425	chr1:150595425	C	T	.	PASS	AN=0;DP=77	GT	0/1
chr1	152285651	152285651	T	-	exonic	FLG	.	frameshift deletion	FLG:NM_002016:exon3:c.1711delA:p.T571Hfs*226	.	.	.	DISEASE: Ichthyosis vulgaris (VI) [MIM:146700]: The most common form of ichthyosis inherited as an autosomal dominant trait. It is characterized by palmar hyperlinearity, keratosis pilaris and a fine scale that is most prominent over the lower abdomen, arms, and legs. Ichthyosis vulgaris is characterized histologically by absent or reduced keratohyalin granules in the epidermis and mild hyperkeratosis. The disease can be associated with frequent asthma, eczema or hay fever. {ECO:0000269|PubMed:16444271}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Dermatitis atopic 2 (ATOD2) [MIM:605803]: Atopic dermatitis is a complex, inflammatory disease with multiple alleles at several loci thought to be involved in the pathogenesis. It commonly begins in infancy or early childhood and is characterized by a chronic relapsing form of skin inflammation, a disturbance of epidermal barrier function that culminates in dry skin, and IgE-mediated sensitization to food and environmental allergens. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. {ECO:0000269|PubMed:16550169, ECO:0000269|PubMed:16815158, ECO:0000269|PubMed:17030239, ECO:0000269|PubMed:17291859}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.08975	.	24.30246465	99.98820477	16458.42079	27.35022	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	18.25	40	chr1	152285650	chr1:152285650	GT	G	18.25	PASS	AN=0;DP=40	GT	0/1
chr1	157103941	157103942	CA	-	exonic	ETV3	.	frameshift deletion	ETV3:NM_001145312:exon4:c.362_363del:p.V121Dfs*41,ETV3:NM_005240:exon4:c.362_363del:p.V121Dfs*13	0.783799556	0.209446439	0.006754005	.	0.1465	0.24163	-0.339715008	30.06605331	22.17717	0.7442	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	22.4	19	chr1	157103940	chr1:157103940	TCA	T	22.4	PASS	AN=0;DP=19	GT	0/1
chr1	167385279	167385279	T	-	UTR3	POU2F1	NM_001198786:c.*232delT;NM_002697:c.*232delT;NM_001198783:c.*232delT	.	.	0.913950638	0.086048322	1.04E-06	.	0.97789	0.41629	-0.334253673	30.70299599	100.87731	2.1746	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	48	chr1	167385278	chr1:167385278	CT	C	42	PASS	AN=2;DP=48	GT	0/1
chr1	174926953	174926953	C	T	intronic	RABGAP1L	.	.	.	0.089172714	0.910824162	3.12E-06	.	0.37939	.	-1.087493118	7.106628922	552.4126	4.7801	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	20	chr1	174926953	chr1:174926953	C	T	.	PASS	AN=0;DP=20	GT	0/1
chr1	184006844	184006844	C	-	UTR5	COLGALT2	NM_001303420:c.-353delG;NM_001303421:c.-59287delG;NM_015101:c.-353delG	.	.	5.02E-07	0.958604921	0.041394577	.	0.12554	0.09957	-0.642904474	16.62538335	297.73119	3.68132	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	16.92	54	chr1	184006843	chr1:184006843	TC	T	16.92	PASS	AN=0;DP=54	GT	0/1
chr1	190066898	190066898	G	A	UTR3	BRINP3	NM_001317188:c.*250C>T;NM_199051:c.*250C>T	.	.	0.003759093	0.994437874	0.001803034	.	0.93585	0.11558	-1.155457828	6.168907761	50.74004	1.40353	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	15	chr1	190066898	chr1:190066898	G	A	.	PASS	AN=0;DP=15	GT	0/1
chr1	204119098	204119098	G	A	intronic	ETNK2	.	.	.	0.007118854	0.920754366	0.07212678	.	0.07996	0.08354	0.016664174	55.21939137	1450.59804	7.10742	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	45	chr1	204119098	chr1:204119098	G	A	.	PASS	AN=0;DP=45	GT	0/1
chr1	204192723	204192723	G	A	intronic	PLEKHA6	.	.	.	0.98196907	0.018030926	4.22E-09	.	0.21929	0.11756	-1.207107349	5.726586459	192.56504	3.00941	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chr1	204192723	chr1:204192723	G	A	.	PASS	AN=0;DP=44	GT	0/1
chr1	207828583	207828583	A	T	intronic	CR1L	.	.	.	3.56E-15	0.020225564	0.979774436	.	0.06963	.	3.872389272	99.64614296	2178.56335	8.59961	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	17	chr1	207828583	chr1:207828583	A	T	.	PASS	AN=0;DP=17	GT	0/1
chr1	215256558	215256558	C	T	intronic	KCNK2	.	.	.	0.339842885	0.657147273	0.003009842	.	0.12841	.	-0.449946534	24.00330267	31.8264	1.00181	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	43	chr1	215256558	chr1:215256558	C	T	.	PASS	AN=0;DP=43	GT	0/1
chr1	220101100	220101100	G	A	ncRNA_intronic	RNU5F-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	49	chr1	220101100	chr1:220101100	G	A	.	PASS	AN=0;DP=49	GT	0/1
chr1	220101115	220101115	C	A	ncRNA_intronic	RNU5F-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	48	chr1	220101115	chr1:220101115	C	A	.	PASS	AN=0;DP=48	GT	0/1
chr1	228646535	228646535	G	C	upstream;downstream	HIST3H2A;HIST3H2BB	dist=975;dist=276	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	293	chr1	228646535	chr1:228646535	G	C	65	PASS	AN=2;DP=293	GT	0/1
chr1	236767238	236767239	TT	-	intronic	HEATR1	.	.	.	0.999999993	6.78E-09	9.22E-25	.	0.09748	0.08985	2.322745612	98.36635999	19763.61088	30.12571	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	13.54	19	chr1	236767237	chr1:236767237	GTT	G	13.54	PASS	AN=0;DP=19	GT	0/1
chr1	241803116	241803116	G	A	intronic	OPN3	.	.	.	0.84628904	0.153140027	0.000570934	.	0.18445	0.20063	0.15257911	64.60839821	559.13945	4.80286	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chr1	241803116	chr1:241803116	G	A	.	PASS	AN=0;DP=44	GT	0/1
chr1	242514199	242514199	-	T	intronic	PLD5	.	.	.	0.124197737	0.874752709	0.001049554	.	0.21114	0.08983	-0.181750739	40.15687662	20.81668	0.70563	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	19.67	31	chr1	242514199	chr1:242514199	C	CT	19.67	PASS	AN=0;DP=31	GT	0/1
chr1	245021338	245021338	C	T	exonic	HNRNPU	.	nonsynonymous SNV	HNRNPU:NM_004501:exon7:c.G1412A:p.G471E,HNRNPU:NM_031844:exon7:c.G1469A:p.G490E	0.999903323	9.67E-05	7.22E-12	.	0.51398	0.38821	-0.60427181	17.74593064	41.32875	1.20799	0.005	0.632	D	1.0	0.899	D	0.998	0.875	D	0.000	0.843	D	1	0.810	D	2.69	0.790	M	0.85	0.475	T	-5.12	0.835	D	0.945	0.940	-0.505	0.685	T	0.301	0.673	T	0.034	0.552	D	5.060	0.681	25.2	0.998	0.892	0.976	0.760	D	c	0.728	0.700	1.000	0.747	0.722	0.854	0	4.94	0.645	7.856	0.852	0.852	0.362	1.000	0.715	0.999	0.750	14.931	0.704	.	.	.	0.5	.	20	chr1	245021338	chr1:245021338	C	T	.	PASS	AN=0;DP=20	GT	0/1
chr2	15769813	15769813	G	-	exonic	DDX1	.	frameshift deletion	DDX1:NM_004939:exon24:c.1963delG:p.E655Rfs*7	0.998606607	0.001393393	1.97E-10	.	0.33127	0.49952	-0.600630256	18.06440198	70.55865	1.7475	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	12	chr2	15769812	chr2:15769812	CG	C	62	PASS	AN=2;DP=12	GT	0/1
chr2	25875419	25875419	C	G	intronic	DTNB	.	.	.	0.000530412	0.999218122	0.000251466	.	0.59206	0.49987	-0.799052816	12.45576787	225.44054	3.24713	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	74	39	chr2	25875419	chr2:25875419	C	G	74	PASS	AN=2;DP=39	GT	0/1
chr2	37234400	37234400	A	T	exonic	HEATR5B	.	nonsynonymous SNV	HEATR5B:NM_019024:exon29:c.T4570A:p.Y1524N	8.10E-10	0.999999998	7.48E-10	.	0.25312	.	-2.513844451	0.914130691	1161.22267	6.48464	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.629	D	1	0.810	D	3.1	0.878	M	0.64	0.529	T	-8.7	0.976	D	0.891	0.880	-0.288	0.753	T	0.342	0.708	T	0.132	0.815	D	6.161	0.850	28.5	0.991	0.517	0.997	0.984	D	c	0.909	0.883	1.000	0.747	0.707	0.730	0	5.9	0.949	9.098	0.935	1.028	0.649	1.000	0.715	1.000	0.888	16.323	0.827	.	.	.	0.5	.	22	chr2	37234400	chr2:37234400	A	T	.	PASS	AN=0;DP=22	GT	0/1
chr2	37234444	37234444	C	T	exonic	HEATR5B	.	nonsynonymous SNV	HEATR5B:NM_019024:exon29:c.G4526A:p.G1509E	8.10E-10	0.999999998	7.48E-10	.	0.25312	.	-2.513844451	0.914130691	1161.22267	6.48464	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.629	D	1	0.810	D	2.715	0.797	M	0.59	0.540	T	-7.67	0.955	D	0.878	0.869	-0.245	0.765	T	0.402	0.753	T	0.058	0.673	D	6.938	0.934	33	0.998	0.876	0.998	0.992	D	c	0.888	0.859	1.000	0.747	0.707	0.730	0	5.78	0.914	7.706	0.835	0.807	0.329	1.000	0.715	0.942	0.416	20.012	0.974	Armadillo-type fold	.	.	0.5	.	19	chr2	37234444	chr2:37234444	C	T	.	PASS	AN=0;DP=19	GT	0/1
chr2	69685902	69685902	G	A	UTR3	AAK1	NM_014911:c.*17099C>T	.	.	0.999320421	0.000679579	1.69E-10	.	0.09908	0.09543	-0.664951379	15.91177164	3996.40242	12.50722	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	31	chr2	69685902	chr2:69685902	G	A	.	PASS	AN=0;DP=31	GT	0/1
chr2	70070226	70070226	G	A	intronic	GMCL1	.	.	.	9.62E-06	0.984465206	0.015525171	.	.	0.11371	-0.448125345	24.19202642	77.54664	1.85338	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	24	chr2	70070226	chr2:70070226	G	A	.	PASS	AN=0;DP=24	GT	0/1
chr2	85662190	85662190	G	A	exonic	SH2D6	.	nonsynonymous SNV	SH2D6:NM_201594:exon18:c.G100A:p.G34R	0.003696498	0.631606602	0.3646969	.	0.05815	.	0.459411326	78.28497287	94.15331	2.08683	0.003	0.682	D	0.997	0.689	D	0.896	0.618	P	0.365	0.136	N	0.828	0.349	D	1.83	0.482	L	-1.11	0.775	T	-2.96	0.617	D	0.244	0.298	-0.148	0.790	T	0.478	0.800	T	0.111	0.790	D	3.134	0.436	22.6	0.986	0.431	0.737	0.358	D	c	0.165	0.059	1.000	0.747	0.403	0.052	0	3.47	0.387	1.742	0.376	1.048	0.713	1.000	0.715	0.049	0.163	10.771	0.453	.	.	.	0.5	.	55	chr2	85662190	chr2:85662190	G	A	.	PASS	AN=0;DP=55	GT	0/1
chr2	96553678	96553678	C	-	exonic	ANKRD36C	.	frameshift deletion	ANKRD36C:NM_001310154:exon71:c.4151delG:p.G1384Efs*23	.	.	.	.	.	.	.	.	2676.37542	9.72635	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	28	chr2	96553677	chr2:96553677	TC	T	58	PASS	AN=2;DP=28	GT	0/1
chr2	96579840	96579877	CTCTTTTCAAAATTACCTCTCCTAGTTTTTTCTCCATC	-	exonic	ANKRD36C	.	frameshift deletion	ANKRD36C:NM_001310154:exon43:c.2707_2728del:p.D903Cfs*8	.	.	.	.	.	.	.	.	2676.37542	9.72635	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	21.82	40	chr2	96579839	chr2:96579839	TCTCTTTTCAAAATTACCTCTCCTAGTTTTTTCTCCATC	T	21.82	PASS	AN=0;DP=40	GT	0/1
chr2	99219135	99219135	C	T	intronic	COA5	.	.	.	0.239646156	0.644552102	0.115801742	DISEASE: Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 3 (CEMCOX3) [MIM:616500]: An infantile disorder with a fatal course in the first weeks of life, characterized by hypertrophic cardiomyopathy and mitochondrial complex IV deficiency. Postmortem microscopic investigations show accumulation of lipid droplets in cardiomyocytes and mitochondrial proliferation. {ECO:0000269|PubMed:21457908}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.1181	.	0.057118534	57.99716914	4.99352	0.18509	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	86	chr2	99219135	chr2:99219135	C	T	.	PASS	AN=0;DP=86	GT	0/1
chr2	108496625	108496648	CACATGTACCCAAGTTTAAAAATT	-	intronic	RGPD4	.	.	.	.	.	.	.	.	.	.	.	3826.98843	12.16508	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	19.32	33	chr2	108496624	chr2:108496624	ACACATGTACCCAAGTTTAAAAATT	A	19.32	PASS	AN=0;DP=33	GT	0/1
chr2	113891129	113891129	-	T	UTR3	IL1RN	NM_173841:c.*681_*682insT;NM_001318914:c.*681_*682insT;NM_173843:c.*681_*682insT;NM_000577:c.*681_*682insT;NM_173842:c.*681_*682insT	.	.	0.340218949	0.645559638	0.014221413	DISEASE: Interleukin 1 receptor antagonist deficiency (DIRA) [MIM:612852]: A rare autoinflammatory disease of skin and bone resulting in sterile multifocal osteomyelitis, periostitis, and pustulosis from birth. The term autoinflammatory disease describes a group of disorders characterized by attacks of seemingly unprovoked inflammation without significant levels of autoantibodies and autoreactive T-cells. {ECO:0000269|PubMed:19494218}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.09392	0.71118	-0.692458599	14.96815287	19.76062	0.67491	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	29.42	32	chr2	113891129	chr2:113891129	A	AT	29.42	PASS	AN=0;DP=32	GT	0/1
chr2	120317539	120317539	C	T	exonic	CFAP221	.	synonymous SNV	CFAP221:NM_001271049:exon5:c.C363T:p.V121V	.	.	.	.	.	.	-0.220384297	37.6032083	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	41	chr2	120317539	chr2:120317539	C	T	.	PASS	AN=0;DP=41	GT	0/1
chr2	166929302	166929302	C	T	intronic	SCN1A	.	.	.	1	4.65E-10	1.62E-25	DISEASE: Generalized epilepsy with febrile seizures plus 2 (GEFS2) [MIM:604403]: A rare autosomal dominant, familial condition with incomplete penetrance and large intrafamilial variability. Patients display febrile seizures persisting sometimes beyond the age of 6 years and/or a variety of afebrile seizure types. This disease combines febrile seizures, generalized seizures often precipitated by fever at age 6 years or more, and partial seizures, with a variable degree of severity. {ECO:0000269|PubMed:10742094, ECO:0000269|PubMed:11254444, ECO:0000269|PubMed:11254445, ECO:0000269|PubMed:11524484, ECO:0000269|PubMed:11756608, ECO:0000269|PubMed:12535936, ECO:0000269|PubMed:12576172, ECO:0000269|PubMed:12919402, ECO:0000269|PubMed:14672992, ECO:0000269|PubMed:15525788, ECO:0000269|PubMed:15694566, ECO:0000269|PubMed:15715999, ECO:0000269|PubMed:16525050, ECO:0000269|PubMed:17347258, ECO:0000269|PubMed:17507202, ECO:0000269|PubMed:17561957, ECO:0000269|PubMed:17927801, ECO:0000269|PubMed:18251839, ECO:0000269|PubMed:18413471, ECO:0000269|PubMed:18566737, ECO:0000269|PubMed:19339291, ECO:0000269|PubMed:19464195, ECO:0000269|PubMed:19522081, ECO:0000269|PubMed:20117752, ECO:0000269|PubMed:20550552, ECO:0000269|PubMed:20600615, ECO:0000269|PubMed:20729507, ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:21864321}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epileptic encephalopathy, early infantile, 6 (EIEE6) [MIM:607208]: A severe form of epileptic encephalopathy characterized by generalized tonic, clonic, and tonic-clonic seizures that are initially induced by fever and begin during the first year of life. Later, patients also manifest other seizure types, including absence, myoclonic, and simple and complex partial seizures. Psychomotor development delay is observed around the second year of life. Some patients manifest a borderline disease phenotype and do not necessarily fulfill all diagnostic criteria for core EIEE6. EIEE6 is considered to be the most severe phenotype within the spectrum of generalized epilepsies with febrile seizures-plus. {ECO:0000269|PubMed:11359211, ECO:0000269|PubMed:12083760, ECO:0000269|PubMed:12566275, ECO:0000269|PubMed:12754708, ECO:0000269|PubMed:12821740, ECO:0000269|PubMed:14504318, ECO:0000269|PubMed:14738421, ECO:0000269|PubMed:15087100, ECO:0000269|PubMed:15944908, ECO:0000269|PubMed:16122630, ECO:0000269|PubMed:16458823, ECO:0000269|PubMed:16713920, ECO:0000269|PubMed:17054684, ECO:0000269|PubMed:17054685, ECO:0000269|PubMed:17129991, ECO:0000269|PubMed:17347258, ECO:0000269|PubMed:17561957, ECO:0000269|PubMed:18413471, ECO:0000269|PubMed:18639757, ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:19522081, ECO:0000269|PubMed:19563458, ECO:0000269|PubMed:19589774, ECO:0000269|PubMed:19783390, ECO:0000269|PubMed:20110217, ECO:0000269|PubMed:20431604, ECO:0000269|PubMed:20452746, ECO:0000269|PubMed:20522430, ECO:0000269|PubMed:20729507, ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:21864321, ECO:0000269|PubMed:22092154, ECO:0000269|PubMed:22612257, ECO:0000269|PubMed:23195492}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Intractable childhood epilepsy with generalized tonic- clonic seizures (ICEGTC) [MIM:607208]: A disorder characterized by generalized tonic-clonic seizures beginning usually in infancy and induced by fever. Seizures are associated with subsequent mental decline, as well as ataxia or hypotonia. ICEGTC is similar to SMEI, except for the absence of myoclonic seizures. {ECO:0000269|PubMed:12566275, ECO:0000269|PubMed:16210358, ECO:0000269|PubMed:17507202, ECO:0000269|PubMed:23195492}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Migraine, familial hemiplegic, 3 (FHM3) [MIM:609634]: A subtype of migraine associated with transient blindness in some families. Migraine is a disabling symptom complex of periodic headaches, usually temporal and unilateral. Headaches are often accompanied by irritability, nausea, vomiting and photophobia, preceded by constriction of the cranial arteries. The two major subtypes are common migraine (migraine without aura) and classic migraine (migraine with aura). Classic migraine is characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred vision, hallucinations, vertigo, numbness and difficulty in concentrating and speaking. {ECO:0000269|PubMed:16054936, ECO:0000269|PubMed:17397047, ECO:0000269|PubMed:18021921, ECO:0000269|PubMed:19332696}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Febrile seizures, familial, 3A (FEB3A) [MIM:604403]: Seizures associated with febrile episodes in childhood without any evidence of intracranial infection or defined pathologic or traumatic cause. It is a common condition, affecting 2-5% of children aged 3 months to 5 years. The majority are simple febrile seizures (generally defined as generalized onset, single seizures with a duration of less than 30 minutes). Complex febrile seizures are characterized by focal onset, duration greater than 30 minutes, and/or more than one seizure in a 24 hour period. The likelihood of developing epilepsy following simple febrile seizures is low. Complex febrile seizures are associated with a moderately increased incidence of epilepsy. {ECO:0000269|PubMed:16326807, ECO:0000269|PubMed:19522081}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=SCN1A mutations may be involved in Panayiotopoulos syndrome, a benign age-related focal seizure disorder occurring in early and mid-childhood. It is characterized by seizures, often prolonged, with predominantly autonomic symptoms, and by an electroencephalogram that shows shifting and/or multiple foci, often with occipital predominance. Autonomic seizures in Panayiotopoulos syndrome consist of episodes of disturbed autonomic function with emesis as the predominant symptom. Cardiorespiratory arrest is exceptional. {ECO:0000269|PubMed:17679682, ECO:0000269|PubMed:19339291, ECO:0000269|PubMed:19522081}.; 	0.25753	0.21408	-1.429430352	4.028072659	148.17021	2.65241	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	66	chr2	166929302	chr2:166929302	C	T	.	PASS	AN=0;DP=66	GT	0/1
chr2	172582125	172582125	C	G	intronic	DYNC1I2	.	.	.	5.19E-07	0.960355697	0.039643784	.	0.2141	0.19929	-0.582225231	18.44184949	26.9112	0.86987	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	30	chr2	172582125	chr2:172582125	C	G	70	PASS	AN=2;DP=30	GT	0/1
chr2	176959252	176959252	G	A	exonic	HOXD13	.	nonsynonymous SNV	HOXD13:NM_000523:exon2:c.G826A:p.G276R	0.332069485	0.652799793	0.015130721	DISEASE: Synpolydactyly 1 (SPD1) [MIM:186000]: Limb malformation that shows a characteristic manifestation in both hands and feet. This condition is inherited as an autosomal dominant trait with reduced penetrance. {ECO:0000269|PubMed:12414828, ECO:0000269|PubMed:8817328}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Brachydactyly D (BDD) [MIM:113200]: A form of brachydactyly. Brachydactyly defines a group of inherited malformations characterized by shortening of the digits due to abnormal development of the phalanges and/or the metacarpals. Brachydactyly type D is characterized by short and broad terminal phalanges of the thumbs and big toes. {ECO:0000269|PubMed:12649808}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Syndactyly 5 (SDTY5) [MIM:186300]: A form of syndactyly, a congenital anomaly of the hand or foot marked by persistence of the webbing between adjacent digits that are more or less completely attached. The characteristic finding in SDTY5 is the presence of an associated metacarpal and metatarsal fusion. The metacarpals and metatarsals most commonly fused are the 4th and 5th or the 3rd and 4th. Soft tissue syndactyly usually affects the 3rd and 4th fingers and the 2nd and 3rd toes. {ECO:0000269|PubMed:17236141}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Brachydactyly-syndactyly syndrome (BDSD) [MIM:610713]: A disease characterized by generalized shortening of the hands and feet, broad and short distal phalanges of the thumbs, and cutaneous syndactyly of toes 2 and 3. The limb phenotypes observed in this syndrome overlap those of brachydactyly types A4, D, E and syndactyly type 1. {ECO:0000269|PubMed:17236141}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Brachydactyly E1 (BDE1) [MIM:113300]: A form of brachydactyly. Brachydactyly defines a group of inherited malformations characterized by shortening of the digits due to abnormal development of the phalanges and/or the metacarpals. Brachydactyly type E is characterized by shortening of the fingers mainly in the metacarpals and metatarsals. Wide variability in the number of digits affected occurs from person to person, even in the same family. Some individuals are moderately short of stature. Brachydactyly type E1 is characterized by shortening limited to fourth metacarpals and/or metatarsals. {ECO:0000269|PubMed:12649808}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: VACTERL association (VACTERL) [MIM:192350]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. {ECO:0000269|PubMed:19006232}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	0.83205	0.40904	-0.095386216	46.48502005	95.62533	2.11131	0.0	0.912	D	0.999	0.764	D	0.995	0.818	D	0.000	0.629	D	1	0.810	D	2.85	0.831	M	-3.7	0.954	D	-7.39	0.947	D	0.736	0.733	1.059	0.983	D	0.931	0.977	D	0.323	0.916	D	6.386	0.882	29.5	0.999	0.992	0.989	0.876	D	c	0.936	0.880	1.0	0.983	0.598	0.340	0	4.99	0.658	9.602	0.976	1.048	0.713	1.000	0.715	0.962	0.444	18.830	0.921	Homeobox domain|Homeodomain-like	.	.	0.5	.	18	chr2	176959252	chr2:176959252	G	A	.	PASS	AN=0;DP=18	GT	0/1
chr2	179357189	179357189	G	A	ncRNA_intronic	MIR548N	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	35	chr2	179357189	chr2:179357189	G	A	.	PASS	AN=0;DP=35	GT	0/1
chr2	198324874	198324874	C	T	intronic	COQ10B	.	.	.	0.140032717	0.840396564	0.01957072	.	0.12177	0.11803	0.014844891	54.94810097	6.81651	0.25234	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	14	chr2	198324874	chr2:198324874	C	T	.	PASS	AN=0;DP=14	GT	0/1
chr2	200134445	200134445	G	A	UTR3	SATB2	NM_001172509:c.*2489C>T;NM_001172517:c.*2489C>T;NM_015265:c.*2489C>T	.	.	0.999563007	0.000436992	1.41E-09	DISEASE: Note=Chromosomal aberrations involving SATB2 are found in isolated cleft palate. Translocation t(2;7); translocation t(2;11). {ECO:0000269|PubMed:12915443}.; DISEASE: Cleft palate isolated (CPI) [MIM:119540]: A congenital fissure of the soft and/or hard palate, due to faulty fusion. Isolated cleft palate is not associated with cleft lips. Some patients may manifest other craniofacial dysmorphic features, mental retardation, and osteoporosis. {ECO:0000269|PubMed:12915443, ECO:0000269|PubMed:17377962}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving SATB2 is found in a patient with classical features of Toriello-Carey syndrome. Translocation t(2;14)(q33;q22). {ECO:0000269|PubMed:19170718}.; 	0.90767	.	-0.868835007	10.65109696	18.7762	0.64879	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	48	chr2	200134445	chr2:200134445	G	A	.	PASS	AN=0;DP=48	GT	0/1
chr2	200134452	200134452	G	A	UTR3	SATB2	NM_001172509:c.*2482C>T;NM_001172517:c.*2482C>T;NM_015265:c.*2482C>T	.	.	0.999563007	0.000436992	1.41E-09	DISEASE: Note=Chromosomal aberrations involving SATB2 are found in isolated cleft palate. Translocation t(2;7); translocation t(2;11). {ECO:0000269|PubMed:12915443}.; DISEASE: Cleft palate isolated (CPI) [MIM:119540]: A congenital fissure of the soft and/or hard palate, due to faulty fusion. Isolated cleft palate is not associated with cleft lips. Some patients may manifest other craniofacial dysmorphic features, mental retardation, and osteoporosis. {ECO:0000269|PubMed:12915443, ECO:0000269|PubMed:17377962}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving SATB2 is found in a patient with classical features of Toriello-Carey syndrome. Translocation t(2;14)(q33;q22). {ECO:0000269|PubMed:19170718}.; 	0.90767	.	-0.868835007	10.65109696	18.7762	0.64879	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chr2	200134452	chr2:200134452	G	A	.	PASS	AN=0;DP=44	GT	0/1
chr2	209223082	209223083	TA	-	UTR3	PIKFYVE	NM_015040:c.*3053_*3054delTA	.	.	0.979802749	0.020197251	5.32E-18	DISEASE: Corneal dystrophy, fleck (CFD) [MIM:121850]: A form of stromal corneal dystrophy characterized by numerous small white flecks scattered in all levels of the stroma, with configurations varying from semicircular to wreath-like, curvilinear, or punctate. Although CFD may occasionally cause mild photophobia, patients are typically asymptomatic and have normal vision. {ECO:0000269|PubMed:15902656}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.40145	0.43176	-1.400183431	4.163717858	374.82497	4.08231	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40.05	19	chr2	209223081	chr2:209223081	TTA	T	40.05	PASS	AN=0;DP=19	GT	0/1
chr2	220308816	220308816	C	-	intronic	SPEG	.	.	.	0.999790422	0.000209578	9.17E-21	DISEASE: Myopathy, centronuclear, 5 (CNM5) [MIM:615959]: A form of centronuclear myopathy, a congenital muscle disorder characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers. CNM5 features include severe neonatal hypotonia with respiratory insufficiency, difficulty feeding, and delayed motor development. Some patients die in infancy, and some develop dilated cardiomyopathy. {ECO:0000269|PubMed:25087613}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.41136	0.12798	-0.055373944	48.92073602	8867.59165	20.31253	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	67	chr2	220308815	chr2:220308815	TC	T	64	PASS	AN=2;DP=67	GT	0/1
chr2	238899036	238899036	C	T	ncRNA_intronic	UBE2F-SCLY	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	48	chr2	238899036	chr2:238899036	C	T	.	PASS	AN=0;DP=48	GT	0/1
chr3	4872710	4872710	-	A	intronic	ITPR1	.	.	.	1	5.90E-12	3.24E-32	DISEASE: Spinocerebellar ataxia 15 (SCA15) [MIM:606658]: Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA15 is an autosomal dominant cerebellar ataxia (ADCA). It is very slow progressing form with a wide range of onset, ranging from childhood to adult. Most patients remain ambulatory. {ECO:0000269|PubMed:17590087, ECO:0000269|PubMed:18579805}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spinocerebellar ataxia 29 (SCA29) [MIM:117360]: An autosomal dominant, congenital spinocerebellar ataxia characterized by early motor delay, hypotonia and mild cognitive delay. Affected individuals develop a very slowly progressive or non-progressive gait and limb ataxia associated with cerebellar atrophy on brain imaging. Additional variable features include nystagmus, dysarthria, and tremor. {ECO:0000269|PubMed:22986007}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.48957	0.4536	-3.352519381	0.401037981	228.28209	3.26405	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	34.26	70	chr3	4872710	chr3:4872710	G	GA	34.26	PASS	AN=0;DP=70	GT	0/1
chr3	9518173	9518173	G	A	UTR3	SETD5	NM_001292043:c.*398G>A;NM_001080517:c.*398G>A;NM_001349451:c.*398G>A	.	.	0.999999564	4.36E-07	2.82E-18	DISEASE: Mental retardation, autosomal dominant 23 (MRD23) [MIM:615761]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD23 patients manifest moderate to severe intellectual disability with additional variable features of brachycephaly, a low hairline, depressed nasal bridge, prominent high nasal root, tubular nose, upslanting palpebral fissures, long and smooth philtrum, micrognathia, thin upper lip, and crowded teeth. Behavioral problems, including obsessive-compulsive disorder, hand flapping with ritualized behavior, and autism, are prominent features. {ECO:0000269|PubMed:24680889}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.46735	0.10674	-0.791786324	12.59731069	500.45582	4.59199	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	34	chr3	9518173	chr3:9518173	G	A	.	PASS	AN=0;DP=34	GT	0/1
chr3	9518244	9518244	G	-	UTR3	SETD5	NM_001292043:c.*469delG;NM_001080517:c.*469delG;NM_001349451:c.*469delG	.	.	0.999999564	4.36E-07	2.82E-18	DISEASE: Mental retardation, autosomal dominant 23 (MRD23) [MIM:615761]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD23 patients manifest moderate to severe intellectual disability with additional variable features of brachycephaly, a low hairline, depressed nasal bridge, prominent high nasal root, tubular nose, upslanting palpebral fissures, long and smooth philtrum, micrognathia, thin upper lip, and crowded teeth. Behavioral problems, including obsessive-compulsive disorder, hand flapping with ritualized behavior, and autism, are prominent features. {ECO:0000269|PubMed:24680889}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.46735	0.10674	-0.791786324	12.59731069	500.45582	4.59199	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	35.74	28	chr3	9518243	chr3:9518243	AG	A	35.74	PASS	AN=0;DP=28	GT	0/1
chr3	9730483	9730483	C	T	intronic	MTMR14	.	.	.	0.002939821	0.99695446	0.000105719	.	0.30998	0.11304	-0.911109353	9.961075725	98.92051	2.15158	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	22	chr3	9730483	chr3:9730483	C	T	.	PASS	AN=0;DP=22	GT	0/1
chr3	10103911	10103911	C	-	intronic	FANCD2	.	.	.	2.48E-14	0.999907163	9.28E-05	DISEASE: Fanconi anemia complementation group D2 (FANCD2) [MIM:227646]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. {ECO:0000269|PubMed:11239453}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.25008	.	-0.920453886	9.790044822	710.41171	5.29622	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	51	chr3	10103910	chr3:10103910	TC	T	41	PASS	AN=2;DP=51	GT	0/1
chr3	38105399	38105399	C	T	exonic	DLEC1	.	nonsynonymous SNV	DLEC1:NM_001321153:exon6:c.C1162T:p.P388S,DLEC1:NM_007335:exon6:c.C1162T:p.P388S,DLEC1:NM_007337:exon6:c.C1162T:p.P388S	6.45E-18	0.99562723	0.00437277	DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Note=The gene represented in this entry may be involved in disease pathogenesis. DLEC1 silencing due to promoter methylation and aberrant transcription are implicated in the development of lung cancer.; DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage. {ECO:0000269|PubMed:10213508}. Note=The gene represented in this entry may be involved in disease pathogenesis. DLEC1 silencing due to promoter methylation and aberrant transcription may be implicated in the development of esophageal cancer.; 	0.98238	0.10873	0.161491526	64.92686954	3130.50362	10.64467	0.127	0.270	T	0.491	0.381	P	0.146	0.323	B	0.234	0.158	N	0.989	0.243	N	1.59	0.404	L	3.61	0.045	T	-1.1	0.285	N	0.06	0.048	-0.979	0.353	T	0.012	0.045	T	0.001	0.012	T	1.076	0.197	11.08	0.949	0.251	0.059	0.117	N	c	-0.641	-0.682	0.062	0.153	0.497	0.185	0	0.627	0.168	0.341	0.195	-0.042	0.124	0.016	0.191	0.976	0.476	3.142	0.060	.	.	.	0.5	.	33	chr3	38105399	chr3:38105399	C	T	.	PASS	AN=0;DP=33	GT	0/1
chr3	43607198	43607198	C	-	exonic	ANO10	.	frameshift deletion	ANO10:NM_001204833:exon6:c.907delG:p.A303Pfs*9,ANO10:NM_001204832:exon7:c.1042delG:p.A348Pfs*9,ANO10:NM_001204834:exon7:c.670delG:p.A224Pfs*9,ANO10:NM_001346466:exon7:c.1042delG:p.A348Pfs*9,ANO10:NM_001346469:exon7:c.1042delG:p.A348Pfs*9,ANO10:NM_001204831:exon8:c.1240delG:p.A414Pfs*9,ANO10:NM_001346463:exon8:c.1240delG:p.A414Pfs*9,ANO10:NM_001346464:exon8:c.1240delG:p.A414Pfs*9,ANO10:NM_001346465:exon8:c.1240delG:p.A414Pfs*9,ANO10:NM_001346467:exon8:c.1240delG:p.A414Pfs*9,ANO10:NM_001346468:exon8:c.1240delG:p.A414Pfs*9,ANO10:NM_018075:exon8:c.1240delG:p.A414Pfs*9	1.92E-06	0.880526516	0.119471561	.	0.13961	0.09565	0.957177419	90.14508139	912.19278	5.8726	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	75	29	chr3	43607197	chr3:43607197	GC	G	75	PASS	AN=2;DP=29	GT	0/1
chr3	71005788	71005788	A	T	UTR3	FOXP1	NM_001244813:c.*2610T>A;NM_001244814:c.*2610T>A;NM_001244815:c.*2610T>A;NM_001244810:c.*2610T>A;NM_001244816:c.*2610T>A;NM_001244812:c.*2610T>A;NM_001244808:c.*2610T>A;NM_032682:c.*2610T>A;NM_001349344:c.*2610T>A;NM_001349342:c.*2610T>A;NM_001349343:c.*2610T>A;NM_001349338:c.*2610T>A;NM_001349339:c.*2610T>A;NM_001349340:c.*2610T>A;NM_001349341:c.*2610T>A;NM_001349337:c.*2610T>A	.	.	0.999750735	0.000249265	1.47E-11	DISEASE: Note=A chromosomal aberration involving FOXP1 is found in acute lymphoblastic leukemia. Translocation t(9;3)(p13;p14.1) with PAX5.; DISEASE: Mental retardation with language impairment and autistic features (MRLIAF) [MIM:613670]: A developmental disorder characterized by mild to moderate mental retardation, language impairment, and autistic features. Patients show global delay, delayed walking, severely delayed speech development, and behavioral abnormalities, including irritability, hyperactivity, aggression, and stereotypical rigid behaviors. {ECO:0000269|PubMed:20950788}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.57291	0.32628	-0.378346116	28.01368247	60.34446	1.57849	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	56	chr3	71005788	chr3:71005788	A	T	.	PASS	AN=0;DP=56	GT	0/1
chr3	129811919	129811919	G	A	ncRNA_intronic	LINC02014	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	64	chr3	129811919	chr3:129811919	G	A	.	PASS	AN=0;DP=64	GT	0/1
chr3	140661001	140661001	G	A	intronic	SLC25A36	.	.	.	0.883013619	0.116709235	0.000277146	.	0.16774	0.10791	-0.405853867	26.23260203	27.59314	0.88809	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	111	chr3	140661001	chr3:140661001	G	A	.	PASS	AN=0;DP=111	GT	0/1
chr3	140661003	140661003	G	A	intronic	SLC25A36	.	.	.	0.883013619	0.116709235	0.000277146	.	0.16774	0.10791	-0.405853867	26.23260203	27.59314	0.88809	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	111	chr3	140661003	chr3:140661003	G	A	.	PASS	AN=0;DP=111	GT	0/1
chr3	168849226	168849285	CCGGCGCCATAGTTTCATGGGGATAGTCTTCGCTCTTCATGAACAGCAGAAGCTCCTCTC	-	exonic	MECOM	.	frameshift deletion	MECOM:NM_001164000:wholegene,MECOM:NM_001105078:wholegene,MECOM:NM_005241:wholegene,MECOM:NM_001163999:wholegene,MECOM:NM_001205194:wholegene	0.999085313	0.000914686	3.49E-10	DISEASE: Note=A chromosomal aberration involving EVI1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with RUNX1/AML1. {ECO:0000269|PubMed:8313895}.; 	0.47994	0.30246	-0.993849454	8.56334041	1129.59722	6.41503	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	14.85	20	chr3	168849225	chr3:168849225	TCCGGCGCCATAGTTTCATGGGGATAGTCTTCGCTCTTCATGAACAGCAGAAGCTCCTCTC	T	14.85	PASS	AN=0;DP=20	GT	0/1
chr3	180680814	180680820	AGGTTCT	-	exonic	FXR1	.	frameshift deletion	FXR1:NM_001013438:exon13:c.1136_1140del:p.G379Efs*3,FXR1:NM_005087:exon13:c.1136_1140del:p.G379Efs*3,FXR1:NM_001013439:exon14:c.881_885del:p.G294Efs*3	0.999992198	7.80E-06	7.76E-14	.	0.83345	0.19444	-0.648365105	16.35999056	32.43007	1.01245	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	21.26	15	chr3	180680813	chr3:180680813	AAGGTTCT	A	21.26	PASS	AN=0;DP=15	GT	0/1
chr3	186917751	186917751	C	G	exonic	RTP1	.	nonsynonymous SNV	RTP1:NM_153708:exon2:c.C685G:p.Q229E	0.563829726	0.423951854	0.01221842	.	0.79035	0.11684	0.064394823	58.84642604	2341.27335	8.96348	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.003	0.351	N	1	0.090	P	0.55	0.145	N	1.62	0.282	T	-0.48	0.154	N	0.056	0.039	-0.976	0.358	T	0.000	0.000	T	.	.	.	0.084	0.102	3.442	0.622	0.067	0.018	0.056	N	c	-0.780	-0.618	0.910	0.263	0.615	0.372	0	5.74	0.900	1.719	0.374	0.133	0.217	0.528	0.269	0.580	0.285	12.993	0.579	.	ENSG00000198491.3|ENSG00000175077.5	Artery_Aorta|Nerve_Tibial	0.5	81	14	chr3	186917751	chr3:186917751	C	G	81	PASS	AN=2;DP=14	GT	1/0
chr3	195477936	195477936	A	G	exonic	MUC4	.	nonsynonymous SNV	MUC4:NM_138297:exon21:c.T2834C:p.V945A,MUC4:NM_004532:exon22:c.T2987C:p.V996A,MUC4:NM_018406:exon23:c.T15695C:p.V5232A	.	.	.	.	0.37408	.	6.320387277	99.8643548	14250.21522	26.01128	0.003	0.682	D	0.996	0.715	D	0.883	0.660	P	0.005	0.331	N	1	0.090	N	1.905	0.510	L	0.88	0.460	T	-3.36	0.666	D	0.382	0.527	-0.851	0.519	T	0.202	0.560	T	0.017	0.393	T	0.664	0.157	8.591	0.452	0.035	0.627	0.316	D	c	0.189	0.072	0.019	0.131	0.581	0.330	0	5.15	0.702	4.639	0.608	1.187	0.908	0.716	0.285	0.010	0.111	11.381	0.488	.	.	.	0.5	69	58	chr3	195477936	chr3:195477936	A	G	69	PASS	AN=2;DP=58	GT	0/1
chr4	950124	950179	CTGGCTGTTGCTTCCTTCCAGCGTCTGCTCCTCCGCGGCCTCATCTGCCTCTTCGT	-	intronic	TMEM175	.	.	.	0.00043963	0.963215421	0.03634495	.	0.16848	.	0.810142476	87.7388535	748.44954	5.42749	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	41	chr4	950123	chr4:950123	GCTGGCTGTTGCTTCCTTCCAGCGTCTGCTCCTCCGCGGCCTCATCTGCCTCTTCGT	G	60	PASS	AN=2;DP=41	GT	0/1
chr4	1741566	1741566	T	C	intronic	TACC3	.	.	.	0.091951814	0.907690378	0.000357807	.	0.60266	0.07352	0.099178678	60.75725407	2050.27567	8.34503	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	93	126	chr4	1741566	chr4:1741566	T	C	93	PASS	AN=2;DP=126	GT	0/1
chr4	2159559	2159559	C	A	intronic	POLN	.	.	.	3.00E-32	1.69E-06	0.999998313	.	0.06562	.	0.653987697	84.18259023	4366.19692	13.18659	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr4	2159559	chr4:2159559	C	A	.	PASS	AN=0;DP=38	GT	0/1
chr4	10443184	10443184	G	A	UTR3	ZNF518B	NM_053042:c.*1544C>T	.	.	0.591536151	0.408038434	0.000425414	.	0.13257	0.08374	0.657639543	84.20028309	1202.5769	6.5715	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	32	chr4	10443184	chr4:10443184	G	A	.	PASS	AN=0;DP=32	GT	0/1
chr4	39924431	39924431	T	A	intronic	PDS5A	.	.	.	0.99985292	0.00014708	3.36E-14	.	0.68436	0.10157	-0.688817379	15.20405756	46.97579	1.3251	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	17	chr4	39924431	chr4:39924431	T	A	.	PASS	AN=0;DP=17	GT	0/1
chr4	42088174	42088174	C	T	UTR3	SLC30A9	NM_006345:c.*31C>T	.	.	0.001423485	0.998515682	6.08E-05	.	0.15803	0.1344	0.531004228	80.87992451	64.38665	1.64576	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	36	chr4	42088174	chr4:42088174	C	T	.	PASS	AN=0;DP=36	GT	0/1
chr4	52780909	52780909	C	T	UTR3	DCUN1D4	NM_015115:c.*1159C>T;NM_001040402:c.*1159C>T;NM_001287757:c.*1159C>T;NM_001287755:c.*1159C>T	.	.	0.160650286	0.836138462	0.003211253	.	0.29277	.	-0.251530012	35.42108988	17.88872	0.62462	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	16	chr4	52780909	chr4:52780909	C	T	.	PASS	AN=0;DP=16	GT	0/1
chr4	57220269	57220269	A	-	exonic	AASDH	.	frameshift deletion	AASDH:NM_001286668:exon7:c.1019delT:p.L340Wfs*42,AASDH:NM_001286669:exon7:c.860delT:p.L287Wfs*42,AASDH:NM_001323893:exon7:c.860delT:p.L287Wfs*42,AASDH:NM_001323899:exon7:c.188delT:p.L63Wfs*42,AASDH:NM_001286671:exon8:c.1319delT:p.L440Wfs*42,AASDH:NM_001286672:exon8:c.1319delT:p.L440Wfs*41,AASDH:NM_001323890:exon8:c.1319delT:p.L440Wfs*42,AASDH:NM_001323892:exon8:c.1319delT:p.L440Wfs*42,AASDH:NM_181806:exon8:c.1319delT:p.L440Wfs*42	2.01E-05	0.998849623	0.001130277	.	0.07506	0.13832	1.054492917	91.3717858	3473.29703	11.34473	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	27	chr4	57220268	chr4:57220268	CA	C	42	PASS	AN=2;DP=27	GT	0/1
chr4	79781098	79781098	C	T	intronic	BMP2K	.	.	.	0.001916525	0.99804383	3.96E-05	.	0.78082	.	0.273728691	70.74781788	1787.12697	7.80244	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	46	chr4	79781098	chr4:79781098	C	T	.	PASS	AN=0;DP=46	GT	0/1
chr4	129208729	129208729	C	T	exonic	PGRMC2	.	nonsynonymous SNV	PGRMC2:NM_006320:exon1:c.G289A:p.V97M	0.403432082	0.557987569	0.038580349	.	0.24502	0.15979	.	.	86.09241	1.98113	0.249	0.341	T	0.379	0.325	B	0.057	0.248	B	0.083	0.208	N	0.615	0.326	D	1.355	0.339	L	-1.12	0.780	T	-0.54	0.172	N	0.186	0.227	-0.714	0.598	T	0.231	0.597	T	0.935	0.995	D	2.226	0.329	17.68	0.984	0.409	0.190	0.203	N	c	-0.432	-0.370	1.000	0.747	0.442	0.072	0	2.05	0.257	0.563	0.231	-0.069	0.120	1.000	0.715	0.996	0.625	1.542	0.024	Cytochrome b5-like heme/steroid binding domain	.	.	0.5	.	36	chr4	129208729	chr4:129208729	C	T	.	PASS	AN=0;DP=36	GT	0/1
chr4	151120063	151120063	C	-	intronic	DCLK2	.	.	.	0.966310095	0.033689808	9.78E-08	.	0.13998	0.10102	-0.378346116	28.01368247	110.56188	2.28968	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	17	chr4	151120062	chr4:151120062	AC	A	42	PASS	AN=2;DP=17	GT	0/1
chr4	151560826	151560826	G	A	intronic	LRBA	.	.	.	0.044229437	0.955770563	1.54E-17	DISEASE: Immunodeficiency, common variable, 8, with autoimmunity (CVID8) [MIM:614700]: An autosomal recessive immunologic disorder associated with defective B-cell differentiation and decreased or absent antibody production. Affected individuals have early- childhood onset of recurrent infections, particularly respiratory infections, and also develop variable autoimmune disorders, including idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and inflammatory bowel disease. {ECO:0000269|PubMed:22608502}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.31593	.	-2.513092117	0.925925926	4753.32179	13.94798	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chr4	151560826	chr4:151560826	G	A	.	PASS	AN=0;DP=44	GT	0/1
chr4	153244050	153244050	C	A	exonic	FBXW7	.	nonsynonymous SNV	FBXW7:NM_001013415:exon11:c.G1753T:p.D585Y,FBXW7:NM_018315:exon11:c.G1867T:p.D623Y,FBXW7:NM_033632:exon12:c.G2107T:p.D703Y,FBXW7:NM_001349798:exon14:c.G2107T:p.D703Y	0.999977859	2.21E-05	9.84E-13	.	0.98577	0.62169	-0.111973265	45.35857514	117.50249	2.35679	0.001	0.784	D	1.0	0.899	D	0.973	0.832	D	0.000	0.843	D	1	0.810	D	2.535	0.741	M	0.3	0.599	T	-8.5	0.975	D	0.763	0.768	-0.126	0.795	T	0.406	0.756	T	0.051	0.645	D	4.761	0.639	24.7	0.991	0.510	0.986	0.840	D	c	0.788	0.742	1.000	0.747	0.706	0.609	0	4.82	0.615	7.874	0.855	0.935	0.490	1.000	0.715	1.000	0.888	15.003	0.710	WD40-repeat-containing domain|WD40/YVTN repeat-like-containing domain	.	.	0.5	.	33	chr4	153244050	chr4:153244050	C	A	.	PASS	AN=0;DP=33	GT	0/1
chr4	155470035	155470035	G	A	exonic	PLRG1	.	nonsynonymous SNV	PLRG1:NM_001201564:exon2:c.C62T:p.T21I,PLRG1:NM_002669:exon2:c.C62T:p.T21I	0.998224783	0.001775215	1.76E-09	.	0.55468	0.15289	-0.291981272	33.20358575	28.74018	0.91926	0.001	0.784	D	0.993	0.715	D	0.9	0.693	P	0.000	0.843	D	1	0.810	D	2.81	0.821	M	-0.64	0.721	T	-4.06	0.755	D	0.306	0.790	0.183	0.856	D	0.568	0.843	D	0.200	0.867	D	6.101	0.841	28.2	0.999	0.953	0.971	0.723	D	c	0.940	0.921	1.0	0.983	0.660	0.490	0	5.72	0.893	9.505	0.970	1.048	0.713	1.000	0.715	1.000	0.888	19.889	0.969	.	.	.	0.5	.	27	chr4	155470035	chr4:155470035	G	A	.	PASS	AN=0;DP=27	GT	0/1
chr5	1064002	1064002	A	-	exonic	SLC12A7	.	frameshift deletion	SLC12A7:NM_006598:exon20:c.2696delT:p.L899Cfs*28	8.45E-11	0.968735953	0.031264047	.	0.09754	.	-2.793650711	0.654635527	209.87901	3.12733	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	267	chr5	1064001	chr5:1064001	CA	C	69	PASS	AN=2;DP=267	GT	0/1
chr5	1078922	1078922	G	A	intronic	SLC12A7	.	.	.	8.45E-11	0.968735953	0.031264047	.	0.09754	.	-2.793650711	0.654635527	209.87901	3.12733	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	52	chr5	1078922	chr5:1078922	G	A	.	PASS	AN=0;DP=52	GT	0/1
chr5	1213547	1213547	C	T	intronic	SLC6A19	.	.	.	8.52E-18	0.004157	0.995843	DISEASE: Hyperglycinuria (HG) [MIM:138500]: A condition characterized by excess of glycine in the urine. In some cases it is associated with renal colic and renal oxalate stones. {ECO:0000269|PubMed:19033659}. Note=The disease may be caused by mutations affecting the gene represented in this entry. SLC6A19 deficiency combined with haploinsufficiency of SLC6A20 or partially inactivating mutations in SLC36A2, can be responsible for hyperglycinuria.; DISEASE: Iminoglycinuria (IG) [MIM:242600]: A disorder of renal tubular reabsorption of glycine and imino acids (proline and hydroxyproline), marked by excessive levels of all three substances in the urine. {ECO:0000269|PubMed:19033659}. Note=The disease may be caused by mutations affecting the gene represented in this entry. SLC6A19 deficiency combined with haploinsufficiency of SLC6A20 or partially inactivating mutations in SLC36A2, can be responsible for iminoglycinuria. Additional polymorphisms and mutations in SLC6A18 can contribute to the IG phenotype in some families.; 	0.20028	0.16452	-1.92362963	1.916725643	1140.864	6.44137	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chr5	1213547	chr5:1213547	C	T	.	PASS	AN=0;DP=44	GT	0/1
chr5	2746912	2746912	G	-	UTR3	IRX2	NM_033267:c.*766delC	.	.	0.648697597	0.345244394	0.006058009	.	0.53433	0.1523	.	.	877.19497	5.76492	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	38	chr5	2746911	chr5:2746911	AG	A	72	PASS	AN=2;DP=38	GT	0/1
chr5	52781430	52781430	C	T	intronic	FST	.	.	.	0.963797332	0.036133213	6.95E-05	.	0.88912	0.4861	0.591694063	82.45458835	44.28611	1.27001	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	29	chr5	52781430	chr5:52781430	C	T	.	PASS	AN=0;DP=29	GT	0/1
chr5	77772515	77772515	C	T	UTR3	SCAMP1	NM_001290229:c.*1024C>T;NM_004866:c.*1024C>T	.	.	0.84227628	0.157111882	0.000611838	.	0.92895	0.10741	.	.	145.44918	2.62753	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	20	chr5	77772515	chr5:77772515	C	T	.	PASS	AN=0;DP=20	GT	0/1
chr5	90671341	90671341	C	T	exonic	ARRDC3	.	synonymous SNV	ARRDC3:NM_020801:exon4:c.G600A:p.K200K	0.978746962	0.021249266	3.77E-06	.	0.7962	0.13881	-0.095386216	46.48502005	15.79241	0.56251	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	34	chr5	90671341	chr5:90671341	C	T	.	PASS	AN=0;DP=34	GT	0/1
chr5	92920263	92920263	G	A	UTR5	NR2F1	NM_005654:c.-467G>A	.	.	.	.	.	DISEASE: Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) [MIM:615722]: An autosomal dominant disorder characterized by optic atrophy associated with developmental delay and intellectual disability. Most patients also have evidence of cerebral visual impairment. {ECO:0000269|PubMed:24462372}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.7496	0.11262	-0.339715008	30.06605331	3.34161	0.12228	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	13	chr5	92920263	chr5:92920263	G	A	.	PASS	AN=0;DP=13	GT	0/1
chr5	110842001	110842002	TG	-	intronic	STARD4	.	.	.	2.96E-07	0.173957488	0.826042216	.	0.12935	0.12152	-0.295622497	32.61972163	25.69887	0.83663	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	29	chr5	110842000	chr5:110842000	CTG	C	69	PASS	AN=2;DP=29	GT	0/1
chr5	112111396	112111396	C	T	exonic	APC	.	nonsynonymous SNV	APC:NM_001127511:exon4:c.C523T:p.L175F,APC:NM_000038:exon5:c.C493T:p.L165F,APC:NM_001127510:exon6:c.C493T:p.L165F	0.999999928	7.23E-08	1.20E-23	DISEASE: Familial adenomatous polyposis (FAP) [MIM:175100]: A cancer predisposition syndrome characterized by adenomatous polyps of the colon and rectum, but also of upper gastrointestinal tract (ampullary, duodenal and gastric adenomas). This is a viciously premalignant disease with one or more polyps progressing through dysplasia to malignancy in untreated gene carriers with a median age at diagnosis of 40 years. {ECO:0000269|PubMed:10470088, ECO:0000269|PubMed:1338691, ECO:0000269|PubMed:1338764, ECO:0000269|PubMed:1338904, ECO:0000269|PubMed:1651563, ECO:0000269|PubMed:7833149, ECO:0000269|PubMed:7833931, ECO:0000269|PubMed:8990002}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hereditary desmoid disease (HDD) [MIM:135290]: Autosomal dominant trait with 100% penetrance and possible variable expression among affected relatives. HDD patients show multifocal fibromatosis of the paraspinal muscles, breast, occiput, arms, lower ribs, abdominal wall, and mesentery. Desmoid tumors appears also as a complication of familial adenomatous polyposis. {ECO:0000269|PubMed:10782927, ECO:0000269|PubMed:8940264}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. {ECO:0000269|PubMed:10666372}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Mismatch repair cancer syndrome (MMRCS) [MIM:276300]: An autosomal recessive, rare, childhood cancer predisposition syndrome encompassing a broad tumor spectrum. This includes hematological malignancies, central nervous system tumors, Lynch syndrome-associated malignancies such as colorectal tumors as well as multiple intestinal polyps, embryonic tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature reminiscent of neurofibromatosis type 1, are often found as first manifestation of the underlying cancer. Areas of skin hypopigmentation have also been reported in MMRCS patients. {ECO:0000269|PubMed:7661930}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	0.53216	0.57092	-2.523543479	0.902335456	395.17068	4.17713	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.843	D	1.000	0.588	D	1.585	0.400	L	-1.58	0.820	D	-3.03	0.651	D	0.31	0.775	0.429	0.895	D	0.669	0.885	D	0.123	0.805	D	6.456	0.891	29.9	0.999	0.977	0.981	0.797	D	c	0.716	0.708	1.000	0.747	0.732	0.924	0	5.3	0.746	5.553	0.668	0.935	0.490	1.000	0.715	1.000	0.888	18.959	0.926	Adenomatous polyposis coli protein|Armadillo-like helical	.	.	0.5	.	32	chr5	112111396	chr5:112111396	C	T	.	PASS	AN=0;DP=32	GT	0/1
chr5	131325197	131325197	G	A	exonic	ACSL6	.	nonsynonymous SNV	ACSL6:NM_001009185:exon5:c.C455T:p.A152V,ACSL6:NM_001205247:exon5:c.C350T:p.A117V,ACSL6:NM_001205248:exon5:c.C380T:p.A127V,ACSL6:NM_001205250:exon5:c.C413T:p.A138V,ACSL6:NM_001205251:exon5:c.C275T:p.A92V,ACSL6:NM_015256:exon5:c.C455T:p.A152V	0.088562272	0.911422111	1.56E-05	DISEASE: Note=A chromosomal aberration involving ACSL6 may be a cause of myelodysplastic syndrome with basophilia. Translocation t(5;12)(q31;p13) with ETV6. {ECO:0000269|PubMed:10502316}.; DISEASE: Note=A chromosomal aberration involving ACSL6 may be a cause of acute myelogenous leukemia with eosinophilia. Translocation t(5;12)(q31;p13) with ETV6. {ECO:0000269|PubMed:10502316}.; DISEASE: Note=A chromosomal aberration involving ACSL6 may be a cause of acute eosinophilic leukemia (AEL). Translocation t(5;12)(q31;p13) with ETV6. {ECO:0000269|PubMed:10502316}.; 	0.05423	0.12209	-0.642904474	16.62538335	97.99912	2.13957	0.498	0.316	T	0.002	0.090	B	0.007	0.149	B	0.003	0.354	N	0.986	0.415	D	1.055	0.270	L	0.95	0.433	T	-0.77	0.463	N	0.064	0.472	-1.049	0.147	T	0.095	0.360	T	0.010	0.258	T	1.030	0.193	10.83	0.977	0.348	0.973	0.734	D	c	-0.320	-0.202	1.000	0.443	0.554	0.283	0	4.51	0.544	4.888	0.626	0.953	0.551	0.992	0.373	0.985	0.512	14.367	0.662	AMP-dependent synthetase/ligase	.	.	0.5	.	40	chr5	131325197	chr5:131325197	G	A	.	PASS	AN=0;DP=40	GT	0/1
chr5	133861381	133861381	G	A	UTR5	JADE2	NM_001289984:c.-10167G>A;NM_001289985:c.-4G>A	.	.	.	.	.	.	0.54969	0.1093	-0.484940685	22.75300778	183.73703	2.94069	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	50	chr5	133861381	chr5:133861381	G	A	.	PASS	AN=0;DP=50	GT	0/1
chr5	133916215	133916215	C	T	UTR3	JADE2	NM_001308143:c.*1208C>T;NM_001289984:c.*1208C>T;NM_001289985:c.*1208C>T;NM_015288:c.*1208C>T	.	.	.	.	.	.	0.54969	0.1093	-0.484940685	22.75300778	183.73703	2.94069	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	53	chr5	133916215	chr5:133916215	C	T	.	PASS	AN=0;DP=53	GT	0/1
chr5	142662264	142662264	C	T	exonic	NR3C1	.	nonsynonymous SNV	NR3C1:NM_000176:exon8:c.G2050A:p.E684K,NR3C1:NM_001018074:exon8:c.G2050A:p.E684K,NR3C1:NM_001018075:exon8:c.G2050A:p.E684K,NR3C1:NM_001018076:exon8:c.G2050A:p.E684K,NR3C1:NM_001018077:exon8:c.G2050A:p.E684K,NR3C1:NM_001020825:exon8:c.G2050A:p.E684K,NR3C1:NM_001024094:exon8:c.G2053A:p.E685K,NR3C1:NM_001204258:exon8:c.G1972A:p.E658K,NR3C1:NM_001204259:exon8:c.G1795A:p.E599K,NR3C1:NM_001204260:exon8:c.G1783A:p.E595K,NR3C1:NM_001204261:exon8:c.G1759A:p.E587K,NR3C1:NM_001204262:exon8:c.G1105A:p.E369K,NR3C1:NM_001204263:exon8:c.G1060A:p.E354K,NR3C1:NM_001204264:exon8:c.G1045A:p.E349K	0.311618466	0.688225337	0.000156198	DISEASE: Glucocorticoid resistance, generalized (GCCR) [MIM:615962]: An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety. {ECO:0000269|PubMed:11589680, ECO:0000269|PubMed:11701741, ECO:0000269|PubMed:12050230, ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:1704018, ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:7683692}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.99538	0.92999	-0.156065314	42.16206653	135.29579	2.53062	0.332	0.137	T	0.012	0.161	B	0.043	0.229	B	0.005	0.330	N	0.523	0.319	D	-1.15	0.009	N	-4.31	0.972	D	-0.72	0.204	N	0.214	0.281	-0.128	0.795	T	0.723	0.905	D	0.026	0.489	D	3.897	0.525	23.5	0.993	0.589	0.864	0.454	D	c	-0.221	0.006	1.000	0.432	0.707	0.730	0	4.66	0.577	0.540	0.227	0.928	0.438	0.991	0.370	0.999	0.750	10.239	0.423	Nuclear hormone receptor, ligand-binding domain	.	.	0.5	.	13	chr5	142662264	chr5:142662264	C	T	.	PASS	AN=0;DP=13	GT	0/1
chr5	168044008	168044008	C	T	intergenic	PANK3;SLIT3	dist=37394;dist=44730	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	166	chr5	168044008	chr5:168044008	C	T	.	PASS	AN=0;DP=166	GT	0/1
chr5	175957072	175957072	C	T	intronic	RNF44	.	.	.	0.567929658	0.431553355	0.000516987	.	0.35919	.	-0.179930907	40.35739561	104.3157	2.20769	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	143	chr5	175957072	chr5:175957072	C	T	.	PASS	AN=0;DP=143	GT	0/1
chr5	179049991	179049991	C	T	intronic	HNRNPH1	.	.	.	0.999148294	0.000851699	7.16E-09	.	0.83563	.	-0.273576253	33.97027601	18.26126	0.63463	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	271	chr5	179049991	chr5:179049991	C	T	.	PASS	AN=0;DP=271	GT	0/1
chr5	179050084	179050084	G	A	exonic	HNRNPH1	.	synonymous SNV	HNRNPH1:NM_001257293:exon2:c.C51T:p.G17G,HNRNPH1:NM_005520:exon2:c.C51T:p.G17G	0.999148294	0.000851699	7.16E-09	.	0.83563	.	-0.273576253	33.97027601	18.26126	0.63463	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	180	chr5	179050084	chr5:179050084	G	A	.	PASS	AN=0;DP=180	GT	0/1
chr5	180004133	180004133	C	T	UTR3	CNOT6	NM_001303241:c.*2933C>T	.	.	0.478458001	0.521329968	0.00021203	.	0.46135	0.12733	-0.291981272	33.20358575	52.51247	1.43432	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	26	chr5	180004133	chr5:180004133	C	T	.	PASS	AN=0;DP=26	GT	0/1
chr6	36169432	36169433	CC	-	exonic	BRPF3	.	frameshift deletion	BRPF3:NM_015695:exon2:c.1333_1334del:p.P445Qfs*42	0.993940981	0.006059011	7.11E-09	.	0.23528	0.10053	-1.059995566	7.537154989	446.92674	4.39883	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	31.94	17	chr6	36169431	chr6:36169431	GCC	G	31.94	PASS	AN=0;DP=17	GT	0/1
chr6	43222886	43222886	G	A	intronic	TTBK1	.	.	.	0.997306963	0.002693036	9.81E-10	.	0.26651	0.11543	-0.459259448	23.69072895	6694.9523	17.33817	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	31	chr6	43222886	chr6:43222886	G	A	.	PASS	AN=0;DP=31	GT	0/1
chr6	44437514	44437514	G	A	intergenic	CDC5L;LOC105375075	dist=19353;dist=76384	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	141	chr6	44437514	chr6:44437514	G	A	.	PASS	AN=0;DP=141	GT	0/1
chr6	49815815	49815815	G	A	intronic	CRISP1	.	.	.	0.000219402	0.741846921	0.257933677	.	0.02698	0.07066	-0.426079032	25.36565228	232.57631	3.29761	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	39	chr6	49815815	chr6:49815815	G	A	.	PASS	AN=0;DP=39	GT	0/1
chr6	50681714	50681714	C	T	UTR5	TFAP2D	NM_172238:c.-55C>T	.	.	0.981586998	0.018399928	1.31E-05	.	0.75149	0.14024	0.016664174	55.21939137	509.04894	4.62407	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	48	chr6	50681714	chr6:50681714	C	T	.	PASS	AN=0;DP=48	GT	0/1
chr6	111527961	111527961	C	T	intronic	SLC16A10	.	.	.	0.067607006	0.918407882	0.013985112	.	0.08076	0.10491	-0.049474214	50.01179523	216.00513	3.17412	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	19	chr6	111527961	chr6:111527961	C	T	.	PASS	AN=0;DP=19	GT	0/1
chr6	137325757	137325757	C	G	splicing	IL20RA	NM_014432:exon6:c.864+1G>C;NM_001278723:exon5:c.531+1G>C;NM_001278722:exon6:c.717+1G>C;NM_001278724:exon5:c.465+1G>C	.	.	0.007575317	0.977001984	0.015422699	.	0.13796	0.11768	0.376678994	75.50719509	564.20193	4.82236	.	.	.	.	.	.	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.099	0.687	25.3	0.994	0.638	0.965	0.693	D	c	1.062	0.903	0.999	0.399	0.054	0.004	0	5.29	0.743	4.088	0.572	0.790	0.321	1.000	0.715	0.991	0.552	14.451	0.668	.	.	.	0.5	70	42	chr6	137325757	chr6:137325757	C	G	70	PASS	AN=2;DP=42	GT	1/0
chr6	148835564	148835564	G	A	exonic	SASH1	.	synonymous SNV	SASH1:NM_001346507:exon2:c.G117A:p.V39V,SASH1:NM_001346508:exon2:c.G117A:p.V39V,SASH1:NM_001346505:exon9:c.G699A:p.V233V,SASH1:NM_015278:exon9:c.G834A:p.V278V,SASH1:NM_001346506:exon10:c.G462A:p.V154V	0.003254445	0.996741817	3.74E-06	.	0.3689	0.11167	-0.562239385	19.06699693	3939.62918	12.40945	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	68	chr6	148835564	chr6:148835564	G	A	.	PASS	AN=0;DP=68	GT	0/1
chr6	169625360	169625392	CCTGGTTGGCGTTGGAGATGTAGGGGCAGTTGT	-	exonic	THBS2	.	nonframeshift deletion	THBS2:NM_003247:exon18:c.2621_2653del:p.D874_Q884del	0.245000803	0.754998734	4.63E-07	.	0.74508	0.52113	-0.470420436	23.04788865	378.07788	4.09997	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	16	chr6	169625359	chr6:169625359	GCCTGGTTGGCGTTGGAGATGTAGGGGCAGTTGT	G	42	PASS	AN=2;DP=16	GT	0/1
chr7	1538589	1538589	C	-	intronic	INTS1	.	.	.	0.224121375	0.775878625	1.91E-10	.	0.15585	.	-5.050633482	0.070771408	422.05224	4.29253	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	41	chr7	1538588	chr7:1538588	AC	A	62	PASS	AN=2;DP=41	GT	0/1
chr7	1579980	1579980	C	-	exonic	MAFK	.	frameshift deletion	MAFK:NM_002360:exon3:c.440delC:p.T148Pfs*168	0.557286406	0.391983491	0.050730103	.	0.18771	0.13279	0.125076652	62.7388535	24.39748	0.80257	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	73	chr7	1579979	chr7:1579979	TC	T	58	PASS	AN=2;DP=73	GT	0/1
chr7	2284095	2284095	G	A	intronic	NUDT1	.	.	.	1.29E-09	0.01462753	0.985372469	.	0.4263	0.18011	-0.025608647	51.91672564	148.84611	2.6606	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	34	chr7	2284095	chr7:2284095	G	A	.	PASS	AN=0;DP=34	GT	0/1
chr7	2284171	2284171	G	A	intronic	NUDT1	.	.	.	1.29E-09	0.01462753	0.985372469	.	0.4263	0.18011	-0.025608647	51.91672564	148.84611	2.6606	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	68	chr7	2284171	chr7:2284171	G	A	.	PASS	AN=0;DP=68	GT	0/1
chr7	18631214	18631214	C	A	exonic	HDAC9	.	nonsynonymous SNV	HDAC9:NM_001204147:exon4:c.C389A:p.P130Q,HDAC9:NM_001204148:exon4:c.C398A:p.P133Q,HDAC9:NM_058176:exon4:c.C482A:p.P161Q,HDAC9:NM_178425:exon4:c.C491A:p.P164Q,HDAC9:NM_001204145:exon5:c.C482A:p.P161Q,HDAC9:NM_001204146:exon5:c.C491A:p.P164Q,HDAC9:NM_001321874:exon5:c.C491A:p.P164Q,HDAC9:NM_001321875:exon5:c.C497A:p.P166Q,HDAC9:NM_001321876:exon5:c.C491A:p.P164Q,HDAC9:NM_001321877:exon5:c.C491A:p.P164Q,HDAC9:NM_001321878:exon5:c.C482A:p.P161Q,HDAC9:NM_001321879:exon5:c.C491A:p.P164Q,HDAC9:NM_001321884:exon5:c.C491A:p.P164Q,HDAC9:NM_001321885:exon5:c.C506A:p.P169Q,HDAC9:NM_001321888:exon5:c.C482A:p.P161Q,HDAC9:NM_001321890:exon5:c.C482A:p.P161Q,HDAC9:NM_001321891:exon5:c.C482A:p.P161Q,HDAC9:NM_001321895:exon5:c.C491A:p.P164Q,HDAC9:NM_001321898:exon5:c.C506A:p.P169Q,HDAC9:NM_001321900:exon5:c.C482A:p.P161Q,HDAC9:NM_001321901:exon5:c.C491A:p.P164Q,HDAC9:NM_001321902:exon5:c.C491A:p.P164Q,HDAC9:NM_014707:exon5:c.C482A:p.P161Q,HDAC9:NM_178423:exon5:c.C482A:p.P161Q,HDAC9:NM_001321868:exon6:c.C548A:p.P183Q,HDAC9:NM_001321869:exon6:c.C557A:p.P186Q,HDAC9:NM_001321870:exon6:c.C548A:p.P183Q,HDAC9:NM_001321871:exon6:c.C563A:p.P188Q,HDAC9:NM_001321872:exon6:c.C557A:p.P186Q,HDAC9:NM_001321873:exon6:c.C557A:p.P186Q,HDAC9:NM_001321886:exon6:c.C389A:p.P130Q,HDAC9:NM_001321887:exon6:c.C398A:p.P133Q,HDAC9:NM_001321889:exon6:c.C398A:p.P133Q,HDAC9:NM_001321893:exon6:c.C482A:p.P161Q,HDAC9:NM_001321894:exon6:c.C491A:p.P164Q,HDAC9:NM_001321896:exon6:c.C398A:p.P133Q,HDAC9:NM_001321897:exon6:c.C491A:p.P164Q,HDAC9:NM_001321899:exon6:c.C491A:p.P164Q,HDAC9:NM_001204144:exon7:c.C608A:p.P203Q	0.998375125	0.001624875	1.17E-11	DISEASE: Note=A chromosomal aberration involving HDAC9 is found in a family with Peters anomaly. Translocation t(1;7)(q41;p21) with TGFB2 resulting in lack of HDAC9 protein. {ECO:0000269|PubMed:12706107}.; 	0.93284	0.71489	-1.061810361	7.519462137	78.75617	1.8735	0.015	0.524	D	0.553	0.500	P	0.146	0.460	B	0.000	0.629	D	0.634	0.345	D	1.7	0.440	L	0.97	0.570	T	-1.32	0.350	N	0.36	0.437	-0.586	0.654	T	0.165	0.502	T	0.011	0.284	T	3.935	0.530	23.5	0.990	0.494	0.980	0.783	D	c	0.357	0.452	1.000	0.747	0.732	0.924	0	5.74	0.900	1.680	0.370	0.935	0.490	1.000	0.715	1.000	0.888	13.172	0.589	.	.	.	0.5	.	29	chr7	18631214	chr7:18631214	C	A	.	PASS	AN=0;DP=29	GT	0/1
chr7	44805177	44805177	G	A	exonic	ZMIZ2	.	synonymous SNV	ZMIZ2:NM_174929:exon14:c.G2163A:p.Q721Q,ZMIZ2:NM_001300959:exon15:c.G2067A:p.Q689Q,ZMIZ2:NM_031449:exon16:c.G2241A:p.Q747Q	0.999620382	0.000379618	4.09E-11	.	0.21655	0.09565	-0.08446956	47.15145081	1705.86311	7.61894	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	46	chr7	44805177	chr7:44805177	G	A	.	PASS	AN=0;DP=46	GT	0/1
chr7	65445227	65445227	T	A	exonic	GUSB	.	nonsynonymous SNV	GUSB:NM_000181:exon2:c.A380T:p.H127L,GUSB:NM_001284290:exon2:c.A380T:p.H127L	4.07E-05	0.997935444	0.002023856	DISEASE: Mucopolysaccharidosis 7 (MPS7) [MIM:253220]: An autosomal recessive lysosomal storage disease characterized by inability to degrade glucuronic acid-containing glycosaminoglycans. The phenotype is highly variable, ranging from severe lethal hydrops fetalis to mild forms with survival into adulthood. Most patients with the intermediate phenotype show hepatomegaly, skeletal anomalies, coarse facies, and variable degrees of mental impairment. {ECO:0000269|PubMed:12522561, ECO:0000269|PubMed:12859417, ECO:0000269|PubMed:1702266, ECO:0000269|PubMed:7573038, ECO:0000269|PubMed:7633414, ECO:0000269|PubMed:7680524, ECO:0000269|PubMed:8089138, ECO:0000269|PubMed:8111412, ECO:0000269|PubMed:8111413, ECO:0000269|PubMed:8644704, ECO:0000269|PubMed:8707294, ECO:0000269|PubMed:9099834, ECO:0000269|PubMed:9490302}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.1733	.	-0.821100135	11.88369899	22.67372	0.75898	0.052	0.390	T	1.0	0.899	D	0.977	0.722	D	0.000	0.843	D	1	0.810	D	2.975	0.857	M	-2.44	0.888	D	-7.29	0.944	D	0.901	0.894	0.834	0.948	D	0.829	0.943	D	0.475	0.948	D	5.659	0.771	26.7	0.964	0.293	0.958	0.661	D	c	0.688	0.592	1.000	0.747	0.722	0.854	0	5.22	0.722	7.419	0.792	1.024	0.645	1.000	0.715	0.853	0.356	14.303	0.658	Galactose-binding domain-like|Glycosyl hydrolases family 2, sugar binding domain	.	.	0.5	.	135	chr7	65445227	chr7:65445227	T	A	.	PASS	AN=0;DP=135	GT	0/1
chr7	65445258	65445258	T	A	exonic	GUSB	.	nonsynonymous SNV	GUSB:NM_000181:exon2:c.A349T:p.T117S,GUSB:NM_001284290:exon2:c.A349T:p.T117S,GUSB:NM_001293105:exon2:c.A20T:p.H7L	4.07E-05	0.997935444	0.002023856	DISEASE: Mucopolysaccharidosis 7 (MPS7) [MIM:253220]: An autosomal recessive lysosomal storage disease characterized by inability to degrade glucuronic acid-containing glycosaminoglycans. The phenotype is highly variable, ranging from severe lethal hydrops fetalis to mild forms with survival into adulthood. Most patients with the intermediate phenotype show hepatomegaly, skeletal anomalies, coarse facies, and variable degrees of mental impairment. {ECO:0000269|PubMed:12522561, ECO:0000269|PubMed:12859417, ECO:0000269|PubMed:1702266, ECO:0000269|PubMed:7573038, ECO:0000269|PubMed:7633414, ECO:0000269|PubMed:7680524, ECO:0000269|PubMed:8089138, ECO:0000269|PubMed:8111412, ECO:0000269|PubMed:8111413, ECO:0000269|PubMed:8644704, ECO:0000269|PubMed:8707294, ECO:0000269|PubMed:9099834, ECO:0000269|PubMed:9490302}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.1733	.	-0.821100135	11.88369899	22.67372	0.75898	0.617	0.060	T	0.192	0.278	B	0.111	0.300	B	0.000	0.452	D	1	0.090	N	1.92	0.515	L	-3.46	0.945	D	-1.2	0.346	N	0.161	0.193	0.020	0.827	D	0.724	0.906	D	0.245	0.889	D	-0.461	0.058	0.275	0.913	0.200	0.495	0.282	N	c	-0.440	-0.430	1.000	0.747	0.707	0.730	0	5.22	0.722	2.719	0.467	1.024	0.645	0.189	0.240	0.057	0.169	10.354	0.429	Galactose-binding domain-like|Glycosyl hydrolases family 2, sugar binding domain	.	.	0.5	.	123	chr7	65445258	chr7:65445258	T	A	.	PASS	AN=0;DP=123	GT	0/1
chr7	72338211	72338211	G	A	ncRNA_intronic	SPDYE7P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	114	chr7	72338211	chr7:72338211	G	A	.	PASS	AN=0;DP=114	GT	0/1
chr7	101936424	101936424	G	A	ncRNA_exonic	MIR4285	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	64	chr7	101936424	chr7:101936424	G	A	.	PASS	AN=0;DP=64	GT	0/1
chr7	102213302	102213302	G	A	upstream	POLR2J3	dist=234	.	.	.	.	.	.	.	0.09141	.	.	170.88018	2.85115	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	417	chr7	102213302	chr7:102213302	G	A	.	PASS	AN=0;DP=417	GT	0/1
chr7	104753296	104753296	C	T	exonic	KMT2E	.	nonsynonymous SNV	KMT2E:NM_018682:exon26:c.C5093T:p.T1698I,KMT2E:NM_182931:exon27:c.C5093T:p.T1698I	0.999999995	5.30E-09	1.49E-21	.	0.43067	0.11436	-1.449682288	3.904222694	397.35924	4.18819	0.002	0.721	D	0.527	0.358	P	0.123	0.309	B	0.119	0.191	U	0.991	0.240	N	0.345	0.112	N	-3.01	0.922	D	-0.77	0.214	N	0.121	0.135	-0.069	0.808	T	0.490	0.806	T	0.193	0.863	D	2.375	0.347	18.66	0.896	0.184	0.960	0.668	D	c	-0.279	-0.155	1.000	0.747	0.672	0.522	0	2.99	0.335	3.171	0.503	0.881	0.386	0.110	0.228	1.000	0.888	14.818	0.695	.	.	.	0.5	.	64	chr7	104753296	chr7:104753296	C	T	.	PASS	AN=0;DP=64	GT	0/1
chr7	107688549	107688549	C	T	exonic	LAMB4	.	nonsynonymous SNV	LAMB4:NM_001318046:exon28:c.G4130A:p.G1377E,LAMB4:NM_007356:exon28:c.G4130A:p.G1377E	3.21E-30	0.002614573	0.997385427	.	0.09686	0.26112	-1.552781294	3.237791932	3441.9669	11.26972	0.002	0.721	D	1.0	0.899	D	0.998	0.916	D	0.009	0.303	N	1.000	0.492	D	1.955	0.530	M	0.98	0.421	T	-7.04	0.950	D	0.564	0.597	-0.763	0.573	T	0.192	0.545	T	0.021	0.442	T	5.092	0.686	25.3	0.994	0.621	0.909	0.521	D	c	0.193	0.074	1.000	0.747	0.487	0.133	0	4.48	0.538	3.525	0.530	0.664	0.294	0.976	0.346	0.011	0.114	16.956	0.861	Laminin EGF domain	.	.	0.5	.	62	chr7	107688549	chr7:107688549	C	T	.	PASS	AN=0;DP=62	GT	0/1
chr7	107688557	107688557	C	T	splicing	LAMB4	NM_001318046:exon28:c.4123-1G>A;NM_007356:exon28:c.4123-1G>A	.	.	3.21E-30	0.002614573	0.997385427	.	0.09686	0.26112	-1.552781294	3.237791932	3441.9669	11.26972	.	.	.	.	.	.	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2.467	0.358	19.26	0.917	0.204	0.784	0.384	D	c	0.510	0.212	0.609	0.218	0.074	0.012	0	2.68	0.307	2.596	0.456	0.664	0.294	1.000	0.715	0.249	0.227	10.102	0.415	.	.	.	0.5	.	59	chr7	107688557	chr7:107688557	C	T	.	PASS	AN=0;DP=59	GT	0/1
chr7	130080669	130080669	C	T	intronic	CEP41	.	.	.	0.000125629	0.956230668	0.043643703	DISEASE: Joubert syndrome 15 (JBTS15) [MIM:614464]: An autosomal recessive disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy, renal disease, liver fibrosis and polydactyly. {ECO:0000269|PubMed:22246503}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Genetic variations in CEP41 may be associated with susceptibility to autism (PubMed:21438139). {ECO:0000269|PubMed:21438139}.; 	0.35352	0.12266	0.551232944	81.48148148	110.55518	2.28931	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	73	chr7	130080669	chr7:130080669	C	T	.	PASS	AN=0;DP=73	GT	0/1
chr7	131113757	131113757	T	-	intronic	MKLN1	.	.	.	0.999577505	0.000422495	5.31E-11	.	0.35761	0.14611	-0.427900189	25.14744043	19.26303	0.66403	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	17	chr7	131113756	chr7:131113756	CT	C	43	PASS	AN=2;DP=17	GT	0/1
chr7	140508052	140508052	C	T	intronic	BRAF	.	.	.	0.999978196	2.18E-05	3.88E-14	DISEASE: Note=Defects in BRAF are found in a wide range of cancers. {ECO:0000269|PubMed:18974108}.; DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:23263490, ECO:0000269|PubMed:24455489}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation. {ECO:0000269|PubMed:18974108}.; 	0.95401	.	-0.60427181	17.74593064	63.2093	1.62731	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	53	chr7	140508052	chr7:140508052	C	T	.	PASS	AN=0;DP=53	GT	0/1
chr7	142120111	142120111	G	T	intergenic	TRY2P;MTRNR2L6	dist=148043;dist=254020	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	20	chr7	142120111	chr7:142120111	G	T	.	PASS	AN=0;DP=20	GT	0/1
chr7	149485964	149486017	CTTTGTGACAACCAGGACGACTGTGGCGATGGCTCTGATGAGGAGGGTGAGTGT	-	exonic	SSPO	.	frameshift deletion	SSPO:NM_198455:exon29:c.4183_4228del:p.L1395Vfs*10	.	.	.	.	0.20432	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	11.79	15	chr7	149485963	chr7:149485963	GCTTTGTGACAACCAGGACGACTGTGGCGATGGCTCTGATGAGGAGGGTGAGTGT	G	11.79	PASS	AN=0;DP=15	GT	0/1
chr8	169317	169317	C	-	ncRNA_exonic	RPL23AP53	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	40	chr8	169316	chr8:169316	TC	T	53	PASS	AN=2;DP=40	GT	0/1
chr8	10753654	10753654	T	-	downstream	XKR6	dist=3	.	.	0.956776701	0.043218854	4.45E-06	.	0.31948	0.1039	-0.824740496	11.67728238	40.49271	1.18751	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	31	chr8	10753653	chr8:10753653	CT	C	54	PASS	AN=2;DP=31	GT	0/1
chr8	12881517	12881517	A	G	UTR3	KIAA1456	NM_020844:c.*1964A>G;NM_001099677:c.*1964A>G	.	.	.	.	.	.	0.08688	0.08809	0.428052693	77.31186601	330.03285	3.86068	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	36	chr8	12881517	chr8:12881517	A	G	41	PASS	AN=2;DP=36	GT	0/1
chr8	29996158	29996158	A	G	exonic	MBOAT4	.	synonymous SNV	MBOAT4:NM_001100916:exon2:c.T234C:p.A78A	.	.	.	.	0.23427	0.10875	1.23654218	93.29440906	215.80004	3.17043	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	8	chr8	29996158	chr8:29996158	A	G	52	PASS	AN=2;DP=8	GT	1/0
chr8	75148840	75148841	CC	-	UTR3	JPH1	NM_001317830:c.*166_*165delGG;NM_020647:c.*446_*445delGG	.	.	0.706129633	0.293141818	0.00072855	.	0.62199	0.14032	0.090079492	60.64519934	307.58841	3.73294	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	34	chr8	75148839	chr8:75148839	TCC	T	61	PASS	AN=2;DP=34	GT	0/1
chr8	104863776	104863776	C	T	intronic	RIMS2	.	.	.	0.999998399	1.60E-06	1.12E-19	.	0.85345	0.13067	-0.5879134	18.28261382	2152.14667	8.53415	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	15	chr8	104863776	chr8:104863776	C	T	.	PASS	AN=0;DP=15	GT	0/1
chr8	116422130	116422130	C	T	UTR3	TRPS1	NM_001282902:c.*4121G>A;NM_014112:c.*4121G>A;NM_001330599:c.*4121G>A;NM_001282903:c.*4121G>A	.	.	0.990109018	0.009890959	2.36E-08	DISEASE: Tricho-rhino-phalangeal syndrome 1 (TRPS1) [MIM:190350]: Autosomal dominant disorder characterized by craniofacial and skeletal abnormalities. It is allelic with tricho-rhino-phalangeal type 3. Typical features include sparse scalp hair, a bulbous tip of the nose, protruding ears, a long flat philtrum and a thin upper vermilion border. Skeletal defects include cone-shaped epiphyses at the phalanges, hip malformations and short stature. {ECO:0000269|PubMed:14560312}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Tricho-rhino-phalangeal syndrome 2 (TRPS2) [MIM:150230]: A syndrome that combines the clinical features of tricho-rhino- phalangeal syndrome type 1 and multiple exostoses type 1. Affected individuals manifest multiple dysmorphic facial features including large, laterally protruding ears, a bulbous nose, an elongated upper lip, as well as sparse scalp hair, winged scapulae, multiple cartilaginous exostoses, redundant skin, and mental retardation. Note=The gene represented in this entry is involved in disease pathogenesis. A chromosomal aberration resulting in the loss of functional copies of TRPS1 and EXT1 has been found in TRPS2 patients.; DISEASE: Tricho-rhino-phalangeal syndrome 3 (TRPS3) [MIM:190351]: Autosomal dominant disorder characterized by craniofacial and skeletal abnormalities. It is allelic with tricho-rhino-phalangeal type 1. In TRPS3 a more severe brachydactyly and growth retardation are observed. {ECO:0000269|PubMed:11112658, ECO:0000269|PubMed:11807863}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.66817	0.13373	-1.747196778	2.359046945	118.19802	2.36482	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	45	chr8	116422130	chr8:116422130	C	T	.	PASS	AN=0;DP=45	GT	0/1
chr8	128750605	128750607	CAG	-	exonic	MYC	.	nonframeshift deletion	MYC:NM_002467:exon2:c.142_144del:p.Q52del	.	.	.	DISEASE: Note=A chromosomal aberration involving MYC may be a cause of a form of B-cell chronic lymphocytic leukemia. Translocation t(8;12)(q24;q22) with BTG1. {ECO:0000269|PubMed:2069907}.; DISEASE: Burkitt lymphoma (BL) [MIM:113970]: A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. {ECO:0000269|PubMed:2166998, ECO:0000269|PubMed:8220424}. Note=The gene represented in this entry is involved in disease pathogenesis. Chromosomal aberrations involving MYC are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22) or t(2;8) which juxtapose MYC to one of the heavy or light chain immunoglobulin gene loci.; 	0.70121	0.98749	-0.003562597	53.72729417	227.85179	3.25935	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	56	chr8	128750604	chr8:128750604	CCAG	C	42	PASS	AN=2;DP=56	GT	0/1
chr8	135725032	135725032	C	T	intronic	ZFAT	.	.	.	0.002928673	0.996965027	0.0001063	.	0.06704	0.1068	-0.385854854	27.08185893	876.35347	5.76073	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	27	chr8	135725032	chr8:135725032	C	T	.	PASS	AN=0;DP=27	GT	0/1
chr8	144801452	144801452	G	A	intronic	MAPK15	.	.	.	1.29E-16	0.002878183	0.997121817	.	0.15685	0.17839	0.565800595	81.72918141	972.94541	6.02994	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	240	chr8	144801452	chr8:144801452	G	A	.	PASS	AN=0;DP=240	GT	0/1
chr8	144887012	144887012	G	A	intronic	SCRIB	.	.	.	0.913273181	0.086726818	1.78E-09	DISEASE: Neural tube defects (NTD) [MIM:182940]: Congenital malformations of the central nervous system and adjacent structures related to defective neural tube closure during the first trimester of pregnancy. Failure of neural tube closure can occur at any level of the embryonic axis. Common NTD forms include anencephaly, myelomeningocele and spina bifida, which result from the failure of fusion in the cranial and spinal region of the neural tube. NTDs have a multifactorial etiology encompassing both genetic and environmental components. {ECO:0000269|PubMed:22095531}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.42375	0.13468	-2.440554124	1.026185421	1336.78509	6.86559	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	168	chr8	144887012	chr8:144887012	G	A	.	PASS	AN=0;DP=168	GT	0/1
chr8	144887074	144887074	T	A	intronic	SCRIB	.	.	.	0.913273181	0.086726818	1.78E-09	DISEASE: Neural tube defects (NTD) [MIM:182940]: Congenital malformations of the central nervous system and adjacent structures related to defective neural tube closure during the first trimester of pregnancy. Failure of neural tube closure can occur at any level of the embryonic axis. Common NTD forms include anencephaly, myelomeningocele and spina bifida, which result from the failure of fusion in the cranial and spinal region of the neural tube. NTDs have a multifactorial etiology encompassing both genetic and environmental components. {ECO:0000269|PubMed:22095531}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.42375	0.13468	-2.440554124	1.026185421	1336.78509	6.86559	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	59	chr8	144887074	chr8:144887074	T	A	.	PASS	AN=0;DP=59	GT	0/1
chr8	144919516	144919516	G	A	intronic	NRBP2	.	.	.	0.002412945	0.92737531	0.070211744	.	0.14009	.	.	.	302.68543	3.70523	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	59	chr8	144919516	chr8:144919516	G	A	.	PASS	AN=0;DP=59	GT	0/1
chr8	145537492	145537492	C	G	intronic	HSF1	.	.	.	0.586374295	0.413181557	0.000444148	.	0.11458	0.16496	-0.865195027	10.79853739	350.11867	3.96676	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	92	chr8	145537492	chr8:145537492	C	G	64	PASS	AN=2;DP=92	GT	0/1
chr8	145542674	145542674	C	T	intronic	DGAT1	.	.	.	2.90E-10	0.274285644	0.725714356	DISEASE: Diarrhea 7 (DIAR7) [MIM:615863]: A life-threatening disease characterized by severe, intractable, watery diarrhea. {ECO:0000269|PubMed:23114594}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.21291	0.34238	-0.841329384	11.36470866	296.55679	3.67459	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	68	chr8	145542674	chr8:145542674	C	T	.	PASS	AN=0;DP=68	GT	0/1
chr8	145755800	145755800	C	-	UTR3	ARHGAP39	NM_025251:c.*6delG;NM_001308207:c.*6delG;NM_001308208:c.*6delG	.	.	0.001681796	0.997152661	0.001165542	.	.	.	-1.390744555	4.305260675	202.55456	3.07112	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	44	chr8	145755799	chr8:145755799	GC	G	43	PASS	AN=2;DP=44	GT	0/1
chr8	145756062	145756062	G	A	intronic	ARHGAP39	.	.	.	0.001681796	0.997152661	0.001165542	.	.	.	-1.390744555	4.305260675	202.55456	3.07112	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	124	chr8	145756062	chr8:145756062	G	A	.	PASS	AN=0;DP=124	GT	0/1
chr9	33071757	33071757	G	A	exonic	SMU1	.	nonsynonymous SNV	SMU1:NM_018225:exon3:c.C371T:p.S124F	0.998978044	0.001021944	1.12E-08	.	0.19476	0.14163	-0.141298762	42.87567823	5.43983	0.20203	0.008	0.586	D	0.859	0.453	P	0.62	0.495	P	0.000	0.843	D	1	0.810	D	2.84	0.828	M	0.57	0.544	T	-3.96	0.735	D	0.668	0.679	-0.338	0.739	T	0.309	0.680	T	0.051	0.646	D	6.539	0.900	31	0.999	0.929	0.998	0.994	D	c	0.821	0.826	1.000	0.747	0.732	0.924	0	5.47	0.803	9.810	0.983	0.998	0.613	1.000	0.715	1.000	0.888	17.187	0.867	.	.	.	0.5	.	19	chr9	33071757	chr9:33071757	G	A	.	PASS	AN=0;DP=19	GT	0/1
chr9	36052363	36052363	T	C	intronic	RECK	.	.	.	0.000196798	0.999760397	4.28E-05	.	0.37337	0.19959	-0.951568548	9.271054494	1398.34528	6.99259	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	22	chr9	36052363	chr9:36052363	T	C	42	PASS	AN=2;DP=22	GT	0/1
chr9	71849367	71849367	G	A	exonic	TJP2	.	nonsynonymous SNV	TJP2:NM_001170415:exon12:c.G1696A:p.D566N,TJP2:NM_001170416:exon12:c.G1777A:p.D593N,TJP2:NM_004817:exon12:c.G1684A:p.D562N,TJP2:NM_201629:exon12:c.G1684A:p.D562N,TJP2:NM_001170414:exon13:c.G1615A:p.D539N	6.24E-07	0.999943176	5.62E-05	DISEASE: Cholestasis, progressive familial intrahepatic, 4 (PFIC4) [MIM:615878]: A disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease before adulthood. {ECO:0000269|PubMed:24614073}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.30256	0.24991	1.458702267	95.175749	1977.00591	8.193	0.053	0.430	T	0.687	0.899	P	0.301	0.875	B	0.000	0.843	D	1	0.810	D	0.94	0.237	L	0.7	0.515	T	-3.45	0.685	D	0.134	0.293	-0.713	0.598	T	0.267	0.638	T	0.012	0.294	T	4.658	0.624	24.5	0.999	0.984	0.996	0.982	D	c	0.660	0.717	1.000	0.747	0.732	0.924	0	5.45	0.796	9.803	0.982	0.953	0.551	1.000	0.715	1.000	0.888	19.655	0.958	PDZ domain	.	.	0.5	.	19	chr9	71849367	chr9:71849367	G	A	.	PASS	AN=0;DP=19	GT	0/1
chr9	86894167	86894167	A	-	intronic	SLC28A3	.	.	.	1.96E-17	0.006793446	0.993206554	.	0.17401	0.11684	0.846940207	88.47605567	2204.23741	8.64325	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	55	chr9	86894166	chr9:86894166	CA	C	69	PASS	AN=2;DP=55	GT	0/1
chr9	105751516	105751516	A	G	intergenic	LINC00587;CYLC2	dist=331725;dist=6077	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	30	chr9	105751516	chr9:105751516	A	G	.	PASS	AN=0;DP=30	GT	0/1
chr9	123715023	123715023	T	C	exonic	C5	.	synonymous SNV	C5:NM_001317163:exon41:c.A5043G:p.G1681G,C5:NM_001735:exon41:c.A5025G:p.G1675G	5.61E-11	0.999999829	1.71E-07	DISEASE: Complement component 5 deficiency (C5D) [MIM:609536]: A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele. {ECO:0000269|PubMed:15995705}.; 	0.25448	0.15814	-0.051509809	49.39254541	5639.16587	15.54132	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	20	chr9	123715023	chr9:123715023	T	C	.	PASS	AN=0;DP=20	GT	0/1
chr9	125866165	125866165	C	T	UTR3	RABGAP1	NM_012197:c.*673C>T	.	.	0.9999998	2.00E-07	1.04E-17	.	0.29209	0.11542	-1.50825116	3.503184713	121.41418	2.40018	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	45	chr9	125866165	chr9:125866165	C	T	.	PASS	AN=0;DP=45	GT	0/1
chr9	132982937	132982937	C	T	intronic	NCS1	.	.	.	0.947220876	0.052601383	0.000177741	.	0.18713	0.18619	-0.141298762	42.87567823	2.47706	0.0911	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	41	chr9	132982937	chr9:132982937	C	T	.	PASS	AN=0;DP=41	GT	0/1
chr9	133271585	133271585	G	C	exonic	HMCN2	.	unknown	UNKNOWN	.	.	.	.	0.12716	.	.	.	2669.68768	9.71594	.	.	.	0.627	0.382	P	0.399	0.427	B	.	.	.	.	.	.	0.15	0.089	N	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-0.781	0.041	0.047	0.411	0.029	0.102	0.156	N	n	-0.008	1.149	0.998	0.358	0.253	0.035	0	-9.45	0.005	-1.542	0.023	-1.392	0.012	0.000	0.063	0.000	0.016	6.662	0.221	Immunoglobulin I-set|Immunoglobulin subtype|Immunoglobulin-like domain|Immunoglobulin-like fold	.	.	0.5	62	189	chr9	133271585	chr9:133271585	G	C	62	PASS	AN=2;DP=189	GT	0/1
chr10	11797352	11797352	G	A	intronic	ECHDC3	.	.	.	0.000536786	0.458749649	0.540713565	.	0.12334	0.16358	0.420771676	77.15852795	961.97162	6.0042	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	106	chr10	11797352	chr10:11797352	G	A	.	PASS	AN=0;DP=106	GT	0/1
chr10	12068570	12068570	C	T	intronic	UPF2	.	.	.	0.999998269	1.73E-06	8.11E-17	.	0.89697	.	-0.885424753	10.4623732	286.42271	3.62468	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	80	chr10	12068570	chr10:12068570	C	T	.	PASS	AN=0;DP=80	GT	0/1
chr10	21807709	21807709	G	T	UTR5	SKIDA1	NM_207371:c.-958C>A	.	.	.	.	.	.	0.891	.	.	.	438.2434	4.36472	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	30	chr10	21807709	chr10:21807709	G	T	.	PASS	AN=0;DP=30	GT	0/1
chr10	42922650	42922651	TA	-	ncRNA_intronic	CCNYL2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	28	chr10	42922649	chr10:42922649	GTA	G	60	PASS	AN=2;DP=28	GT	0/1
chr10	63661555	63661555	C	T	intronic	ARID5B	.	.	.	0.999889943	0.000110057	4.89E-11	DISEASE: Note=Defects in ARID5B may be a cause of susceptibility to coronary atherosclerosis in the Japanese population.; DISEASE: Leukemia, acute lymphoblastic (ALL) [MIM:613065]: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphonodes. {ECO:0000269|PubMed:19684603, ECO:0000269|PubMed:19684604, ECO:0000269|PubMed:20042726, ECO:0000269|PubMed:20054350, ECO:0000269|PubMed:20189245, ECO:0000269|PubMed:20460642, ECO:0000269|PubMed:21098271}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.79023	0.1136	-1.03794674	7.832035858	133.85694	2.51593	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	124	chr10	63661555	chr10:63661555	C	T	.	PASS	AN=0;DP=124	GT	0/1
chr10	79163748	79163780	CCTGGCTTGAGCCATTGTTAATCTTCTGGGCCT	-	exonic	KCNMA1	.	nonframeshift deletion	KCNMA1:NM_001014797:exon2:c.380_412del:p.E127_Q137del,KCNMA1:NM_001161352:exon2:c.380_412del:p.E127_Q137del,KCNMA1:NM_001161353:exon2:c.380_412del:p.E127_Q137del,KCNMA1:NM_001271519:exon2:c.380_412del:p.E127_Q137del,KCNMA1:NM_001322829:exon2:c.380_412del:p.E127_Q137del,KCNMA1:NM_001322830:exon2:c.380_412del:p.E127_Q137del,KCNMA1:NM_001322832:exon2:c.380_412del:p.E127_Q137del,KCNMA1:NM_001322835:exon2:c.380_412del:p.E127_Q137del,KCNMA1:NM_001322836:exon2:c.380_412del:p.E127_Q137del,KCNMA1:NM_001322837:exon2:c.380_412del:p.E127_Q137del,KCNMA1:NM_002247:exon2:c.380_412del:p.E127_Q137del	0.999216603	0.000783397	1.98E-12	DISEASE: Generalized epilepsy and paroxysmal dyskinesia (GEPD) [MIM:609446]: Epilepsy is one of the most common and debilitating neurological disorders. Paroxysmal dyskinesias are neurological disorders characterized by sudden, unpredictable, disabling attacks of involuntary movement often requiring life-long treatment. The coexistence of epilepsy and paroxysmal dyskinesia in the same individual or family is an increasingly recognized phenomenon. Patients manifest absence seizures, generalized tonic- clonic seizures, paroxysmal nonkinesigenic dyskinesia, involuntary dystonic or choreiform movements. Onset is usually in childhood and patients may have seizures only, dyskinesia only, or both. {ECO:0000269|PubMed:15937479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.76173	0.14035	-1.682848699	2.653927813	154.36657	2.71502	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	12.8	19	chr10	79163747	chr10:79163747	GCCTGGCTTGAGCCATTGTTAATCTTCTGGGCCT	G	12.8	PASS	AN=0;DP=19	GT	0/1
chr10	81273578	81273578	C	-	UTR3	EIF5AL1	NM_001099692:c.*708delC	.	.	.	.	.	.	.	0.29774	.	.	18.72537	0.64596	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	23.07	77	chr10	81273577	chr10:81273577	TC	T	23.07	PASS	AN=0;DP=77	GT	0/1
chr10	93809881	93809881	T	C	UTR3	CPEB3	NM_001178137:c.*2088A>G;NM_014912:c.*2088A>G	.	.	0.994664052	0.005335821	1.27E-07	.	0.78253	0.1114	-0.426079032	25.36565228	524.24587	4.67134	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	25	chr10	93809881	chr10:93809881	T	C	.	PASS	AN=0;DP=25	GT	0/1
chr10	120631623	120631623	C	T	intergenic	CACUL1;NANOS1	dist=116865;dist=157605	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	20	chr10	120631623	chr10:120631623	C	T	.	PASS	AN=0;DP=20	GT	0/1
chr11	372810	372810	G	A	intronic	B4GALNT4	.	.	.	0.816930491	0.183069195	3.15E-07	.	0.13468	0.09235	.	.	1517.92316	7.2418	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	57	chr11	372810	chr11:372810	G	A	.	PASS	AN=0;DP=57	GT	0/1
chr11	792780	792780	A	G	intronic	SLC25A22	.	.	.	0.568405565	0.42907803	0.002516405	.	0.4027	0.12155	0.128714042	63.19886766	219.59154	3.20559	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	84	128	chr11	792780	chr11:792780	A	G	84	PASS	AN=2;DP=128	GT	0/1
chr11	1031096	1031096	C	T	intronic	MUC6	.	.	.	1.09E-32	4.75E-05	0.999952489	.	0.16113	0.17704	1.26225728	93.56569946	5602.29835	15.48599	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	59	chr11	1031096	chr11:1031096	C	T	.	PASS	AN=0;DP=59	GT	0/1
chr11	1457375	1457375	C	T	intronic	BRSK2	.	.	.	0.779570081	0.220416998	1.29E-05	.	0.16676	0.10676	-1.506435464	3.544468035	64.45039	1.64641	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	40	chr11	1457375	chr11:1457375	C	T	.	PASS	AN=0;DP=40	GT	0/1
chr11	4116260	4116291	AGGTGAGGGGGGGACGAGGTGGGCGAGAAGGA	-	exonic	RRM1	.	frameshift deletion	RRM1:NM_001033:exon1:c.18_19del:p.D7Wfs*8	0.999994804	5.20E-06	2.88E-14	.	0.9905	0.35194	-0.644723694	16.52512385	49.59769	1.37845	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	22.24	21	chr11	4116259	chr11:4116259	GAGGTGAGGGGGGGACGAGGTGGGCGAGAAGGA	G	22.24	PASS	AN=0;DP=21	GT	0/1
chr11	12400051	12400051	C	T	intronic	PARVA	.	.	.	0.34376402	0.655640245	0.000595734	.	0.24069	0.17061	-0.405853867	26.23260203	31.71128	0.99845	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	40	chr11	12400051	chr11:12400051	C	T	.	PASS	AN=0;DP=40	GT	0/1
chr11	33891508	33891508	C	T	UTR5	LMO2	NM_005574:c.-246G>A;NM_001142315:c.-576G>A	.	.	0.753952193	0.236452305	0.009595502	DISEASE: Note=A chromosomal aberration involving LMO2 may be a cause of a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(11,14)(p13;q11) with TCRD.; 	0.91591	0.38765	.	.	26.24832	0.85065	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	55	chr11	33891508	chr11:33891508	C	T	.	PASS	AN=0;DP=55	GT	0/1
chr11	40162349	40162349	A	G	splicing	LRRC4C	NM_020929:exon4:UTR5;NM_001258419:exon6:UTR5	.	.	0.953730869	0.046141223	0.000127908	.	0.85527	0.14229	-0.799052816	12.45576787	78.16654	1.86462	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	21	chr11	40162349	chr11:40162349	A	G	.	PASS	AN=0;DP=21	GT	0/1
chr11	50276137	50276166	AATACAACTGAAGTTACTCAGCCAAGAACA	-	intergenic	LOC441601;LOC646813	dist=18504;dist=92152	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	10.07	24	chr11	50276136	chr11:50276136	CAATACAACTGAAGTTACTCAGCCAAGAACA	C	10.07	PASS	AN=0;DP=24	GT	0/1
chr11	62139512	62139512	G	A	intronic	ASRGL1	.	.	.	0.000386788	0.626060265	0.373552947	.	0.09435	0.27804	-0.314027422	31.9297004	41.01491	1.20213	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	33	chr11	62139512	chr11:62139512	G	A	.	PASS	AN=0;DP=33	GT	0/1
chr11	62565992	62565992	G	A	intronic	NXF1	.	.	.	0.998990475	0.001009525	1.82E-11	.	0.58705	0.1604	-0.66859065	15.76433121	35.98594	1.08112	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	34	chr11	62565992	chr11:62565992	G	A	.	PASS	AN=0;DP=34	GT	0/1
chr11	63683050	63683050	G	T	exonic	RCOR2	.	nonsynonymous SNV	RCOR2:NM_173587:exon2:c.C161A:p.A54D	0.115753697	0.883058055	0.001188248	.	0.15407	0.11192	-0.514264485	21.41424864	38.78816	1.14828	0.001	0.784	D	1.0	0.899	D	0.979	0.728	D	0.000	0.629	D	1	0.810	D	3.075	0.874	M	-1.43	0.807	T	-5.04	0.826	D	0.894	0.883	0.460	0.900	D	0.683	0.890	D	0.497	0.951	D	6.028	0.829	27.9	0.996	0.758	0.996	0.976	D	c	0.740	0.644	1.000	0.747	0.652	0.477	0	3.6	0.402	6.290	0.725	0.873	0.381	1.000	0.715	0.996	0.625	11.397	0.489	ELM2 domain	.	.	0.5	.	98	chr11	63683050	chr11:63683050	G	T	.	PASS	AN=0;DP=98	GT	0/1
chr11	63683077	63683077	A	T	exonic	RCOR2	.	nonsynonymous SNV	RCOR2:NM_173587:exon2:c.T134A:p.M45K	0.115753697	0.883058055	0.001188248	.	0.15407	0.11192	-0.514264485	21.41424864	38.78816	1.14828	0.922	0.023	T	0.963	0.537	D	0.53	0.467	P	0.000	0.843	D	1.000	0.548	D	1.105	0.287	L	1.67	0.273	T	0.06	0.063	N	0.85	0.837	-1.089	0.057	T	0.042	0.179	T	0.023	0.458	T	1.302	0.221	12.28	0.940	0.235	0.967	0.701	D	c	-0.013	0.075	1.000	0.747	0.726	0.872	0	4.1	0.470	3.656	0.540	0.995	0.605	1.000	0.715	1.000	0.888	12.499	0.551	ELM2 domain	.	.	0.5	.	126	chr11	63683077	chr11:63683077	A	T	.	PASS	AN=0;DP=126	GT	0/1
chr11	64985172	64985172	G	A	intronic	SLC22A20	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	49	chr11	64985172	chr11:64985172	G	A	.	PASS	AN=0;DP=49	GT	0/1
chr11	66045990	66045990	C	T	exonic	CNIH2	.	synonymous SNV	CNIH2:NM_182553:exon1:c.C63T:p.I21I	0.894540207	0.104434209	0.001025584	.	0.16073	0.11262	-0.119252484	44.53880632	2.28818	0.07752	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	216	chr11	66045990	chr11:66045990	C	T	.	PASS	AN=0;DP=216	GT	0/1
chr11	66046015	66046015	C	T	intronic	CNIH2	.	.	.	0.894540207	0.104434209	0.001025584	.	0.16073	0.11262	-0.119252484	44.53880632	2.28818	0.07752	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	175	chr11	66046015	chr11:66046015	C	T	.	PASS	AN=0;DP=175	GT	0/1
chr11	68133156	68133156	G	T	exonic	LRP5	.	nonsynonymous SNV	LRP5:NM_002335:exon5:c.G1001T:p.R334M	0.99835557	0.00164443	2.44E-12	DISEASE: Vitreoretinopathy, exudative 4 (EVR4) [MIM:601813]: A disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. {ECO:0000269|PubMed:15024691, ECO:0000269|PubMed:15346351, ECO:0000269|PubMed:15981244, ECO:0000269|PubMed:16929062, ECO:0000269|PubMed:19324841, ECO:0000269|PubMed:20340138, ECO:0000269|PubMed:24715757}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Osteoporosis (OSTEOP) [MIM:166710]: A systemic skeletal disorder characterized by decreased bone mass and deterioration of bone microarchitecture without alteration in the composition of bone. The result is fragile bones and an increased risk of fractures, even after minimal trauma. Osteoporosis is a chronic condition of multifactorial etiology and is usually clinically silent until a fracture occurs. {ECO:0000269|PubMed:14727154, ECO:0000269|PubMed:15824851, ECO:0000269|PubMed:16234968}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Osteoporosis-pseudoglioma syndrome (OPPG) [MIM:259770]: A disease characterized by congenital or infancy-onset blindness and severe juvenile-onset osteoporosis and spontaneous fractures. Additional clinical manifestations may include microphthalmos, abnormalities of the iris, lens or vitreous, cataracts, short stature, microcephaly, ligamental laxity, mental retardation and hypotonia. {ECO:0000269|PubMed:11719191, ECO:0000269|PubMed:16252235, ECO:0000269|PubMed:16679074, ECO:0000269|PubMed:17437160, ECO:0000269|PubMed:18602879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: High bone mass trait (HBM) [MIM:601884]: Rare phenotype characterized by exceptionally dense bones. HBM individuals show otherwise a completely normal skeletal structure and no other unusual clinical findings. {ECO:0000269|PubMed:11741193, ECO:0000269|PubMed:12015390, ECO:0000269|PubMed:15824861, ECO:0000269|PubMed:17295608}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endosteal hyperostosis, Worth type (WENHY) [MIM:144750]: An autosomal dominant sclerosing bone dysplasia clinically characterized by elongation of the mandible, increased gonial angle, flattened forehead, and the presence of a slowly enlarging osseous prominence of the hard palate (torus palatinus). Serum calcium, phosphorus and alkaline phosphatase levels are normal. Radiologically, it is characterized by early thickening of the endosteum of long bones, the skull and of the mandible. With advancing age, the trabeculae of the metaphysis become thickened. WENHY becomes clinically and radiologically evident by adolescence, does not cause deformity except in the skull and mandible, and is not associated with bone pain or fracture. Affected patients have normal height, proportion, intelligence and longevity. {ECO:0000269|PubMed:12579474}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Osteopetrosis, autosomal dominant 1 (OPTA1) [MIM:607634]: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTA1 is an autosomal dominant form characterized by generalized osteosclerosis most pronounced in the cranial vault. Patients are often asymptomatic, but some suffer from pain and hearing loss. It appears to be the only type of osteopetrosis not associated with an increased fracture rate. {ECO:0000269|PubMed:12579474}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Van Buchem disease 2 (VBCH2) [MIM:607636]: VBCH2 is an autosomal dominant sclerosing bone dysplasia characterized by cranial osteosclerosis, thickened calvaria and cortices of long bones, enlarged mandible and normal serum alkaline phosphatase levels. {ECO:0000269|PubMed:12579474}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.07666	0.10394	-3.724445291	0.241802312	2445.60749	9.20072	0.057	0.379	T	0.646	0.386	P	0.492	0.456	P	0.420	0.129	U	0.821	0.289	N	2.155	0.604	M	-4.24	0.970	D	-1.25	0.316	N	0.266	0.323	0.643	0.925	D	0.873	0.958	D	0.195	0.865	D	2.065	0.309	16.62	0.948	0.250	0.842	0.430	D	c	-0.207	-0.266	0.997	0.356	0.672	0.522	0	-0.917	0.099	1.950	0.397	-0.165	0.106	1.000	0.715	0.995	0.604	9.825	0.399	EGF-like domain	.	.	0.5	.	48	chr11	68133156	chr11:68133156	G	T	.	PASS	AN=0;DP=48	GT	0/1
chr11	118350956	118350956	A	T	intronic	KMT2A	.	.	.	1	1.88E-16	1.78E-42	DISEASE: Wiedemann-Steiner syndrome (WDSTS) [MIM:605130]: A syndrome characterized by hairy elbows (hypertrichosis cubiti), intellectual disability, a distinctive facial appearance, and short stature. Facial characteristics include long eyelashes, thick or arched eyebrows with a lateral flare, and downslanting and vertically narrow palpebral fissures. {ECO:0000269|PubMed:22795537}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Chromosomal aberrations involving KMT2A are a cause of acute leukemias. Translocation t(1;11)(q21;q23) with MLLT11/AF1Q; translocation t(3;11)(p21;q23) with NCKIPSD/AF3p21; translocation t(3,11)(q25,q23) with GMPS; translocation t(4;11)(q21;q23) with AFF1/MLLT2/AF4; insertion ins(5;11)(q31;q13q23) with AFF4/AF5Q31; translocation t(5;11)(q12;q23) with AF5-alpha/CENPK; translocation t(6;11)(q27;q23) with MLLT4/AF6; translocation t(9;11)(p22;q23) with MLLT3/AF9; translocation t(10;11)(p11.2;q23) with ABI1; translocation t(10;11)(p12;q23) with MLLT10/AF10; t(11;15)(q23;q14) with CASC5 and ZFYVE19; translocation t(11;17)(q23;q21) with MLLT6/AF17; translocation t(11;19)(q23;p13.3) with ELL; translocation t(11;19)(q23;p13.3) with MLLT1/ENL; translocation t(11;19)(q23;p23) with GAS7; translocation t(X;11)(q13;q23) with FOXO4/AFX1. Translocation t(3;11)(q28;q23) with LPP. Translocation t(10;11)(q22;q23) with TET1. Translocation t(9;11)(q34;q23) with DAB2IP. Translocation t(4;11)(p12;q23) with FRYL. Fusion proteins KMT2A-MLLT1, KMT2A- MLLT3 and KMT2A-ELL interact with PPP1R15A and, on the contrary to unfused KMT2A, inhibit PPP1R15A-induced apoptosis. {ECO:0000269|PubMed:10490642}.; DISEASE: Note=A chromosomal aberration involving KMT2A may be a cause of chronic neutrophilic leukemia. Translocation t(4;11)(q21;q23) with SEPT11. {ECO:0000269|PubMed:10490642}.; 	0.58012	0.48908	-3.347291482	0.406935598	416.01763	4.26932	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	20	chr11	118350956	chr11:118350956	A	T	.	PASS	AN=0;DP=20	GT	0/1
chr11	129763186	129763186	A	G	intronic	NFRKB	.	.	.	0.752744578	0.247255416	6.10E-09	.	0.21273	0.12979	-2.651579643	0.76079264	181.58645	2.92847	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	33	chr11	129763186	chr11:129763186	A	G	42	PASS	AN=2;DP=33	GT	0/1
chr11	129763191	129763191	C	T	intronic	NFRKB	.	.	.	0.752744578	0.247255416	6.10E-09	.	0.21273	0.12979	-2.651579643	0.76079264	181.58645	2.92847	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	20	chr11	129763191	chr11:129763191	C	T	.	PASS	AN=0;DP=20	GT	0/1
chr12	2997016	2997016	C	T	intronic	RHNO1	.	.	.	0.000558185	0.704918917	0.294522899	.	0.10242	.	.	.	34.24976	1.04792	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	33	chr12	2997016	chr12:2997016	C	T	.	PASS	AN=0;DP=33	GT	0/1
chr12	6840995	6840995	G	A	UTR3	COPS7A	NM_016319:c.*790G>A;NM_001164094:c.*790G>A;NM_001164095:c.*790G>A;NM_001164093:c.*790G>A	.	.	0.922072581	0.077830341	9.71E-05	.	0.53766	0.12327	-0.317668748	31.45789101	18.82591	0.6506	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	16	chr12	6840995	chr12:6840995	G	A	.	PASS	AN=0;DP=16	GT	0/1
chr12	23818504	23818504	G	A	intronic	SOX5	.	.	.	0.999398884	0.000601115	1.25E-10	.	0.63083	0.17821	-0.957024976	9.088228356	16.39611	0.58125	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	16	chr12	23818504	chr12:23818504	G	A	.	PASS	AN=0;DP=16	GT	0/1
chr12	27109510	27109510	C	A	exonic	FGFR1OP2	.	nonsynonymous SNV	FGFR1OP2:NM_001171887:exon3:c.C170A:p.A57E,FGFR1OP2:NM_001171888:exon3:c.C170A:p.A57E,FGFR1OP2:NM_015633:exon3:c.C170A:p.A57E	0.429728003	0.568760515	0.001511482	.	0.16605	0.12716	-0.361761279	28.6329323	26.47953	0.85687	0.005	0.682	D	0.992	0.629	D	0.686	0.565	P	0.000	0.843	D	1	0.810	D	1.89	0.503	L	.	.	.	-3.14	0.650	D	0.972	0.974	-0.383	0.726	T	0.358	0.720	T	0.015	0.350	T	6.291	0.869	29.1	0.995	0.682	0.992	0.922	D	c	0.496	0.529	1.000	0.747	0.706	0.609	0	4.65	0.575	7.280	0.778	0.875	0.382	1.000	0.715	0.996	0.625	18.420	0.905	.	.	.	0.5	.	21	chr12	27109510	chr12:27109510	C	A	.	PASS	AN=0;DP=21	GT	0/1
chr12	48184753	48184753	C	G	intronic	HDAC7	.	.	.	0.998019873	0.001980126	4.64E-10	.	0.1103	.	-0.038558137	50.51899033	940.4494	5.94619	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	18	chr12	48184753	chr12:48184753	C	G	.	PASS	AN=0;DP=18	GT	0/1
chr12	48191136	48191136	C	T	intronic	HDAC7	.	.	.	0.998019873	0.001980126	4.64E-10	.	0.1103	.	-0.038558137	50.51899033	940.4494	5.94619	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	58	chr12	48191136	chr12:48191136	C	T	.	PASS	AN=0;DP=58	GT	0/1
chr12	49691409	49691409	C	A	ncRNA_exonic	LOC101927267	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	39	chr12	49691409	chr12:49691409	C	A	.	PASS	AN=0;DP=39	GT	0/1
chr12	52174448	52174448	C	T	exonic	SCN8A	.	nonsynonymous SNV	SCN8A:NM_001330260:exon21:c.C3835T:p.L1279F,SCN8A:NM_014191:exon21:c.C3835T:p.L1279F	0.99999829	1.71E-06	3.22E-18	DISEASE: Cognitive impairment with or without cerebellar ataxia (CIAT) [MIM:614306]: A disorder characterized by markedly delayed cognitive and motor development, attention deficit disorder, and cerebellar ataxia. Features include bilateral esophoria, strabismatic amblyopia, unsustained gaze evoked nystagmus on horizontal gaze, ataxic gait, dysmetria in the upper limbs and dysarthria, with normal strength, tone, and reflexes. {ECO:0000269|PubMed:16236810}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epileptic encephalopathy, early infantile, 13 (EIEE13) [MIM:614558]: A form of epilepsy characterized by frequent tonic seizures or spasms beginning in infancy with a specific EEG finding of suppression-burst patterns, characterized by high- voltage bursts alternating with almost flat suppression phases. Patients may progress to West syndrome, which is characterized by tonic spasms with clustering, arrest of psychomotor development, and hypsarrhythmia on EEG. EIEE13 is a severe form consisting of early-onset seizures, features of autism, intellectual disability, ataxia, and sudden unexplained death in epilepsy. {ECO:0000269|PubMed:22365152, ECO:0000269|PubMed:24352161, ECO:0000269|PubMed:24874546, ECO:0000269|PubMed:24888894, ECO:0000269|PubMed:25239001}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.6031	0.25451	-1.749006627	2.341354093	100.07778	2.16874	0.004	0.654	D	0.995	0.657	D	0.944	0.663	D	0.000	0.843	D	1	0.810	D	2.06	0.569	M	-5.09	0.987	D	-3.56	0.688	D	0.835	0.822	1.071	0.986	D	0.965	0.989	D	0.629	0.968	D	5.019	0.676	25.2	0.999	0.946	0.939	0.592	D	c	0.708	0.682	1.000	0.747	0.497	0.185	0	5.28	0.740	2.784	0.472	0.931	0.441	1.000	0.715	1.000	0.888	19.559	0.953	Ion transport domain|Voltage-dependent channel, four helix bundle domain	.	.	0.5	.	41	chr12	52174448	chr12:52174448	C	T	.	PASS	AN=0;DP=41	GT	0/1
chr12	53873421	53873421	G	T	UTR3	PCBP2	NM_001128914:c.*195G>T;NM_001098620:c.*195G>T;NM_001128913:c.*195G>T;NM_001128912:c.*195G>T;NM_031989:c.*195G>T;NM_005016:c.*195G>T;NM_001128911:c.*195G>T	.	.	0.98703033	0.01296855	1.12E-06	.	0.33122	.	-0.185391282	39.67916962	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	28	chr12	53873421	chr12:53873421	G	T	.	PASS	AN=0;DP=28	GT	0/1
chr12	56622981	56622981	G	A	exonic	NABP2	.	nonsynonymous SNV	NABP2:NM_024068:exon7:c.G620A:p.R207K	0.956804648	0.043087592	0.00010776	.	0.29478	.	-0.141298762	42.87567823	1.67296	0.05407	0.0	0.912	D	0.841	0.445	P	0.745	0.540	P	0.000	0.629	D	0.684	0.332	D	0.975	0.246	L	0.1	0.614	T	-1.36	0.338	N	0.524	0.582	-0.350	0.736	T	0.299	0.670	T	0.031	0.537	D	6.159	0.850	28.5	0.993	0.598	0.961	0.673	D	c	0.558	0.586	1.000	0.747	0.732	0.924	0	5.39	0.775	4.212	0.581	1.048	0.713	1.000	0.715	1.000	0.888	16.442	0.837	.	.	.	0.5	.	47	chr12	56622981	chr12:56622981	G	A	.	PASS	AN=0;DP=47	GT	0/1
chr12	64891457	64891457	T	A	exonic	TBK1	.	nonsynonymous SNV	TBK1:NM_013254:exon19:c.T1989A:p.F663L	0.995096971	0.004903028	8.57E-10	DISEASE: Glaucoma 1, open angle, P (GLC1P) [MIM:177700]: A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. GLC1P is characterized by early onset, thin central corneas and low intraocular pressure. {ECO:0000269|PubMed:21447600, ECO:0000269|PubMed:22306015}. Note=The disease may be caused by mutations affecting the gene represented in this entry. A copy number variation on chromosome 12q14 consisting of a 300 kb duplication that includes TBK1, XPOT, RASSF3 and GNS has been found in individuals affected by glaucoma. TBK1 is the most likely candidate for the disorder (PubMed:21447600). {ECO:0000269|PubMed:21447600}.; DISEASE: Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 (FTDALS4) [MIM:616439]: A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. {ECO:0000269|PubMed:25803835, ECO:0000269|PubMed:25943890}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.17165	0.35025	-0.291981272	33.20358575	93.23558	2.0775	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.000	0.491	N	0.753	0.339	D	-0.855	0.015	N	0.02	0.623	T	0.59	0.026	N	0.081	0.084	-1.024	0.225	T	0.100	0.371	T	0.013	0.324	T	1.540	0.247	13.53	0.600	0.062	0.818	0.409	D	c	-0.536	-0.374	0.003	0.099	0.719	0.830	0	1.49	0.219	0.277	0.184	0.045	0.158	0.995	0.385	0.584	0.286	6.979	0.237	.	.	.	0.5	.	30	chr12	64891457	chr12:64891457	T	A	.	PASS	AN=0;DP=30	GT	0/1
chr12	93130307	93130307	C	T	UTR5	PLEKHG7	NM_001004330:c.-988C>T	.	.	3.68E-11	0.089094005	0.910905995	.	0.1916	.	0.463046108	78.58575136	319.25993	3.79421	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	21	chr12	93130307	chr12:93130307	C	T	.	PASS	AN=0;DP=21	GT	0/1
chr12	110910825	110910826	CA	-	intronic	FAM216A	.	.	.	0.001116299	0.834605539	0.164278162	.	0.04692	.	0.170987912	65.5579146	62.01365	1.60508	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	58	chr12	110910824	chr12:110910824	TCA	T	64	PASS	AN=2;DP=58	GT	0/1
chr12	121471308	121471389	GCAGTCCCCCTGGTCTGGATGGTGAAGACGAGAGCATCGGGGACTCTCTGCTCCATCCTCAGGTCCTCGAGCCCGAGGTCCA	-	exonic	OASL	.	frameshift deletion	OASL:NM_001261825:exon2:c.356_437del:p.L119Rfs*29,OASL:NM_003733:exon2:c.356_437del:p.L119Rfs*29,OASL:NM_198213:exon2:c.356_437del:p.L119Rfs*29	5.07E-12	0.014859491	0.985140509	.	0.10031	0.10724	-0.398573136	26.92852088	65.07146	1.66071	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	11.21	23	chr12	121471307	chr12:121471307	CGCAGTCCCCCTGGTCTGGATGGTGAAGACGAGAGCATCGGGGACTCTCTGCTCCATCCTCAGGTCCTCGAGCCCGAGGTCCA	C	11.21	PASS	AN=0;DP=23	GT	0/1
chr12	121783849	121783849	G	A	intronic	ANAPC5	.	.	.	4.18E-05	0.99800999	0.00194821	.	0.36079	.	-0.554717505	19.79830149	76.22212	1.8303	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	23	chr12	121783849	chr12:121783849	G	A	.	PASS	AN=0;DP=23	GT	0/1
chr12	124074896	124074896	G	A	exonic	TMED2	.	synonymous SNV	TMED2:NM_006815:exon3:c.G381A:p.Q127Q,TMED2:NM_001321445:exon4:c.G402A:p.Q134Q	0.797679588	0.19667058	0.005649831	.	0.70097	0.11835	-0.119252484	44.53880632	7.09498	0.26483	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	18	chr12	124074896	chr12:124074896	G	A	.	PASS	AN=0;DP=18	GT	0/1
chr12	132445261	132445261	A	G	exonic	EP400	.	nonsynonymous SNV	EP400:NM_015409:exon2:c.A97G:p.N33D	1	1.17E-10	1.58E-32	.	0.18578	0.27854	-3.863869047	0.218211842	4549.61959	13.54811	0.004	0.654	D	0.634	0.577	P	0.124	0.473	B	0.021	0.270	N	1.000	0.090	N	1.955	0.530	M	-2.76	0.910	D	-2.59	0.558	D	0.092	0.129	0.063	0.835	D	0.703	0.898	D	0.140	0.823	D	1.401	0.231	12.79	0.599	0.062	0.853	0.442	D	c	-0.163	-0.229	0.999	0.379	0.732	0.924	0	4.54	0.551	3.487	0.527	1.199	0.960	0.388	0.258	0.144	0.203	11.455	0.492	E1A-binding protein p400, N-terminal	.	.	0.5	58	143	chr12	132445261	chr12:132445261	A	G	58	PASS	AN=2;DP=143	GT	0/1
chr13	20302531	20302531	C	T	intronic	PSPC1	.	.	.	0.99260702	0.007392697	2.82E-07	.	0.15131	0.1143	-0.405853867	26.23260203	58.28959	1.54636	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	49	chr13	20302531	chr13:20302531	C	T	.	PASS	AN=0;DP=49	GT	0/1
chr14	19118367	19118367	G	A	intergenic	NONE;OR11H12	dist=NONE;dist=259227	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	58	chr14	19118367	chr14:19118367	G	A	.	PASS	AN=0;DP=58	GT	0/1
chr14	50361284	50361284	G	A	UTR3	ARF6	NM_001663:c.*302G>A	.	.	0.600609559	0.361887013	0.037503427	.	0.43767	0.41336	-0.141298762	42.87567823	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	24	chr14	50361284	chr14:50361284	G	A	.	PASS	AN=0;DP=24	GT	0/1
chr14	50647379	50647379	C	G	exonic	SOS2	.	nonsynonymous SNV	SOS2:NM_006939:exon7:c.G880C:p.E294Q	0.999427841	0.000572159	1.86E-13	.	0.94123	0.11519	-0.927704399	9.719273414	277.52939	3.56927	0.355	0.168	T	0.971	0.715	D	0.893	0.659	P	0.000	0.843	D	1	0.810	D	2.455	0.715	M	-0.03	0.631	T	-1.2	0.305	N	0.733	0.731	-0.377	0.728	T	0.424	0.768	T	0.022	0.445	T	4.390	0.588	24.1	0.997	0.803	0.993	0.946	D	c	0.772	0.773	1.000	0.747	0.732	0.924	0	5.6	0.849	7.902	0.860	0.935	0.490	1.000	0.715	1.000	0.888	19.669	0.959	Dbl homology (DH) domain	.	.	0.5	64	15	chr14	50647379	chr14:50647379	C	G	64	PASS	AN=2;DP=15	GT	0/1
chr14	64989352	64989395	ATGTCAGCATAAAAAAAAGTGGTAGGAAAACTCTAAAACCTCGA	-	exonic	ZBTB1	.	frameshift deletion	ZBTB1:NM_001123329:exon2:c.1130_1173del:p.I380Kfs*2,ZBTB1:NM_014950:exon2:c.1130_1173del:p.I380Kfs*2	0.973423964	0.026569485	6.55E-06	.	0.46339	0.10423	-0.247889024	35.98726115	429.66774	4.32847	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	11.79	15	chr14	64989351	chr14:64989351	GATGTCAGCATAAAAAAAAGTGGTAGGAAAACTCTAAAACCTCGA	G	11.79	PASS	AN=0;DP=15	GT	0/1
chr14	69619703	69619705	CCG	-	UTR5	DCAF5	NM_001284206:c.-8_-10delCGG;NM_003861:c.-8_-10delCGG;NM_001284208:c.-8_-10delCGG	.	.	0.999968932	3.11E-05	2.25E-12	.	0.58383	0.10764	-1.105907904	6.86482661	58.69346	1.55207	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	28	chr14	69619702	chr14:69619702	ACCG	A	42	PASS	AN=2;DP=28	GT	0/1
chr14	81574701	81574701	T	C	intronic	TSHR	.	.	.	5.80E-06	0.879485782	0.120508415	DISEASE: Note=Defects in TSHR are found in patients affected by hyperthyroidism with different etiologies. Somatic, constitutively activating TSHR mutations and/or constitutively activating G(s)alpha mutations have been identified in toxic thyroid nodules (TTNs) that are the predominant cause of hyperthyroidism in iodine deficient areas. These mutations lead to TSH independent activation of the cAMP cascade resulting in thyroid growth and hormone production. TSHR mutations are found in autonomously functioning thyroid nodules (AFTN), toxic multinodular goiter (TMNG) and hyperfunctioning thyroid adenomas (HTA). TMNG encompasses a spectrum of different clinical entities, ranging from a single hyperfunctioning nodule within an enlarged thyroid, to multiple hyperfunctioning areas scattered throughout the gland. HTA are discrete encapsulated neoplasms characterized by TSH- independent autonomous growth, hypersecretion of thyroid hormones, and TSH suppression. Defects in TSHR are also a cause of thyroid neoplasms (papillary and follicular cancers).; DISEASE: Note=Autoantibodies against TSHR are directly responsible for the pathogenesis and hyperthyroidism of Graves disease. Antibody interaction with TSHR results in an uncontrolled receptor stimulation.; DISEASE: Hypothyroidism, congenital, non-goitrous, 1 (CHNG1) [MIM:275200]: A non-autoimmune condition characterized by resistance to thyroid-stimulating hormone (TSH) leading to increased levels of plasma TSH and low levels of thyroid hormone. It presents variable severity depending on the completeness of the defect. Most patients are euthyroid and asymptomatic, with a normal sized thyroid gland. Only a subset of patients develop hypothyroidism and present a hypoplastic thyroid gland. {ECO:0000269|PubMed:10720030, ECO:0000269|PubMed:11095460, ECO:0000269|PubMed:11442002, ECO:0000269|PubMed:12050212, ECO:0000269|PubMed:14725684, ECO:0000269|PubMed:15531543, ECO:0000269|PubMed:7528344, ECO:0000269|PubMed:8954020, ECO:0000269|PubMed:9100579, ECO:0000269|PubMed:9185526, ECO:0000269|PubMed:9329388}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Familial gestational hyperthyroidism (HTFG) [MIM:603373]: A condition characterized by abnormally high levels of serum thyroid hormones occurring during early pregnancy. {ECO:0000269|PubMed:9854118}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperthyroidism, non-autoimmune (HTNA) [MIM:609152]: A condition characterized by abnormally high levels of serum thyroid hormones, thyroid hyperplasia, goiter and lack of anti-thyroid antibodies. Typical features of Graves disease such as exophthalmia, myxedema, antibodies anti-TSH receptor and lymphocytic infiltration of the thyroid gland are absent. {ECO:0000269|PubMed:10199795, ECO:0000269|PubMed:10852462, ECO:0000269|PubMed:11081252, ECO:0000269|PubMed:11127522, ECO:0000269|PubMed:11201847, ECO:0000269|PubMed:11517004, ECO:0000269|PubMed:11549687, ECO:0000269|PubMed:15163335, ECO:0000269|PubMed:7800007, ECO:0000269|PubMed:7920658, ECO:0000269|PubMed:8636266, ECO:0000269|PubMed:8964822, ECO:0000269|PubMed:9349581, ECO:0000269|PubMed:9360555, ECO:0000269|PubMed:9398746, ECO:0000269|PubMed:9589634}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.19628	0.35681	0.005534202	54.09884407	850.31473	5.69844	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	13	chr14	81574701	chr14:81574701	T	C	71	PASS	AN=2;DP=13	GT	0/1
chr14	93705836	93705836	C	T	UTR3	BTBD7	NM_001002860:c.*2783G>A;NM_001289133:c.*2783G>A	.	.	0.682366257	0.317633428	3.16E-07	.	0.4057	.	-0.947938165	9.341825902	455.53339	4.4332	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	47	chr14	93705836	chr14:93705836	C	T	.	PASS	AN=0;DP=47	GT	0/1
chr14	102771215	102771223	CCTCAAGCT	-	intronic	MOK	.	.	.	5.96E-17	0.001830666	0.998169334	.	0.14379	.	1.023320772	91.04741684	2990.39023	10.37744	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	73	chr14	102771214	chr14:102771214	CCCTCAAGCT	C	69	PASS	AN=2;DP=73	GT	0/1
chr14	104136556	104136591	GTAAAAGAGGGAAGTACAAAGAAGCAGAGCCGTTGT	-	exonic	KLC1	.	nonframeshift deletion	KLC1:NM_001130107:exon7:c.923_958del:p.G311_R322del,KLC1:NM_005552:exon7:c.923_958del:p.G311_R322del,KLC1:NM_182923:exon7:c.923_958del:p.G311_R322del	0.514955332	0.485012289	3.24E-05	.	0.2206	0.15408	-0.492218069	22.35786742	40.10824	1.17876	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	23.97	61	chr14	104136555	chr14:104136555	GGTAAAAGAGGGAAGTACAAAGAAGCAGAGCCGTTGT	G	23.97	PASS	AN=0;DP=61	GT	0/1
chr14	105181013	105181013	G	-	exonic	INF2	.	frameshift deletion	INF2:NM_001031714:exon21:c.3514delG:p.E1172Rfs*26,INF2:NM_022489:exon21:c.3514delG:p.E1172Rfs*26	0.999083288	0.000916712	7.09E-11	DISEASE: Focal segmental glomerulosclerosis 5 (FSGS5) [MIM:613237]: A renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation. {ECO:0000269|PubMed:20023659, ECO:0000269|PubMed:21258034, ECO:0000269|PubMed:21866090, ECO:0000269|PubMed:22971997, ECO:0000269|PubMed:25165188}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Charcot-Marie-Tooth disease, dominant, intermediate type, E (CMTDIE) [MIM:614455]: A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. The dominant intermediate type E is characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. Patients additionally manifest focal segmental glomerulonephritis, proteinuria, progression to end- stage renal disease, and a characteristic histologic pattern on renal biopsy. {ECO:0000269|PubMed:22187985, ECO:0000269|PubMed:24174593, ECO:0000269|PubMed:24750328, ECO:0000269|PubMed:25165188, ECO:0000269|PubMed:25676889}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	.	.	-0.033100763	50.56027365	2152.91209	8.53891	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	30.54	29	chr14	105181012	chr14:105181012	TGAGGAC	TAGGAC,T	30.54	PASS	AN=0;DP=29	GT	0/1
chr14	105181013	105181018	GAGGAC	-	exonic	INF2	.	nonframeshift deletion	INF2:NM_001031714:exon21:c.3514_3519del:p.D1175_E1176del,INF2:NM_022489:exon21:c.3514_3519del:p.D1175_E1176del	0.999083288	0.000916712	7.09E-11	DISEASE: Focal segmental glomerulosclerosis 5 (FSGS5) [MIM:613237]: A renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation. {ECO:0000269|PubMed:20023659, ECO:0000269|PubMed:21258034, ECO:0000269|PubMed:21866090, ECO:0000269|PubMed:22971997, ECO:0000269|PubMed:25165188}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Charcot-Marie-Tooth disease, dominant, intermediate type, E (CMTDIE) [MIM:614455]: A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. The dominant intermediate type E is characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. Patients additionally manifest focal segmental glomerulonephritis, proteinuria, progression to end- stage renal disease, and a characteristic histologic pattern on renal biopsy. {ECO:0000269|PubMed:22187985, ECO:0000269|PubMed:24174593, ECO:0000269|PubMed:24750328, ECO:0000269|PubMed:25165188, ECO:0000269|PubMed:25676889}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	.	.	-0.033100763	50.56027365	2152.91209	8.53891	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	30.54	29	chr14	105181012	chr14:105181012	TGAGGAC	TAGGAC,T	30.54	PASS	AN=0;DP=29	GT	0/1
chr14	105344239	105344239	G	A	exonic	CEP170B	.	nonsynonymous SNV	CEP170B:NM_015005:exon3:c.G3A:p.M1I,CEP170B:NM_001112726:exon4:c.G213A:p.M71I	0.87050986	0.12948953	6.11E-07	.	0.17272	.	-1.690488621	2.600849257	961.44284	6.00066	0.048	0.538	D	0.009	0.163	B	0.012	0.149	B	0.032	0.251	N	1	0.810	D	-0.84	0.015	N	1.52	0.307	T	0.5	0.030	N	0.128	0.146	-1.080	0.073	T	0.026	0.112	T	0.011	0.279	T	2.085	0.312	16.76	0.977	0.348	0.247	0.222	N	c	-0.796	-0.668	0.999	0.377	0.707	0.730	0	2.61	0.301	0.594	0.235	0.902	0.416	0.997	0.399	0.992	0.562	5.009	0.136	Forkhead-associated (FHA) domain|SMAD/FHA domain	.	.	0.5	.	84	chr14	105344239	chr14:105344239	G	A	.	PASS	AN=0;DP=84	GT	0/1
chr14	105954731	105954731	C	T	intronic	CRIP1	.	.	.	0.00135796	0.422344924	0.576297116	.	0.16635	0.11262	0.281220278	71.07808445	288.32797	3.63595	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chr14	105954731	chr14:105954731	C	T	.	PASS	AN=0;DP=44	GT	0/1
chr15	41021637	41021638	GT	-	intronic	RAD51	.	.	.	0.990418088	0.00957928	2.63E-06	DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. {ECO:0000269|PubMed:10807537}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Mirror movements 2 (MRMV2) [MIM:614508]: A disorder characterized by contralateral involuntary movements that mirror voluntary ones. While mirror movements are occasionally found in young children, persistence beyond the age of 10 is abnormal. Mirror movements occur more commonly in the upper extremities. {ECO:0000269|PubMed:22305526}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.99998	0.9588	-0.139478553	43.29440906	27.3455	0.88074	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	37	chr15	41021636	chr15:41021636	GGT	G	60	PASS	AN=2;DP=37	GT	0/1
chr15	41793794	41793794	G	A	intronic	ITPKA	.	.	.	0.821022369	0.17811602	0.000861612	.	0.21376	0.12708	.	.	45.24026	1.29149	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	36	chr15	41793794	chr15:41793794	G	A	.	PASS	AN=0;DP=36	GT	0/1
chr15	43512886	43512886	C	T	intronic	EPB42	.	.	.	1.56E-07	0.955587191	0.044412653	DISEASE: Spherocytosis 5 (SPH5) [MIM:612690]: Spherocytosis is a hematologic disorder leading to chronic hemolytic anemia and characterized by numerous abnormally shaped erythrocytes which are generally spheroidal. Absence of band 4.2 associated with spur or target erythrocytes has also been reported. {ECO:0000269|PubMed:10406914, ECO:0000269|PubMed:1558976, ECO:0000269|PubMed:7772513, ECO:0000269|PubMed:7819064, ECO:0000269|PubMed:8547071, ECO:0000269|PubMed:8547605}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.41009	0.12721	-0.194700582	39.24274593	150.84156	2.68319	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	130	chr15	43512886	chr15:43512886	C	T	.	PASS	AN=0;DP=130	GT	0/1
chr15	43903130	43903130	C	T	exonic	STRC	.	nonsynonymous SNV	STRC:NM_153700:exon14:c.G3359A:p.C1120Y	0.005321845	0.994633321	4.48E-05	DISEASE: Deafness, autosomal recessive, 16 (DFNB16) [MIM:603720]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:11687802}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness-infertility syndrome (DIS) [MIM:611102]: Characterized by deafness and infertility and is caused by large contiguous gene deletions at 15q15.3 that removes both STRC and CATSPER2 genes. {ECO:0000269|PubMed:17098888}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.14418	.	.	.	4206.67564	12.90457	0.009	0.574	D	0.997	0.689	D	0.991	0.782	D	0.001	0.425	D	1	0.810	D	0.975	0.246	L	-1.24	0.790	T	-1.08	0.281	N	0.798	0.788	-0.133	0.793	T	0.447	0.783	T	0.074	0.719	D	5.878	0.806	27.4	0.997	0.771	0.939	0.593	D	c	0.433	0.414	0.005	0.108	0.554	0.246	0	4.13	0.475	3.425	0.523	0.850	0.350	1.000	0.715	0.993	0.574	12.075	0.528	.	.	.	0.5	.	35	chr15	43903130	chr15:43903130	C	T	.	PASS	AN=0;DP=35	GT	0/1
chr15	89876718	89876718	G	C	exonic	POLG	.	nonsynonymous SNV	POLG:NM_001126131:exon2:c.C268G:p.Q90E,POLG:NM_002693:exon2:c.C268G:p.Q90E	4.12E-05	0.99995541	3.35E-06	DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1 (PEOA1) [MIM:157640]: A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism. {ECO:0000269|PubMed:12210792, ECO:0000269|PubMed:15351195, ECO:0000269|PubMed:15534189, ECO:0000269|PubMed:17420318, ECO:0000269|PubMed:18575922}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive, 1 (PEOB1) [MIM:258450]: A severe form of progressive external ophthalmoplegia, a disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. It is clinically more heterogeneous than the autosomal dominant forms. {ECO:0000269|PubMed:11431686, ECO:0000269|PubMed:12565911, ECO:0000269|PubMed:12707443, ECO:0000269|PubMed:12872260, ECO:0000269|PubMed:12975295, ECO:0000269|PubMed:14635118, ECO:0000269|PubMed:15349879, ECO:0000269|PubMed:15351195, ECO:0000269|PubMed:15477547, ECO:0000269|PubMed:15917273, ECO:0000269|PubMed:16401742, ECO:0000269|PubMed:16621917, ECO:0000269|PubMed:16634032, ECO:0000269|PubMed:16639411}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) [MIM:607459]: A systemic disorder resulting from mitochondrial dysfunction associated with mitochondrial depletion in skeletal muscle and peripheral nerve tissue. The clinical triad of symptoms consists of sensory ataxic neuropathy, dysarthria, and ophthalmoparesis. However, the phenotype varies widely, even within the same family, and can also include myopathy, seizures, and hearing loss. An atypical form of the disease is characterized by headaches and/or seizures manifesting in childhood or adolescence, followed by development of cerebellar and sensory ataxia, dysarthria, progressive external ophthalmoplegia, and myoclonus in early adulthood. {ECO:0000269|PubMed:12565911, ECO:0000269|PubMed:14745080, ECO:0000269|PubMed:15477547, ECO:0000269|PubMed:15824347, ECO:0000269|PubMed:15917273, ECO:0000269|PubMed:16080118, ECO:0000269|PubMed:16621917, ECO:0000269|PubMed:16639411, ECO:0000269|PubMed:16919951}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Mitochondrial DNA depletion syndrome 4A (MTDPS4A) [MIM:203700]: An autosomal recessive hepatocerebral syndrome due to mitochondrial dysfunction. The typical course of the disease includes severe developmental delay, intractable seizures, liver failure, and death in childhood. Refractory seizures, cortical blindness, progressive liver dysfunction, and acute liver failure after exposure to valproic acid are considered diagnostic features. The neuropathological hallmarks are neuronal loss, spongiform degeneration, and astrocytosis of the visual cortex. Liver biopsy results show steatosis, often progressing to cirrhosis. {ECO:0000269|PubMed:15122711, ECO:0000269|PubMed:15689359, ECO:0000269|PubMed:15929042, ECO:0000269|PubMed:16621917, ECO:0000269|PubMed:16639411, ECO:0000269|PubMed:18828154}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Mitochondrial DNA depletion syndrome 4B (MTDPS4B) [MIM:613662]: An autosomal recessive progressive multisystem disorder due to mitochondrial dysfunction. It is clinically characterized by chronic gastrointestinal dysmotility and pseudo- obstruction, cachexia, progressive external ophthalmoplegia, axonal sensory ataxic neuropathy, and muscle weakness. {ECO:0000269|PubMed:12825077, ECO:0000269|PubMed:19307547}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:18828154}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.23758	0.34185	-0.031281682	50.5779665	540.1607	4.73561	1.0	0.010	T	0.0	0.026	B	0.001	0.040	B	0.927	0.075	N	0.997	0.229	N	0.77	0.194	N	-3.9	0.960	D	-0.47	0.152	N	0.055	0.037	-0.333	0.741	T	0.617	0.865	D	0.092	0.759	D	-0.940	0.034	0.021	0.884	0.174	0.343	0.248	N	c	-0.916	-0.831	1.000	0.747	0.840	1.000	0	1.39	0.212	0.414	0.207	-0.730	0.036	0.150	0.234	0.805	0.338	2.669	0.047	.	.	.	0.5	42	36	chr15	89876718	chr15:89876718	G	C	42	PASS	AN=2;DP=36	GT	0/1
chr15	90838939	90838939	G	A	intergenic	NGRN;GABARAPL3	dist=23496;dist=50824	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	73	chr15	90838939	chr15:90838939	G	A	.	PASS	AN=0;DP=73	GT	0/1
chr15	91527977	91527977	C	T	exonic	PRC1	.	synonymous SNV	PRC1:NM_001267580:exon2:c.G90A:p.G30G,PRC1:NM_003981:exon2:c.G90A:p.G30G,PRC1:NM_199413:exon2:c.G90A:p.G30G	0.01597584	0.984015149	9.01E-06	.	0.68082	0.15466	-0.200157416	39.11299835	294.41154	3.66477	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	26	chr15	91527977	chr15:91527977	C	T	.	PASS	AN=0;DP=26	GT	0/1
chr15	101562089	101562089	G	A	exonic	LRRK1	.	synonymous SNV	LRRK1:NM_024652:exon14:c.G1779A:p.Q593Q	1.59E-05	0.999984068	2.20E-08	.	0.13723	0.10871	-1.611828042	2.972399151	4789.19708	14.03707	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	26	chr15	101562089	chr15:101562089	G	A	.	PASS	AN=0;DP=26	GT	0/1
chr16	628970	628970	C	T	intronic	PIGQ	.	.	.	3.39E-10	0.16521487	0.83478513	.	0.12183	0.14652	0.07895234	59.21207832	128.11911	2.46745	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	40	chr16	628970	chr16:628970	C	T	.	PASS	AN=0;DP=40	GT	0/1
chr16	697898	697898	C	T	intronic	MCRIP2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	48	chr16	697898	chr16:697898	C	T	.	PASS	AN=0;DP=48	GT	0/1
chr16	1036706	1036706	A	C	UTR3	SOX8	NM_014587:c.*1320A>C	.	.	0.87370846	0.124658748	0.001632792	.	0.14736	.	.	.	35.61411	1.0723	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	42	chr16	1036706	chr16:1036706	A	C	.	PASS	AN=0;DP=42	GT	0/1
chr16	1808124	1808190	CTCTGTGCGTCGCTGGACTCGCCAGGGGAGTTCTCAGGTGAGTATCTCACTCTCCTGTCTGTCTCCC	-	exonic	MAPK8IP3	.	nonframeshift deletion	MAPK8IP3:NM_001318852:exon9:c.1217_1228del:p.G406_S409del,MAPK8IP3:NM_015133:exon9:c.1214_1225del:p.G405_S408del	0.999999971	2.91E-08	9.42E-20	.	0.31764	0.18911	-2.649793416	0.766690257	619.3755	5.02096	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	24.15	20	chr16	1808123	chr16:1808123	TCTCTGTGCGTCGCTGGACTCGCCAGGGGAGTTCTCAGGTGAGTATCTCACTCTCCTGTCTGTCTCCC	T	24.15	PASS	AN=0;DP=20	GT	0/1
chr16	1821328	1821328	G	A	exonic	NME3	.	nonsynonymous SNV	NME3:NM_002513:exon2:c.C130T:p.R44C	2.37E-06	0.086504203	0.913493423	.	0.27797	0.18492	.	.	94.46567	2.09186	0.019	0.501	D	1.0	0.899	D	1.0	0.971	D	0.000	0.843	D	1	0.810	D	4.56	0.992	H	0.31	0.586	T	-7.42	0.948	D	0.763	0.780	0.057	0.834	D	0.454	0.787	T	0.762	0.981	D	6.809	0.925	32	0.995	0.663	0.927	0.560	D	c	0.741	0.609	1.000	0.747	0.767	0.994	0	3.61	0.403	6.192	0.718	0.881	0.386	1.000	0.715	0.998	0.697	11.253	0.481	.	.	.	0.5	.	55	chr16	1821328	chr16:1821328	G	A	.	PASS	AN=0;DP=55	GT	0/1
chr16	2837452	2837452	T	C	upstream	PRSS33	dist=744	.	.	0.000160244	0.439783392	0.560056365	.	0.05419	.	.	.	451.00798	4.41353	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	147	505	chr16	2837452	chr16:2837452	T	C	147	PASS	AN=2;DP=505	GT	0/1
chr16	15159105	15159105	G	-	exonic	RRN3	.	frameshift deletion	RRN3:NM_001301064:exon15:c.1587delC:p.F530Sfs*7,RRN3:NM_018427:exon16:c.1677delC:p.F560Sfs*7	0.00047458	0.998071537	0.001453883	.	0.09916	0.13442	0.378498378	75.58386412	586.40473	4.91226	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	21.76	55	chr16	15159104	chr16:15159104	AG	A	21.76	PASS	AN=0;DP=55	GT	0/1
chr16	29817529	29817529	C	G	intronic	MAZ	.	.	.	0.953969622	0.045904111	0.000126268	.	0.32161	0.20668	.	.	18.8914	0.6524	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	175	chr16	29817529	chr16:29817529	C	G	58	PASS	AN=2;DP=175	GT	0/1
chr16	31177199	31177199	G	A	intergenic	PRSS36;FUS	dist=15784;dist=14232	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	29	chr16	31177199	chr16:31177199	G	A	.	PASS	AN=0;DP=29	GT	0/1
chr16	50117908	50117908	G	A	exonic	HEATR3	.	nonsynonymous SNV	HEATR3:NM_001329731:exon7:c.G409A:p.E137K,HEATR3:NM_182922:exon8:c.G1102A:p.E368K,HEATR3:NM_001329729:exon9:c.G751A:p.E251K,HEATR3:NM_001329730:exon9:c.G751A:p.E251K	0.000127665	0.990470629	0.009401706	.	0.10176	.	0.110306132	62.00165133	346.43566	3.94743	0.0	0.912	D	1.0	0.899	D	0.984	0.807	D	0.000	0.843	D	1	0.810	D	2.72	0.798	M	1.48	0.317	T	-3.5	0.681	D	0.975	0.976	-0.751	0.579	T	0.222	0.585	T	0.080	0.734	D	7.392	0.950	34	0.999	0.991	0.995	0.968	D	c	0.923	0.923	1.000	0.747	0.732	0.924	0	6.03	0.978	9.140	0.937	1.048	0.713	1.000	0.715	1.000	0.888	20.575	0.994	.	.	.	0.5	.	30	chr16	50117908	chr16:50117908	G	A	.	PASS	AN=0;DP=30	GT	0/1
chr16	56281373	56281373	G	-	intronic	GNAO1	.	.	.	0.984288177	0.015702972	8.85E-06	DISEASE: Epileptic encephalopathy, early infantile, 17 (EIEE17) [MIM:615473]: A severe neurologic disorder characterized by onset of intractable seizures in the first weeks or months of life and usually associated with EEG abnormalities. Affected infants have very poor psychomotor development and may have brain abnormalities, such as cerebral atrophy or thin corpus callosum. Some patients may show involuntary movements. {ECO:0000269|PubMed:23993195}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.24762	0.17859	-0.736552314	13.93606983	11.79169	0.42714	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	34	chr16	56281372	chr16:56281372	TG	T	52	PASS	AN=2;DP=34	GT	0/1
chr16	57054540	57054540	C	T	intronic	NLRC5	.	.	.	6.72E-05	0.999932818	2.78E-09	.	0.07927	0.08967	0.514279338	80.30195801	898.09245	5.83754	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	59	chr16	57054540	chr16:57054540	C	T	.	PASS	AN=0;DP=59	GT	0/1
chr16	68057932	68057932	G	-	intronic	DUS2	.	.	.	0.000272032	0.999072268	0.0006557	.	0.08346	0.11249	-0.400392389	26.85185185	261.28866	3.47039	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	18.23	39	chr16	68057931	chr16:68057931	TG	T	18.23	PASS	AN=0;DP=39	GT	0/1
chr16	72820886	72820886	C	T	UTR3	ZFHX3	NM_006885:c.*177G>A;NM_001164766:c.*177G>A	.	.	1	1.41E-10	8.85E-27	.	0.74579	0.15507	-4.263203714	0.117952347	6032.74571	16.21079	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	115	chr16	72820886	chr16:72820886	C	T	.	PASS	AN=0;DP=115	GT	0/1
chr16	74922137	74922137	T	A	exonic	WDR59	.	nonsynonymous SNV	WDR59:NM_030581:exon22:c.A2276T:p.Q759L	3.44E-11	0.995036935	0.004963065	.	0.21989	0.10981	-1.256630467	5.343241331	409.53463	4.24211	0.202	0.202	T	0.244	0.481	B	0.049	0.612	B	0.000	0.843	D	1	0.810	D	1.5	0.380	L	-0.35	0.686	T	-1.63	0.391	N	0.838	0.825	-0.514	0.681	T	0.347	0.712	T	0.032	0.543	D	3.417	0.469	23.0	0.988	0.454	0.989	0.890	D	c	0.261	0.375	1.000	0.747	0.732	0.924	0	5.77	0.910	4.161	0.577	1.061	0.807	1.000	0.715	0.998	0.697	16.099	0.809	.	.	.	0.5	.	42	chr16	74922137	chr16:74922137	T	A	.	PASS	AN=0;DP=42	GT	0/1
chr16	87936017	87936017	G	C	intronic	CA5A	.	.	.	0.010723138	0.946445827	0.042831035	DISEASE: Hyperammonemia due to carbonic anhydrase VA deficiency (CA5AD) [MIM:615751]: An autosomal recessive inborn error of metabolism, clinically characterized by infantile hyperammonemic encephalopathy. Metabolic abnormalities include hypoglycemia, hyperlactatemia, metabolic acidosis and respiratory alkalosis. {ECO:0000269|PubMed:24530203}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.11209	0.10917	-0.001743238	53.85114414	62.38928	1.61312	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	82	chr16	87936017	chr16:87936017	G	C	71	PASS	AN=2;DP=82	GT	0/1
chr17	3969786	3969816	CTTCTGCTTCATTCCCCAGGCTCATCAGGGA	-	exonic	ZZEF1	.	frameshift deletion	ZZEF1:NM_015113:exon28:c.4174_4204del:p.S1392Kfs*9	0.999923091	7.69E-05	6.61E-24	.	0.3881	0.10288	-3.376061946	0.389242746	5318.26057	15.07421	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	15.7	27	chr17	3969785	chr17:3969785	TCTTCTGCTTCATTCCCCAGGCTCATCAGGGA	T	15.7	PASS	AN=0;DP=27	GT	0/1
chr17	5118249	5118249	G	A	exonic	SCIMP	.	nonsynonymous SNV	SCIMP:NM_001271842:exon4:c.C233T:p.P78L,SCIMP:NM_001319190:exon4:c.C233T:p.P78L,SCIMP:NM_207103:exon4:c.C254T:p.P85L	0.012575344	0.855696202	0.131728455	.	0.1304	.	-0.163345027	41.24793583	10.11893	0.36946	.	.	.	0.946	0.514	P	0.324	0.413	B	0.001	0.425	N	0.995	0.426	D	2.045	0.562	M	.	.	.	.	.	.	0.424	0.544	-0.885	0.494	T	0.133	0.446	T	0.010	0.257	T	5.229	0.706	25.6	0.998	0.866	0.830	0.418	D	c	0.145	0.124	0.017	0.130	0.707	0.730	0	4.06	0.464	2.724	0.467	1.048	0.713	1.000	0.715	0.769	0.327	9.318	0.369	.	.	.	0.5	.	59	chr17	5118249	chr17:5118249	G	A	.	PASS	AN=0;DP=59	GT	0/1
chr17	7751192	7751192	C	T	exonic	KDM6B	.	nonsynonymous SNV	KDM6B:NM_001080424:exon11:c.C1586T:p.P529L,KDM6B:NM_001348716:exon11:c.C1586T:p.P529L	0.999994425	5.58E-06	2.83E-16	.	0.20577	0.12653	-1.31556435	4.794762916	5734.22375	15.68691	0.0	0.912	D	0.014	0.156	B	0.006	0.112	B	0.330	0.141	N	0.686	0.333	D	0.345	0.112	N	3.16	0.077	T	0.15	0.053	N	0.143	0.168	-0.992	0.321	T	0.013	0.048	T	0.015	0.354	T	0.288	0.122	5.572	0.920	0.207	0.543	0.293	D	c	-0.874	-0.797	0.097	0.163	0.615	0.372	0	1.06	0.193	0.637	0.242	0.736	0.307	0.000	0.063	0.796	0.335	7.492	0.265	.	.	.	0.5	.	45	chr17	7751192	chr17:7751192	C	T	.	PASS	AN=0;DP=45	GT	0/1
chr17	8025659	8025671	ACCCGGGGGCTCC	-	exonic	HES7	.	frameshift deletion	HES7:NM_001165967:exon3:c.216_226del:p.E73Rfs*97,HES7:NM_032580:exon3:c.216_226del:p.E73Gfs*92	0.78288357	0.210284915	0.006831516	DISEASE: Spondylocostal dysostosis 4, autosomal recessive (SCDO4) [MIM:613686]: A rare condition of variable severity characterized by vertebral and costal anomalies. The main feature include dwarfism, vertebral fusion, hemivertebrae, posterior rib fusion, reduced rib number, and other rib malformations. {ECO:0000269|PubMed:18775957, ECO:0000269|PubMed:20087400}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.27407	0.1136	.	.	14.20939	0.51375	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	13.18	34	chr17	8025658	chr17:8025658	TACCCGGGGGCTCC	T	13.18	PASS	AN=0;DP=34	GT	0/1
chr17	18286711	18286711	G	A	intronic	EVPLL	.	.	.	2.73E-08	0.085818228	0.914181744	.	.	.	0.858082312	88.55862232	308.50866	3.73819	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	24	chr17	18286711	chr17:18286711	G	A	.	PASS	AN=0;DP=24	GT	0/1
chr17	29349022	29349022	C	T	exonic	LOC107984974	.	synonymous SNV	LOC107984974:NM_001350575:exon2:c.C147T:p.I49I,LOC107984974:NM_001350578:exon2:c.C147T:p.I49I,LOC107984974:NM_001350579:exon2:c.C147T:p.I49I	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	25	chr17	29349022	chr17:29349022	C	T	.	PASS	AN=0;DP=25	GT	0/1
chr17	29559138	29559138	G	A	exonic	NF1	.	nonsynonymous SNV	NF1:NM_000267:exon25:c.G3245A:p.G1082D,NF1:NM_001042492:exon25:c.G3245A:p.G1082D	0.999999846	1.54E-07	1.06E-27	DISEASE: Neurofibromatosis 1 (NF1) [MIM:162200]: A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors. {ECO:0000269|PubMed:10220149, ECO:0000269|PubMed:10336779, ECO:0000269|PubMed:10607834, ECO:0000269|PubMed:10712197, ECO:0000269|PubMed:10980545, ECO:0000269|PubMed:11258625, ECO:0000269|PubMed:11735023, ECO:0000269|PubMed:11857752, ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:12552569, ECO:0000269|PubMed:12746402, ECO:0000269|PubMed:1302608, ECO:0000269|PubMed:15060124, ECO:0000269|PubMed:15146469, ECO:0000269|PubMed:15520408, ECO:0000269|PubMed:15523642, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:17160901, ECO:0000269|PubMed:2114220, ECO:0000269|PubMed:21838856, ECO:0000269|PubMed:23758643, ECO:0000269|PubMed:24413922, ECO:0000269|PubMed:7981679, ECO:0000269|PubMed:8081387, ECO:0000269|PubMed:8544190, ECO:0000269|PubMed:8807336, ECO:0000269|PubMed:8834249, ECO:0000269|PubMed:9003501, ECO:0000269|PubMed:9101300, ECO:0000269|PubMed:9150739, ECO:0000269|PubMed:9298829, ECO:0000269|PubMed:9668168}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Watson syndrome (WTSN) [MIM:193520]: A syndrome characterized by the presence of pulmonary stenosis, cafe-au-lait spots, and mental retardation. It is considered as an atypical form of neurofibromatosis. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Familial spinal neurofibromatosis (FSNF) [MIM:162210]: Considered to be an alternative form of neurofibromatosis, showing multiple spinal tumors. {ECO:0000269|PubMed:11704931}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Neurofibromatosis-Noonan syndrome (NFNS) [MIM:601321]: Characterized by manifestations of both NF1 and Noonan syndrome (NS). NS is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. {ECO:0000269|PubMed:12707950, ECO:0000269|PubMed:16380919, ECO:0000269|PubMed:19845691}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	0.6001	0.90845	-3.091147521	0.471809389	198.4465	3.04463	0.145	0.251	T	0.999	0.899	D	0.971	0.832	D	0.000	0.843	D	1	0.810	D	2.215	0.627	M	3.15	0.094	T	-4.43	0.775	D	0.936	0.930	-1.162	0.007	T	0.071	0.289	T	0.861	0.989	D	3.165	0.440	22.6	0.998	0.882	0.992	0.926	D	c	0.538	0.606	1.000	0.747	0.732	0.924	0	5.35	0.762	9.493	0.969	0.998	0.613	1.000	0.715	0.998	0.697	19.059	0.930	.	.	.	0.5	.	55	chr17	29559138	chr17:29559138	G	A	.	PASS	AN=0;DP=55	GT	0/1
chr17	30621266	30621268	TCC	-	intronic	RHBDL3	.	.	.	0.001523114	0.967948766	0.03052812	.	0.1589	0.10761	-0.249709319	35.74545883	2655.56199	9.68692	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	28.53	14	chr17	30621265	chr17:30621265	TTCC	T	28.53	PASS	AN=0;DP=14	GT	0/1
chr17	45727590	45727590	G	A	UTR5	KPNB1	NM_002265:c.-21G>A	.	.	0.999994328	5.67E-06	7.22E-15	.	0.99948	0.5595	-0.624497208	17.16206653	28.74247	0.91953	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	31	chr17	45727590	chr17:45727590	G	A	.	PASS	AN=0;DP=31	GT	0/1
chr17	48639434	48639434	T	A	ncRNA_exonic	CACNA1G-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	99	chr17	48639434	chr17:48639434	T	A	.	PASS	AN=0;DP=99	GT	0/1
chr17	48639445	48639445	C	T	ncRNA_exonic	CACNA1G-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	101	chr17	48639445	chr17:48639445	C	T	.	PASS	AN=0;DP=101	GT	0/1
chr17	58469177	58469178	TA	-	intronic	USP32	.	.	.	0.999999997	2.88E-09	5.68E-25	.	0.99543	0.10507	-2.078019896	1.580561453	184.4083	2.94681	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	81	111	chr17	58469176	chr17:58469176	TTA	T	81	PASS	AN=2;DP=111	GT	0/1
chr17	62502195	62502212	CTCGGTCCCGGCCGCGGT	-	exonic	DDX5	.	nonframeshift deletion	DDX5:NM_004396:exon1:c.26_43del:p.D9_R14del,DDX5:NM_001320595:exon2:c.26_43del:p.D9_R14del,DDX5:NM_001320596:exon2:c.26_43del:p.D9_R14del	0.997454099	0.00254588	2.09E-08	.	0.99513	0.25991	-0.712684326	14.49634348	217.31003	3.18659	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	331	chr17	62502194	chr17:62502194	CCTCGGTCCCGGCCGCGGT	C	71	PASS	AN=2;DP=331	GT	0/1
chr17	74470461	74470461	G	A	exonic	RHBDF2	.	synonymous SNV	RHBDF2:NM_001005498:exon11:c.C1458T:p.D486D,RHBDF2:NM_024599:exon12:c.C1545T:p.D515D	0.000966721	0.998509275	0.000524004	.	0.22785	0.10899	-0.367438677	28.29087049	609.30799	4.99073	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	35	chr17	74470461	chr17:74470461	G	A	.	PASS	AN=0;DP=35	GT	0/1
chr17	74476031	74476031	C	T	intronic	RHBDF2	.	.	.	0.000966721	0.998509275	0.000524004	.	0.22785	0.10899	-0.367438677	28.29087049	609.30799	4.99073	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	124	chr17	74476031	chr17:74476031	C	T	.	PASS	AN=0;DP=124	GT	0/1
chr17	74722933	74722933	G	T	UTR5	METTL23	NM_001206985:c.-6244G>T;NM_001302705:c.-2855G>T;NM_001080510:c.-2860G>T;NM_001302703:c.-2860G>T;NM_001206987:c.-6244G>T;NM_001302704:c.-6244G>T;NM_001206984:c.-2860G>T;NM_001206986:c.-6244G>T;NM_001206983:c.-2860G>T	.	.	0.113237609	0.778025357	0.108737034	DISEASE: Mental retardation, autosomal recessive 44 (MRT44) [MIM:615942]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT44 manifestations include mild to severe cognitive impairment, delayed psychomotor development, seizures in some patients, and dysmorphic features. {ECO:0000269|PubMed:24501276, ECO:0000269|PubMed:24626631}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	.	0.08223	0.349177632	74.18023119	73.16169	1.78753	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	95	chr17	74722933	chr17:74722933	G	T	.	PASS	AN=0;DP=95	GT	0/1
chr18	13643440	13643440	G	A	intronic	LDLRAD4	.	.	.	0.377306395	0.611933101	0.010760504	.	0.53888	0.09904	-0.115612493	45.12856806	49.8811	1.38578	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr18	13643440	chr18:13643440	G	A	.	PASS	AN=0;DP=38	GT	0/1
chr18	31432437	31432438	CA	-	UTR3	NOL4	NM_001198548:c.*369_*368delTG;NM_001282527:c.*369_*368delTG;NM_001198549:c.*369_*368delTG;NM_003787:c.*369_*368delTG;NM_001198547:c.*369_*368delTG;NM_001198546:c.*369_*368delTG	.	.	0.998788438	0.001211561	6.92E-10	.	0.33775	0.11098	-0.66859065	15.76433121	32.86908	1.01975	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	14	chr18	31432436	chr18:31432436	CCA	C	54	PASS	AN=2;DP=14	GT	0/1
chr18	55144025	55144025	A	-	UTR3	ONECUT2	NM_004852:c.*70delA	.	.	0.903998414	0.095195415	0.000806171	.	0.11843	0.18435	-0.60427181	17.74593064	16.33351	0.57897	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	9	chr18	55144024	chr18:55144024	GA	G	58	PASS	AN=2;DP=9	GT	1/0
chr18	61325749	61325778	TTCGTTTGACTTTCCACCCAGGAGTTAATC	-	exonic	SERPINB3	.	nonframeshift deletion	SERPINB3:NM_006919:exon5:c.438_467del:p.K146_T155del	8.69E-14	0.00261773	0.99738227	.	0.3168	0.31828	2.177262001	98.07147912	707.88934	5.28346	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	10.84	23	chr18	61325748	chr18:61325748	ATTCGTTTGACTTTCCACCCAGGAGTTAATC	A	10.84	PASS	AN=0;DP=23	GT	0/1
chr18	67860479	67860479	T	A	intronic	RTTN	.	.	.	2.40E-13	0.999999994	5.97E-09	DISEASE: Polymicrogyria with seizures (PMGYS) [MIM:614833]: A disease characterized by many irregular small gyri in the brain surface and fusion of the molecular layer over multiple small gyri, which gives a festooned appearance to the cortical surface, without abnormal neuronal migration. Polymicrogyria is a heterogeneous disorder, considered to be the result of postmigratory abnormal cortical organization. PMGYS patients have moderate to severe mental retardation, poor speech, dysarthria and seizures. {ECO:0000269|PubMed:22939636}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.25498	0.10307	0.18719002	66.27742392	829.75241	5.64516	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	128	chr18	67860479	chr18:67860479	T	A	.	PASS	AN=0;DP=128	GT	0/1
chr19	646805	646805	C	T	downstream	RNF126	dist=721	.	.	0.774554603	0.223811494	0.001633903	.	0.14462	0.11239	-0.468351206	23.42533616	439.52593	4.36897	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	17	chr19	646805	chr19:646805	C	T	.	PASS	AN=0;DP=17	GT	0/1
chr19	1122672	1122672	C	T	exonic	SBNO2	.	nonsynonymous SNV	SBNO2:NM_001100122:exon6:c.G728A:p.R243Q,SBNO2:NM_014963:exon9:c.G899A:p.R300Q	0.024423765	0.975552528	2.37E-05	.	0.41647	0.11239	-2.2729502	1.250294881	880.95739	5.7817	0.002	0.721	D	1.0	0.899	D	0.999	0.916	D	0.000	0.843	D	1.000	0.548	D	2.63	0.772	M	-3.24	0.935	D	-3.56	0.688	D	0.655	0.668	1.036	0.978	D	0.902	0.968	D	0.532	0.956	D	5.231	0.707	25.6	0.999	0.985	0.989	0.886	D	c	0.627	0.501	1.000	0.747	0.672	0.522	0	4.1	0.470	7.751	0.839	0.771	0.312	1.000	0.715	0.709	0.311	15.679	0.770	P-loop containing nucleoside triphosphate hydrolase	.	.	0.5	.	21	chr19	1122672	chr19:1122672	C	T	.	PASS	AN=0;DP=21	GT	0/1
chr19	1605428	1605428	C	T	UTR5	UQCR11	NM_006830:c.-20G>A	.	.	0.030503461	0.595980384	0.373516155	.	0.14335	0.14499	-0.009020804	52.8544468	8.08743	0.29633	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	57	chr19	1605428	chr19:1605428	C	T	.	PASS	AN=0;DP=57	GT	0/1
chr19	2432366	2432366	C	T	intronic	LMNB2	.	.	.	0.995599597	0.004400324	7.95E-08	DISEASE: Partial acquired lipodystrophy (APLD) [MIM:608709]: A rare childhood disease characterized by loss of subcutaneous fat from the face and trunk. Fat deposition on the pelvic girdle and lower limbs is normal or excessive. Most frequently, onset between 5 and 15 years of age. Most affected subjects are females and some show no other abnormality, but many develop glomerulonephritis, diabetes mellitus, hyperlipidemia, and complement deficiency. Mental retardation in some cases. APLD is a sporadic disorder of unknown etiology. {ECO:0000269|PubMed:16826530, ECO:0000269|PubMed:22768673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epilepsy, progressive myoclonic 9 (EPM9) [MIM:616540]: An autosomal recessive form of progressive myoclonic epilepsy, a rare disease initially responsive to antiepileptic drugs which over time becomes refractory and can be associated with cognitive decline. EPM9 features include myoclonus, tonic-clonic seizures, ataxia, and psychomotor development. {ECO:0000269|PubMed:25954030}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; 	0.8376	0.24333	-1.129772626	6.505071951	299.25483	3.68858	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	80	chr19	2432366	chr19:2432366	C	T	.	PASS	AN=0;DP=80	GT	0/1
chr19	8176845	8176845	G	-	intronic	FBN3	.	.	.	1.35E-27	0.999811749	0.000188251	.	0.09923	0.13532	7.067302466	99.89384289	18901.16442	29.48902	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	83	chr19	8176844	chr19:8176844	TG	T	72	PASS	AN=2;DP=83	GT	0/1
chr19	9873861	9873861	G	A	intronic	ZNF846	.	.	.	3.75E-16	0.000756524	0.999243476	.	.	.	0.466683681	78.73908941	1291.14567	6.76427	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	22	chr19	9873861	chr19:9873861	G	A	.	PASS	AN=0;DP=22	GT	0/1
chr19	11564730	11564731	CC	-	UTR3	ELAVL3	NM_001420:c.*611_*610delGG;NM_032281:c.*611_*610delGG	.	.	0.822602584	0.176556392	0.000841025	.	0.39015	0.23372	-0.780646273	12.77423921	9.21155	0.33694	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	115	chr19	11564729	chr19:11564729	TCC	T	69	PASS	AN=2;DP=115	GT	0/1
chr19	13209514	13209514	C	T	UTR3	NFIX	NM_002501:c.*4086C>T;NM_001271044:c.*4086C>T;NM_001271043:c.*4051C>T	.	.	0.989066455	0.010929908	3.64E-06	DISEASE: Sotos syndrome 2 (SOTOS2) [MIM:614753]: A form of Sotos syndrome, a childhood overgrowth syndrome characterized by prenatal and postnatal overgrowth, developmental delay, mental retardation, advanced bone age, and abnormal craniofacial morphology. SOTOS2 patients have macrocephaly, long narrow face, high forehead, slender habitus, scoliosis, and unusual behavior characterized especially by anxiety. {ECO:0000269|PubMed:22301465}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Marshall-Smith syndrome (MRSHSS) [MIM:602535]: A distinct malformation syndrome characterized by accelerated skeletal maturation, relative failure to thrive, respiratory difficulties, mental retardation, and unusual facies, including prominent forehead, shallow orbits, blue sclerae, depressed nasal bridge, and micrognathia. Additional skeletal findings include long and thin tubular bones, broad middle phalanges with relatively narrow distal phalanges, and scoliosis. {ECO:0000269|PubMed:20673863}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.35172	0.09375	-0.273576253	33.97027601	1.20885	0.03724	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	84	chr19	13209514	chr19:13209514	C	T	.	PASS	AN=0;DP=84	GT	0/1
chr19	16770215	16770215	G	A	exonic	SMIM7	.	nonsynonymous SNV	SMIM7:NM_001300925:exon3:c.C112T:p.P38S,SMIM7:NM_024104:exon3:c.C112T:p.P38S	0.417815347	0.547200563	0.03498409	.	0.22364	.	0.013025609	54.62962963	5.74285	0.21555	0.616	0.209	T	0.0	0.026	B	0.003	0.080	B	0.067	0.218	U	0.538	0.314	N	.	.	.	.	.	.	-3.89	0.728	D	0.19	0.243	-0.885	0.494	T	0.118	0.415	T	0.005	0.141	T	3.148	0.438	22.6	0.999	0.944	0.877	0.471	D	c	0.042	0.188	1.000	0.747	0.628	0.401	0	4.53	0.548	5.680	0.676	1.044	0.665	1.000	0.715	0.872	0.365	12.978	0.578	.	.	.	0.5	.	22	chr19	16770215	chr19:16770215	G	A	.	PASS	AN=0;DP=22	GT	0/1
chr19	18544389	18544389	C	T	intronic	SSBP4	.	.	.	0.961658882	0.038337822	3.30E-06	.	0.20604	0.10821	-0.293801652	32.93819297	37.43039	1.11514	.	.	.	.	.	.	.	.	.	.	.	.	0.899	0.361	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.103	0.777	D	0.729	0.163	9.014	0.934	0.225	0.033	0.083	N	n	1.267	5.403	1.000	0.747	0.090	0.018	0	0.216	0.145	-0.156	0.100	0.667	0.294	0.000	0.063	0.067	0.174	4.762	0.124	.	.	.	0.5	.	29	chr19	18544389	chr19:18544389	C	T	.	PASS	AN=0;DP=29	GT	0/1
chr19	33353558	33353558	C	T	intronic	SLC7A9	.	.	.	0.246082408	0.752570593	0.001347	.	0.15776	0.27325	-0.529034136	20.85987261	2700.38343	9.7809	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	63	chr19	33353558	chr19:33353558	C	T	.	PASS	AN=0;DP=63	GT	0/1
chr19	36211475	36211475	C	T	exonic	KMT2B	.	nonsynonymous SNV	KMT2B:NM_014727:exon3:c.C1226T:p.P409L	0.999999997	2.55E-09	2.07E-24	.	0.69282	0.10507	-5.294103076	0.064873791	1636.68668	7.47877	0.003	0.682	D	0.998	0.715	D	0.981	0.736	D	.	.	.	0.988	0.408	D	0.345	0.112	N	-2.33	0.879	D	-1.52	0.370	N	0.413	0.508	0.045	0.831	D	0.545	0.833	D	0.500	0.952	D	2.537	0.366	19.71	0.986	0.424	0.875	0.468	D	c	0.170	0.151	1.000	0.747	0.696	0.567	0	3.55	0.396	3.033	0.492	0.919	0.430	0.921	0.317	0.931	0.405	10.809	0.455	.	.	.	0.5	.	161	chr19	36211475	chr19:36211475	C	T	.	PASS	AN=0;DP=161	GT	0/1
chr19	38924410	38924410	G	A	UTR5	RYR1	NM_000540:c.-60G>A;NM_001042723:c.-60G>A	.	.	1.61E-07	0.999999839	2.45E-26	DISEASE: Malignant hyperthermia 1 (MHS1) [MIM:145600]: Autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the 'in vitro' contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively). {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10484775, ECO:0000269|PubMed:10612851, ECO:0000269|PubMed:10823104, ECO:0000269|PubMed:10888602, ECO:0000269|PubMed:11241852, ECO:0000269|PubMed:11389482, ECO:0000269|PubMed:11525881, ECO:0000269|PubMed:11575529, ECO:0000269|PubMed:11928716, ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12066726, ECO:0000269|PubMed:12123492, ECO:0000269|PubMed:12208234, ECO:0000269|PubMed:12411788, ECO:0000269|PubMed:12709367, ECO:0000269|PubMed:12883402, ECO:0000269|PubMed:1354642, ECO:0000269|PubMed:14732627, ECO:0000269|PubMed:14985404, ECO:0000269|PubMed:15221887, ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:1774074, ECO:0000269|PubMed:19191329, ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:20681998, ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24013571, ECO:0000269|PubMed:7751854, ECO:0000269|PubMed:7849712, ECO:0000269|PubMed:7881417, ECO:0000269|PubMed:8012359, ECO:0000269|PubMed:9066328, ECO:0000269|PubMed:9138151, ECO:0000269|PubMed:9389851, ECO:0000269|PubMed:9450902, ECO:0000269|PubMed:9497245}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Central core disease of muscle (CCD) [MIM:117000]: Autosomal dominant congenital myopathy, but a severe autosomal recessive form also exists. Both clinical and histological variability is observed. Affected individuals typically display hypotonia and proximal muscle weakness in infancy, leading to the delay of motor milestones. The clinical course of the disorder is usually slow or nonprogressive in adulthood, and the severity of the symptoms may vary from normal to significant muscle weakness. Microscopic examination of CCD-affected skeletal muscle reveals a predominance of type I fibers containing amorphous-looking areas (cores) that do not stain with oxidative and phosphorylase histochemical techniques. {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10097181, ECO:0000269|PubMed:11113224, ECO:0000269|PubMed:11709545, ECO:0000269|PubMed:11741831, ECO:0000269|PubMed:12112081, ECO:0000269|PubMed:12136074, ECO:0000269|PubMed:12565913, ECO:0000269|PubMed:12566385, ECO:0000269|PubMed:12937085, ECO:0000269|PubMed:14670767, ECO:0000269|PubMed:14985404, ECO:0000269|PubMed:17204054, ECO:0000269|PubMed:17226826, ECO:0000269|PubMed:18253926, ECO:0000269|PubMed:18312400, ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:21674524, ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24561095, ECO:0000269|PubMed:7829078, ECO:0000269|PubMed:8220422, ECO:0000269|PubMed:8220423, ECO:0000269|PubMed:9497245}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Multiminicore disease with external ophthalmoplegia (MMDO) [MIM:255320]: Clinically heterogeneous neuromuscular disorder. General features include neonatal hypotonia, delayed motor development, and generalized muscle weakness and amyotrophy, which may progress slowly or remain stable. Muscle biopsy shows multiple, poorly circumscribed, short areas of sarcomere disorganization and mitochondria depletion (areas termed minicores) in most muscle fibers. Typically, no dystrophic signs, such as muscle fiber necrosis or regeneration or significant endomysial fibrosis, are present in multiminicore disease. {ECO:0000269|PubMed:12719381, ECO:0000269|PubMed:16380615}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, congenital, with fiber-type disproportion (CFTD) [MIM:255310]: A genetically heterogeneous disorder in which there is relative hypotrophy of type 1 muscle fibers compared to type 2 fibers on skeletal muscle biopsy. However, these findings are not specific and can be found in many different myopathic and neuropathic conditions. {ECO:0000269|PubMed:20583297}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in RYR1 may be a cause of Samaritan myopathy, a congenital myopathy with benign course. Patients display severe hypotonia and respiratory distress at birth. Unlike other congenital myopathies, the health status constantly improves and patients are minimally affected at adulthood.; 	0.22212	.	-8.291678111	0.005897617	2142.38985	8.51518	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	73	chr19	38924410	chr19:38924410	G	A	.	PASS	AN=0;DP=73	GT	0/1
chr19	39227910	39227910	C	T	exonic	CAPN12	.	synonymous SNV	CAPN12:NM_144691:exon10:c.G1248A:p.A416A	7.48E-20	0.000491944	0.999508056	.	0.38998	0.11824	-0.523584927	20.93654164	2537.68423	9.40302	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	152	chr19	39227910	chr19:39227910	C	T	.	PASS	AN=0;DP=152	GT	0/1
chr19	42595035	42595035	G	-	UTR3	POU2F2	NM_001247994:c.*722delC;NM_002698:c.*669delC;NM_001207025:c.*669delC	.	.	0.97379428	0.026199392	6.33E-06	.	0.49246	0.27788	-0.538132194	20.26421326	113.2753	2.31761	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	38	chr19	42595034	chr19:42595034	TG	T	41	PASS	AN=2;DP=38	GT	0/1
chr19	42755585	42755585	T	G	intronic	ERF	.	.	.	0.807144401	0.19263935	0.000216249	DISEASE: Craniosynostosis 4 (CRS4) [MIM:600775]: A primary abnormality of skull growth involving premature fusion of one or more cranial sutures. The growth velocity of the skull often cannot match that of the developing brain resulting in an abnormal head shape and, in some cases, increased intracranial pressure, which must be treated promptly to avoid permanent neurodevelopmental disability. {ECO:0000269|PubMed:23354439}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.63786	0.13887	-0.424258538	25.56027365	41.74458	1.21591	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	31	chr19	42755585	chr19:42755585	T	G	.	PASS	AN=0;DP=31	GT	0/1
chr19	45419456	45419456	C	A	exonic	APOC1	.	nonsynonymous SNV	APOC1:NM_001321065:exon3:c.C68A:p.P23Q,APOC1:NM_001645:exon3:c.C68A:p.P23Q,APOC1:NM_001321066:exon4:c.C68A:p.P23Q	0.050738273	0.691173387	0.25808834	.	0.0944	0.47132	-0.053113545	49.38664779	30.95619	0.97866	.	.	.	0.997	0.689	D	0.957	0.682	D	0.001	0.428	D	1	0.810	D	.	.	.	1.34	0.732	T	.	.	.	0.342	0.403	-0.998	0.304	T	0.160	0.495	T	0.124	0.806	D	5.320	0.720	25.8	0.988	0.467	0.773	0.377	D	c	0.261	0.178	1.000	0.404	0.635	0.413	0	3.29	0.366	1.860	0.388	0.903	0.418	0.895	0.311	0.921	0.396	8.289	0.309	.	.	.	0.5	.	64	chr19	45419456	chr19:45419456	C	A	.	PASS	AN=0;DP=64	GT	0/1
chr19	45683434	45683434	G	-	UTR3	BLOC1S3	NM_212550:c.*271delG	.	.	0.01842977	0.494019384	0.487550846	DISEASE: Hermansky-Pudlak syndrome 8 (HPS8) [MIM:614077]: A form of Hermansky-Pudlak syndrome, a genetically heterogeneous autosomal recessive disorder characterized by oculocutaneous albinism, bleeding due to platelet storage pool deficiency, and lysosomal storage defects. This syndrome results from defects of diverse cytoplasmic organelles including melanosomes, platelet dense granules and lysosomes. Ceroid storage in the lungs is associated with pulmonary fibrosis, a common cause of premature death in individuals with HPS. {ECO:0000269|PubMed:16385460}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.0538	0.23912	.	.	73.74289	1.79457	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	20.31	35	chr19	45683433	chr19:45683433	TG	T	20.31	PASS	AN=0;DP=35	GT	0/1
chr19	45684896	45684938	TCCGATCCCAGCTCTGGTCCCTCAGCCGCATTCATATTTACTC	-	UTR3	BLOC1S3	NM_212550:c.*1733_*1775delTCCGATCCCAGCTCTGGTCCCTCAGCCGCATTCATATTTACTC	.	.	0.01842977	0.494019384	0.487550846	DISEASE: Hermansky-Pudlak syndrome 8 (HPS8) [MIM:614077]: A form of Hermansky-Pudlak syndrome, a genetically heterogeneous autosomal recessive disorder characterized by oculocutaneous albinism, bleeding due to platelet storage pool deficiency, and lysosomal storage defects. This syndrome results from defects of diverse cytoplasmic organelles including melanosomes, platelet dense granules and lysosomes. Ceroid storage in the lungs is associated with pulmonary fibrosis, a common cause of premature death in individuals with HPS. {ECO:0000269|PubMed:16385460}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.0538	0.23912	.	.	73.74289	1.79457	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	10.67	22	chr19	45684895	chr19:45684895	TTCCGATCCCAGCTCTGGTCCCTCAGCCGCATTCATATTTACTC	T	10.67	PASS	AN=0;DP=22	GT	0/1
chr19	48197667	48197667	C	T	exonic	BICRA	.	nonsynonymous SNV	BICRA:NM_015711:exon8:c.C2579T:p.P860L	.	.	.	.	.	.	.	.	.	.	0.053	0.388	T	0.741	0.410	P	0.04	0.225	B	.	.	.	0.822	0.288	N	1.7	0.440	L	1.47	0.320	T	-0.37	0.132	N	0.297	0.357	-1.073	0.088	T	0.030	0.130	T	0.538	0.957	D	2.044	0.306	16.49	0.822	0.136	0.134	0.177	N	c	-0.418	-0.431	0.074	0.157	0.646	0.450	0	2.11	0.262	0.256	0.180	0.739	0.307	0.023	0.197	0.003	0.074	4.790	0.125	.	.	.	0.5	.	81	chr19	48197667	chr19:48197667	C	T	.	PASS	AN=0;DP=81	GT	0/1
chr19	48198672	48198672	C	G	exonic	BICRA	.	nonsynonymous SNV	BICRA:NM_015711:exon10:c.C3127G:p.P1043A	.	.	.	.	.	.	.	.	.	.	0.022	0.486	D	0.93	0.498	P	0.758	0.545	P	.	.	.	0.895	0.278	N	0.895	0.225	L	1.49	0.315	T	-1.27	0.320	N	0.149	0.176	-1.058	0.123	T	0.084	0.330	T	0.034	0.559	D	1.885	0.287	15.50	0.983	0.398	0.779	0.381	D	c	0.077	0.037	0.959	0.284	0.696	0.567	0	3.35	0.373	0.904	0.279	0.807	0.329	0.010	0.182	0.974	0.471	10.533	0.440	.	.	.	0.5	67	127	chr19	48198672	chr19:48198672	C	G	67	PASS	AN=2;DP=127	GT	0/1
chr19	48660232	48660232	G	A	intronic	LIG1	.	.	.	0.017705097	0.982287161	7.74E-06	.	0.97979	0.38753	0.36555769	74.7287096	466.53831	4.47469	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	88	chr19	48660232	chr19:48660232	G	A	.	PASS	AN=0;DP=88	GT	0/1
chr19	49207731	49207731	C	T	UTR3	FUT2	NM_001097638:c.*486C>T;NM_000511:c.*486C>T	.	.	5.47E-12	0.004200172	0.995799828	.	0.05184	.	0.823072022	88.03963199	10077.22821	21.87521	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	25	chr19	49207731	chr19:49207731	C	T	.	PASS	AN=0;DP=25	GT	0/1
chr19	50180555	50180556	CG	-	exonic	PRMT1	.	frameshift deletion	PRMT1:NM_001207042:exon1:c.18_19del:p.A7Efs*14,PRMT1:NM_001536:exon1:c.18_19del:p.A7Efs*12,PRMT1:NM_198318:exon1:c.18_19del:p.A7Efs*14	0.993587787	0.006411228	9.85E-07	.	0.91947	0.4592	-0.560178693	19.30879925	19.62667	0.67361	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	50	chr19	50180554	chr19:50180554	CCG	C	42	PASS	AN=2;DP=50	GT	0/1
chr19	50764680	50764680	C	T	intronic	MYH14	.	.	.	0.999847921	0.000152079	6.12E-17	DISEASE: Deafness, autosomal dominant, 4A (DFNA4A) [MIM:600652]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:15015131, ECO:0000269|PubMed:16222661}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Peripheral neuropathy, myopathy, hoarseness, and hearing loss (PNMHH) [MIM:614369]: A complex phenotype of progressive peripheral neuropathy and distal myopathy, with later onset of hoarseness and hearing loss. Affected individuals develop distal muscle weakness at a mean age of 10.6 years, followed by progressive atrophy of these muscles. The lower limbs are more severely affected than the upper limbs, and the muscle weakness first affects anterior leg muscles and later posterior leg muscles. {ECO:0000269|PubMed:21480433}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.22477	0.14506	-2.236665977	1.309271054	1826.33006	7.88079	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	42	chr19	50764680	chr19:50764680	C	T	.	PASS	AN=0;DP=42	GT	0/1
chr19	53905458	53905458	C	T	intronic	ZNF765;ZNF765-ZNF761	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	101	chr19	53905458	chr19:53905458	C	T	.	PASS	AN=0;DP=101	GT	0/1
chr19	54802380	54802394	CCCTTAGGACCCCCA	-	intronic	LILRA3	.	.	.	0.002925351	0.941785239	0.055289411	.	0.06888	.	3.561548721	99.50460014	1102.81114	6.34939	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	125	chr19	54802379	chr19:54802379	TCCCTTAGGACCCCCA	T	69	PASS	AN=2;DP=125	GT	0/1
chr19	54802435	54802435	G	A	intronic	LILRA3	.	.	.	0.002925351	0.941785239	0.055289411	.	0.06888	.	3.561548721	99.50460014	1102.81114	6.34939	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	88	chr19	54802435	chr19:54802435	G	A	.	PASS	AN=0;DP=88	GT	0/1
chr19	55698866	55698866	G	A	intronic	PTPRH	.	.	.	5.10E-29	7.03E-05	0.999929729	.	0.0771	.	1.111434312	92.06770465	5182.51875	14.81765	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	19	chr19	55698866	chr19:55698866	G	A	.	PASS	AN=0;DP=19	GT	0/1
chr20	307644	307644	C	T	UTR3	SOX12	NM_006943:c.*128C>T	.	.	.	.	.	.	0.28694	.	.	.	119.21572	2.37593	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	32	chr20	307644	chr20:307644	C	T	.	PASS	AN=0;DP=32	GT	0/1
chr20	309111	309111	G	T	UTR3	SOX12	NM_006943:c.*1595G>T	.	.	.	.	.	.	0.28694	.	.	.	119.21572	2.37593	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	41	chr20	309111	chr20:309111	G	T	.	PASS	AN=0;DP=41	GT	0/1
chr20	20029070	20029070	C	T	exonic	CRNKL1	.	nonsynonymous SNV	CRNKL1:NM_001278628:exon4:c.G372A:p.M124I,CRNKL1:NM_001278625:exon5:c.G819A:p.M273I,CRNKL1:NM_001278626:exon5:c.G3A:p.M1I,CRNKL1:NM_001278627:exon5:c.G3A:p.M1I,CRNKL1:NM_016652:exon5:c.G855A:p.M285I	0.881981247	0.118018734	1.96E-08	.	0.29171	0.17515	1.049013545	91.34819533	676.59451	5.19663	0.029	0.457	D	0.771	0.425	P	0.549	0.511	P	0.000	0.843	D	1	0.810	D	3.08	0.875	M	1.37	0.342	T	-2.76	0.589	D	0.874	0.862	-0.723	0.593	T	0.223	0.587	T	0.015	0.354	T	5.003	0.673	25.1	0.997	0.777	0.982	0.805	D	c	0.719	0.751	1.000	0.747	0.732	0.924	0	6.07	0.987	6.160	0.715	0.935	0.490	1.000	0.715	1.000	0.888	20.659	0.996	Tetratricopeptide repeat-containing domain|Tetratricopeptide-like helical domain	.	.	0.5	.	17	chr20	20029070	chr20:20029070	C	T	.	PASS	AN=0;DP=17	GT	0/1
chr20	31035145	31035145	C	T	UTR3	NOL4L	NM_001256798:c.*254G>A;NM_001351680:c.*454G>A;NM_080616:c.*254G>A	.	.	.	.	.	.	0.66654	0.11152	-1.045216355	7.661004954	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-0.308	0.068	0.637	0.658	0.076	0.813	0.404	D	c	-0.518	-0.527	0.814	0.244	0.295	0.044	0	1.83	0.242	1.587	0.360	-0.429	0.058	1.000	0.715	0.155	0.206	7.611	0.271	.	.	.	0.5	.	34	chr20	31035145	chr20:31035145	C	T	.	PASS	AN=0;DP=34	GT	0/1
chr20	32298283	32298283	C	T	intronic	PXMP4	.	.	.	0.604956427	0.38624188	0.008801693	.	0.1038	0.10278	0.527368849	80.73248408	67.7056	1.70224	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	76	chr20	32298283	chr20:32298283	C	T	.	PASS	AN=0;DP=76	GT	0/1
chr20	33422076	33422076	A	G	ncRNA_exonic	HMGB3P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	28	chr20	33422076	chr20:33422076	A	G	43	PASS	AN=2;DP=28	GT	0/1
chr20	33565481	33565481	G	A	exonic	MYH7B	.	nonsynonymous SNV	MYH7B:NM_020884:exon4:c.G52A:p.E18K	1.33E-23	0.792349353	0.207650647	.	0.15291	0.32389	-0.893455413	10.17338995	2287.01575	8.85125	0.665	0.046	T	.	.	.	.	.	.	.	.	.	0.999	0.219	N	.	.	.	-2.03	0.856	D	-0.06	0.079	N	0.134	0.155	-0.556	0.666	T	0.458	0.789	T	0.101	0.775	D	3.523	0.481	23.1	0.996	0.734	0.487	0.280	N	c	0.741	0.543	1.000	0.517	0.554	0.283	0	4.25	0.495	2.248	0.426	0.847	0.346	1.000	0.715	0.903	0.383	7.002	0.238	.	.	.	0.5	.	56	chr20	33565481	chr20:33565481	G	A	.	PASS	AN=0;DP=56	GT	0/1
chr20	57569709	57569709	C	T	exonic	NELFCD	.	nonsynonymous SNV	NELFCD:NM_198976:exon15:c.C1778T:p.S593F	0.20597781	0.793941076	8.11E-05	.	0.20699	0.42266	-1.199555187	5.761972163	20.6141	0.70093	.	.	.	0.99	0.615	D	0.856	0.592	P	0.000	0.843	D	1	0.810	D	1.1	0.281	L	.	.	.	.	.	.	0.465	0.884	-0.548	0.669	T	0.259	0.630	T	0.006	0.172	T	7.250	0.947	34	0.998	0.905	0.994	0.950	D	c	0.608	0.641	1.000	0.747	0.646	0.442	0	5.15	0.702	6.897	0.753	0.932	0.445	1.000	0.715	0.995	0.604	18.977	0.927	.	.	.	0.5	.	35	chr20	57569709	chr20:57569709	C	T	.	PASS	AN=0;DP=35	GT	0/1
chr20	62843465	62843465	G	T	exonic	MYT1	.	synonymous SNV	MYT1:NM_004535:exon9:c.G1491T:p.V497V	0.999871802	0.000128198	5.88E-13	.	0.9384	0.11581	-1.631512986	2.848549186	268.65953	3.51606	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	78	chr20	62843465	chr20:62843465	G	T	.	PASS	AN=0;DP=78	GT	0/1
chr21	40714775	40714775	C	T	UTR3	HMGN1	NM_004965:c.*263G>A	.	.	0.425365462	0.541410677	0.033223861	.	0.46691	0.07886	0.3032669	72.009908	414.2321	4.26339	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	33	chr21	40714775	chr21:40714775	C	T	.	PASS	AN=0;DP=33	GT	0/1
chr21	43291488	43291488	G	A	intronic	PRDM15	.	.	.	0.753744615	0.246255384	1.22E-09	.	0.0747	0.10154	-2.001084103	1.733899505	875.44322	5.75655	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	71	chr21	43291488	chr21:43291488	G	A	.	PASS	AN=0;DP=71	GT	0/1
chr21	46554694	46554694	G	A	intronic	ADARB1	.	.	.	0.843939347	0.155939433	0.00012122	.	0.28156	0.13431	-0.800872469	12.33191791	35.57047	1.07201	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	39	chr21	46554694	chr21:46554694	G	A	.	PASS	AN=0;DP=39	GT	0/1
chr21	46957709	46957709	G	A	exonic	SLC19A1	.	synonymous SNV	SLC19A1:NM_001205206:exon2:c.C165T:p.P55P,SLC19A1:NM_194255:exon2:c.C165T:p.P55P	0.0123881	0.952273227	0.035338672	.	0.0749	.	-0.286522835	33.47487615	1149.843	6.46099	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	49	chr21	46957709	chr21:46957709	G	A	.	PASS	AN=0;DP=49	GT	0/1
chr22	22041874	22041874	G	A	intronic	PPIL2	.	.	.	0.027492987	0.97240894	9.81E-05	.	0.24149	0.11289	-0.596992387	18.18825195	85.07728	1.96609	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	26	chr22	22041874	chr22:22041874	G	A	.	PASS	AN=0;DP=26	GT	0/1
chr22	31859660	31859660	G	C	intronic	EIF4ENIF1	.	.	.	0.999689054	0.000310946	1.03E-12	.	0.37607	0.23099	-0.973616687	8.8995046	113.80534	2.32557	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	68	94	chr22	31859660	chr22:31859660	G	C	68	PASS	AN=2;DP=94	GT	0/1
chr22	32211320	32211320	G	A	intronic	DEPDC5	.	.	.	0.999999934	6.60E-08	9.62E-24	DISEASE: Note=Inactivating mutations and truncating deletions in the genes encoding GATOR1 proteins, including DEPDC5, are detected in glioblastoma and ovarian tumors and are associated with loss of heterozygosity events. Inactivation of GATOR1 proteins promotes constitutive localization of mTORC1 to the lysosomal membrane and blocks mTORC1 inactivation following amino acid withdrawal (PubMed:23723238). {ECO:0000269|PubMed:23723238}.; 	0.19403	0.09278	-1.115293937	6.623024298	895.81677	5.83244	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	28	chr22	32211320	chr22:32211320	G	A	.	PASS	AN=0;DP=28	GT	0/1
chr22	36113816	36113816	A	-	upstream	APOL5	dist=103	.	.	1.01E-08	0.170032073	0.829967917	.	0.05935	.	0.887394731	89.18966737	7067.29	18.01366	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	117	chr22	36113815	chr22:36113815	GA	G	59	PASS	AN=2;DP=117	GT	0/1
chr22	37964453	37964453	G	A	exonic	CDC42EP1	.	nonsynonymous SNV	CDC42EP1:NM_152243:exon3:c.G802A:p.G268S	1.06E-05	0.197795982	0.802193447	.	0.08861	0.10603	-0.442665927	24.53408823	193.55365	3.0183	0.369	0.116	T	0.0	0.026	B	0.001	0.040	B	.	.	.	1	0.090	N	0.345	0.112	N	1.59	0.288	T	0.21	0.048	N	0.159	0.191	-0.985	0.339	T	0.025	0.108	T	0.003	0.064	T	-0.512	0.055	0.205	0.349	0.022	0.171	0.195	N	c	-1.455	-1.501	1.000	0.747	0.672	0.522	0	-0.736	0.105	0.126	0.155	-1.241	0.015	0.000	0.063	0.000	0.016	3.638	0.076	.	.	.	0.5	.	88	chr22	37964453	chr22:37964453	G	A	.	PASS	AN=0;DP=88	GT	0/1
chr22	38543532	38543532	G	-	intronic	PLA2G6	.	.	.	2.66E-08	0.901102432	0.098897542	DISEASE: Neurodegeneration with brain iron accumulation 2A (NBIA2A) [MIM:256600]: A neurodegenerative disease characterized by pathologic axonal swelling and spheroid bodies in the central nervous system. Onset is within the first 2 years of life with death by age 10 years. {ECO:0000269|PubMed:16783378, ECO:0000269|PubMed:17033970, ECO:0000269|PubMed:23749988}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Parkinson disease 14 (PARK14) [MIM:612953]: An adult- onset progressive neurodegenerative disorder characterized by parkinsonism, dystonia, severe cognitive decline, cerebral and cerebellar atrophy and absent iron in the basal ganglia on magnetic resonance imaging. {ECO:0000269|PubMed:18570303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.16881	0.17642	-1.591018721	3.084453881	148.63297	2.65978	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	48	chr22	38543531	chr22:38543531	TG	T	53	PASS	AN=2;DP=48	GT	0/1
chr22	39910495	39910517	TTTTGTTACCCAACTCTTCCTAT	-	UTR3	MIEF1	NM_019008:c.*167_*189delTTTTGTTACCCAACTCTTCCTAT	.	.	0.062893833	0.921465906	0.015640262	.	0.12261	0.09986	0.420771676	77.15852795	1019.99486	6.14357	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	17.15	17	chr22	39910494	chr22:39910494	ATTTTGTTACCCAACTCTTCCTAT	A	17.15	PASS	AN=0;DP=17	GT	0/1
chrX	19037766	19037766	C	A	exonic	ADGRG2	.	nonsynonymous SNV	ADGRG2:NM_001184835:exon12:c.G547T:p.V183F,ADGRG2:NM_001079860:exon13:c.G595T:p.V199F,ADGRG2:NM_001184836:exon13:c.G589T:p.V197F,ADGRG2:NM_001184837:exon13:c.G571T:p.V191F,ADGRG2:NM_001079859:exon14:c.G619T:p.V207F,ADGRG2:NM_001184833:exon14:c.G613T:p.V205F,ADGRG2:NM_001079858:exon15:c.G661T:p.V221F,ADGRG2:NM_001184834:exon15:c.G661T:p.V221F,ADGRG2:NM_005756:exon15:c.G652T:p.V218F	.	.	.	.	0.53967	0.10442	0.510776592	80.23708422	.	.	0.208	0.327	T	0.0	0.026	B	0.0	0.063	B	0.725	0.099	N	1	0.090	N	1.24	0.311	L	1.46	0.334	T	-1.66	0.424	N	0.16	0.193	-1.014	0.257	T	0.033	0.143	T	0.003	0.067	T	1.348	0.226	12.52	0.931	0.222	0.015	0.050	N	.	.	.	0.749	0.233	.	.	.	-0.717	0.106	-0.715	0.051	-0.415	0.060	0.002	0.151	0.910	0.387	0.727	0.009	.	.	.	0.5	.	33	chrX	19037766	chrX:19037766	C	A	.	PASS	AN=0;DP=33	GT	0/1
chrX	23724764	23724764	G	A	exonic	ACOT9	.	nonsynonymous SNV	ACOT9:NM_001330259:exon9:c.C616T:p.L206F,ACOT9:NM_001033583:exon10:c.C796T:p.L266F,ACOT9:NM_001037171:exon11:c.C823T:p.L275F	1.91E-05	0.889292965	0.110687943	.	0.14996	0.09121	0.439181676	77.69521113	204.02566	3.08375	0.028	0.477	D	1.0	0.899	D	0.998	0.916	D	0.000	0.843	D	1.000	0.588	D	3.125	0.882	M	1.34	0.350	T	-3.36	0.665	D	0.747	0.778	-0.537	0.673	T	0.251	0.621	T	0.621	0.967	D	6.515	0.898	31	0.999	0.963	0.986	0.846	D	.	.	.	1.000	0.747	.	.	.	5.51	0.817	7.557	0.811	1.045	0.669	1.000	0.715	0.978	0.483	11.891	0.517	HotDog domain;HotDog domain|Hotdog acyl-CoA thioesterase (ACOT)-type domain	.	.	0.5	.	33	chrX	23724764	chrX:23724764	G	A	.	PASS	AN=0;DP=33	GT	0/1
chrX	41092154	41092154	C	T	UTR3	USP9X	NM_001039591:c.*377C>T;NM_001039590:c.*377C>T	.	.	1	2.36E-11	2.78E-27	.	0.58131	0.10304	-1.618506764	2.925218212	35.92323	1.07855	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	34	chrX	41092154	chrX:41092154	C	T	.	PASS	AN=0;DP=34	GT	0/1
chrX	45606437	45606437	C	G	ncRNA_exonic	MIR222	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	54	chrX	45606437	chrX:45606437	C	G	60	PASS	AN=2;DP=54	GT	0/1
chrX	47460695	47460744	AAATTCCTAGAAAGACACAAACTACAAAAACTGACTCAGTAAGAAATGGA	-	intronic	SYN1	.	.	.	0.879529753	0.120170955	0.000299292	DISEASE: Epilepsy X-linked, with variable learning disabilities and behavior disorders (XELBD) [MIM:300491]: A neurologic disorder characterized by variable combinations of epilepsy, learning difficulties, macrocephaly, and aggressive behavior. {ECO:0000269|PubMed:14985377}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.66764	0.6282	.	.	164.73159	2.80346	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	18.06	27	chrX	47460694	chrX:47460694	CAAATTCCTAGAAAGACACAAACTACAAAAACTGACTCAGTAAGAAATGGA	C	18.06	PASS	AN=0;DP=27	GT	0/1
chrX	70767720	70767720	C	T	ncRNA_intronic	BCYRN1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	37	chrX	70767720	chrX:70767720	C	T	.	PASS	AN=0;DP=37	GT	0/1
chrX	96171499	96171499	C	-	exonic	DIAPH2	.	frameshift deletion	DIAPH2:NM_006729:exon8:c.795delC:p.K267Nfs*4,DIAPH2:NM_007309:exon8:c.795delC:p.K267Nfs*3	0.9991191	0.0008809	6.44E-11	DISEASE: Premature ovarian failure 2A (POF2A) [MIM:300511]: An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. {ECO:0000269|PubMed:9497258}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.56881	0.27299	-0.999300439	8.368719038	38.85136	1.15117	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	85	chrX	96171498	chrX:96171498	AC	A	61	PASS	AN=2;DP=85	GT	0/1
chrX	99924370	99924370	C	T	intronic	SRPX2	.	.	.	0.962529393	0.037467495	3.11E-06	DISEASE: Rolandic epilepsy with speech dyspraxia and mental retardation X-linked (RESDX) [MIM:300643]: A condition characterized by the association of rolandic seizures with oral and speech dyspraxia, and mental retardation. Rolandic seizures occur during a period of significant brain maturation. During this time, dysfunction of neural network activities such as focal discharges may be associated with specific developmental disabilities resulting in specific cognitive impairments of language, visuo-spatial abilities or attention. {ECO:0000269|PubMed:16497722}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.30928	0.13849	0.174625237	65.9648502	51.08082	1.40844	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	139	chrX	99924370	chrX:99924370	C	T	.	PASS	AN=0;DP=139	GT	0/1
chrX	102528736	102528806	CTGCTGGTAACAAGAGTGACACCTAAAGGAAAGTATCAGCTTAAGGTTAAAGCACATAGGCCGGCAAATGC	-	UTR3	TCEAL5	NM_001012979:c.*135_*65delGCATTTGCCGGCCTATGTGCTTTAACCTTAAGCTGATACTTTCCTTTAGGTGTCACTCTTGTTACCAGCAG	.	.	0.666797567	0.310905197	0.022297235	.	0.10123	.	0.191216164	66.57230479	730.81358	5.36747	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	32.99	25	chrX	102528735	chrX:102528735	TCTGCTGGTAACAAGAGTGACACCTAAAGGAAAGTATCAGCTTAAGGTTAAAGCACATAGGCCGGCAAATGC	T	32.99	PASS	AN=0;DP=25	GT	0/1
chrX	105201339	105201339	G	A	UTR3	NRK	NM_198465:c.*1747G>A	.	.	0.763369951	0.236629918	1.31E-07	.	0.3258	0.31202	.	.	2428.62657	9.15478	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chrX	105201339	chrX:105201339	G	A	.	PASS	AN=0;DP=44	GT	0/1
chrX	114468474	114468476	CCG	-	exonic	LRCH2	.	nonframeshift deletion	LRCH2:NM_001243963:exon1:c.129_131del:p.G44del,LRCH2:NM_020871:exon1:c.129_131del:p.G44del	0.915538079	0.08443772	2.42E-05	.	0.16063	0.09365	-0.007201372	53.19061099	42.20239	1.22827	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	104	110	chrX	114468473	chrX:114468473	CCCG	C	104	PASS	AN=2;DP=110	GT	0/1
chrX	132351100	132351100	G	A	exonic	TFDP3	.	synonymous SNV	TFDP3:NM_016521:exon1:c.C1188T:p.D396D	2.30E-06	0.085066935	0.91493076	.	0.05413	0.05691	0.729426781	86.17008728	225.71159	3.2476	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	30	chrX	132351100	chrX:132351100	G	A	.	PASS	AN=0;DP=30	GT	0/1
chrX	153881436	153881436	C	-	intronic	CTAG2	.	.	.	0.005954387	0.494134005	0.499911607	.	0.13765	.	0.905808022	89.4373673	99.89657	2.16581	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	75	73	chrX	153881435	chrX:153881435	GC	G	75	PASS	AN=2;DP=73	GT	0/1
